text
this news has been read 10557 times kuwait city june 7 recent data from the sovereign wealth fund institute swfi showed that global sovereign wealth funds have assigned 1 259 trillion to invest in us listed stocks out of their total assets of 10 06 trillion reports al rai daily the institute stated that these funds allocate 12 52 percent of their assets to invest in us stocks the ftse russell 3000 index which tracks the us stock market estimated on may 6 the market value of the us stock market at 44 9 trillion dollars while the analysis of the distributions of sovereign wealth funds indicates that these funds constitute 2 804 percent of the american stock market large swfs are known as contrarian investors who often invest when others are going down and their investments are usually long term in nature among the largest sovereign funds investing in us stocks are the kuwait investment authority the norwegian fund the china investment corporation the abu dhabi investment authority the gic private limited the saudi public investment fund the qatar investment authority and the korea investment corporation the institute revealed that gulf sovereign funds have allocated about 520 billion to invest in us stocks this news has been read 10557 times
five things you ll only hear in minnesota farm country a memorial day weekend spent on the farm with my girlfriend diana s family always brings a lot of laughs good food and things you ll only hear in minnesota farm country oh we should show him the driveway photo by rabe diana her sister pat and i were out driving they were giving me a bit of an extended geographical tour we saw various homes that d belonged to friends a place pat used to live a super dangerous road all of it out in the country nothing but freshly planted fields around us all of a sudden pat says oh we should show him the driveway wheee i thought but then realized she means the driveway that used to lead to a house that was special to the family but the house is long gone now in its place freshly planted beans or corn did you just put bacon grease in the chicken stock farm fresh bacon butchered by diana s dad and cured locally photo by rabe this one is all my fault we made bacon eggs and toast fresh from the farm bacon is another level you can t even imagine anyway i m cleaning up and realize i m pouring bacon grease not into the grease bottle but into a bottle of frozen chicken stock in my defense the bottles look very similar like old miracle whip jars there are like 10 jars that look alike in the freezer all old mw jars i only poured in a bit when i realized the mistake as i was quickly putting the chicken stock back in the freezer diana comes into the room and says did you just put bacon grease in the chicken stock me no also me yes this is the blanket with the blind dog because mice chewed his eyes out creativenature_nl her sister bev comes up to me and tells me a story about how mice had gotten into a tote and ruined a bunch of gifts she d managed to save this blanket a gift for me the mice chewed up most of the gifts even a down comforter and all of it had to be thrown out but bev thought sister pat from the first story could save the blanket with a patch you see she said the blanket was folded in such a way that the mice could only nibble this one part she hands me the blanket i felt where she pointed and could feel little oval saucers where the eyes were pat had managed to save it with some penguin fleece so now when i run my fingers over the blanket it s super easy to find the special puppy as she presented it to me bev said this is the blanket with the blind dog because mice chewed his eyes out low maintenance means no maintenance but don t tell the lawyer that aaron savage townsquare media pat and diana were showing me a road that s closed in the winter and usually there s a closed road sign but not always there is a low maintenance road sign but since it s almost exclusively used by locals they know because they know the closed sign doesn t always go up well way back in the day an attorney wanted to sue the county for not maintaining the road because he got super stuck on it messed up his fancy car something awful which sucks but you don t get much sympathy when instead of being embarrassed you drove on such an obviously bad road you demand people pay for your mistake photo by piotr adamowicz thinkstock from what i heard the judge said you don t have a case city slicker and that was that maybe the judge didn t say city slicker that may just be me assuming what the judge wanted to say as they say in minnesota farm country low maintenance road means no maintenance road the sounds of silence when you get to the evans family farm and you re done with supper it might be a bit cool so you put on hoodies and you sit outside for a bit and talk as you sit you begin to notice an immense quiet around you don t be fooled it s not really the sounds of silence it s the lack of noise you re noticing without the noise you can hear the breeze birds flapping their wings around the bird feeder and someone walking down the gravel road and most importantly each other we sat around a fire with some friends last friday and had a great time much of it not saying a word just listening to the things you can t hear when you re in the city other farm country stories worth checking out i ve written about the five things you don t want to hear on a minnesota farm she must have been desperate if she put that in her mouth read more five things you don t want to hear on a minnesota farm 5 things you don t want to step in on a minnesota farm including mouse catchers as always if you have a comment complaint or concern about something i wrote here please let me know james rabe townsquaremedia com click play to hear the y 105fm early morning show radio on demand podcast listen on demand with the y105fm app and on the following podcast platforms apple podcasts google podcasts spotify if you love farmhouse style homes you will love this one i don t know that i ve ever been in a farmhouse with this sort of look lol
new york june 07 2022 globe newswire viasat inc nasdaq vsat lifshitz law pllc announces investigation into possible breach of fiduciary duties in connection with the proposed acquisition of inmarsat by vsat under the terms of the merger agreement inmarsat s shareholders would receive 850 million total in cash and 46 36 million newly issued vsat shares if you are an investor and would like additional information about our investigation please complete the information request form or contact joshua lifshitz esq by telephone at 516 493 9780 or e mail at info jlclasslaw com catchmark timber trust inc nyse ctt lifshitz law pllc announces investigation into possible breach of fiduciary duties in connection with the sale of ctt to potlatchdeltic corp for 0 23 common shares of potlatchdeltic stock for each common share of ctt if you are an investor and would like additional information about our investigation please complete the information request form or contact joshua lifshitz esq by telephone at 516 493 9780 or e mail at info jlclasslaw com turning point therapeutics inc nasdaq tptx lifshitz law pllc announces investigation into possible breach of fiduciary duties in connection with the sale of tptx to bristol myers squibb for 76 00 per share is fair to turning point shareholders if you are an investor and would like information about our investigation please complete the information request form or contact joshua lifshitz esq by telephone at 516 493 9780 or e mail at info jlclasslaw com switch inc nyse swch lifshitz law pllc announces investigation into possible breach of fiduciary duties in connection with the sale of swch to digitalbridge group inc for 34 25 in cash per share of swch owned if you are an investor and would like additional information about our investigation please complete the information request form or contact joshua lifshitz esq by telephone at 516 493 9780 or e mail at info jlclasslaw com attorney advertising 2022 lifshitz law pllc the law firm responsible for this advertisement is lifshitz law pllc 1190 broadway hewlett new york 11557 tel 516 493 9780 prior results do not guarantee or predict a similar outcome with respect to any future matter contact
business combination anticipated to close on or about june 15 2022 ordinary shares of alvotech expected to trade under the new ticker symbol alvo from june 16 2022 on the nasdaq stock market in new york and from june 23 2022 on the nasdaq first north growth market in iceland warrants expected to trade on the nasdaq stock market in new york under the new ticker symbol alvow reykjavik iceland los angeles business wire alvotech holdings s a alvotech s a a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide and oaktree acquisition corp ii oacb nyse oacb a special purpose acquisition company sponsored by an affiliate of oaktree capital management l p oaktree announced today that their previously announced business combination between alvotech s a oacb and the legal entity named alvotech previously named alvotech lux holdings s a s with alvotech as the surviving entity the business combination was approved by oacb shareholders at an extraordinary general meeting the egm on june 7 2022 it is anticipated that the business combination will close on or about june 15 2022 subject to the satisfaction of all other applicable closing conditions the ordinary shares of alvotech are expected to trade under the new ticker symbol alvo on the nasdaq stock market in new york and the nasdaq first north growth market in reykjavik and the warrants of alvotech are expected to trade on the nasdaq stock market in new york under the new ticker symbol alvow this is an exciting time for the alvotech team our partners and everyone else demanding more affordable high quality biologic medicines said robert wessman founder and chairman of alvotech since our inception a decade ago we have dedicated ourselves to expanding patient access to life altering treatments alvotech is becoming a public company at a pivotal inflection point in the global healthcare industry a time when demand for increased affordability and accessibility has never been greater said zaid pardesi cfo head of m a of oaktree acquisition corp ii we are proud to partner with a company that is transforming the lives of patients and enhancing the sustainability of healthcare systems and look forward to continuing to work with the alvotech team in achieving their goal of becoming a leading supplier of biosimilar medicine in all major markets around the world about alvotech alvotech is a biotech company founded by robert wessman focused solely on the development and manufacture of biosimilar medicines for patients worldwide alvotech seeks to be a global leader in the biosimilar space by delivering high quality cost effective products and services enabled by a fully integrated approach and broad in house capabilities alvotech s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders eye disorders osteoporosis respiratory disease and cancer alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the u s europe japan china and other asian countries and large parts of south america africa and the middle east alvotech s commercial partners include teva pharmaceuticals a us affiliate of teva pharmaceutical industries ltd nyse and tase teva us stada arzneimittel ag eu and select other territories fuji pharma co ltd tse 4554 japan cipla cipla gulf cipla med pro nse cipla australia new zealand south africa africa jamp pharma corporation canada yangtze river pharmaceutical group co ltd china dksh swx dksh taiwan hong kong cambodia malaysia singapore indonesia india bangladesh and pakistan yas holding llc middle east and north africa abdi ibrahim turkey kamada ltd nasdaq and tase kmda israel mega labs stein libbs tuteur and saval latin america and lotus pharmaceuticals co ltd 1795 tt thailand vietnam philippines and south korea each commercial partnership covers a unique set of product s and territories except as specifically set forth therein alvotech disclaims responsibility for the content of periodic filings disclosures and other reports made available by its partners for more information please visit www alvotech com about oaktree acquisition corp ii the oaktree acquisition corp franchise was formed to partner with high quality growing companies to facilitate their successful entry to the public markets by leveraging the deep capabilities and experience of its sponsor an affiliate of oaktree which manages 164 billion in assets under management as of march 31 2022 oaktree acquisition corp seeks to provide best in class resources and execution coupled with a focus on long term partnership and shareholder value creation for more information about oaktree acquisition corp ii please visit www oaktreeacquisitioncorp com additional information in connection with the business combination oacb alvotech s a and the legal entity named alvotech previously named alvotech lux holdings s a s topco filed with the u s securities and exchange commission a registration statement on form f 4 as amended or supplemented through the date hereof the registration statement containing a proxy statement of oacb and a prospectus of topco this communication is not intended to form the basis of any investment decision investors and other interested persons are advised to read the registration statement and other documents filed in connection with the business combination as these materials contain important information about alvotech s a oacb the business combination and the combined company after the business combination shareholders of oacb can also obtain copies of the registration statement and other documents filed with the sec without charge at the sec s website at www sec gov or by directing a written request to oaktree acquisition corp ii 333 south grand avenue 28th floor los angeles california 90071 forward looking statements certain statements in this communication may be considered forward looking statements forward looking statements generally relate to future events or the future financial operating performance of oacb or alvotech for example alvotech s expectations regarding future growth results of operations performance future capital and other expenditures including the development of critical infrastructure for the global healthcare markets competitive advantages business prospects and opportunities including pipeline product development future plans and intentions results level of activities performance goals or achievements or other future events the timing of the announcement of clinical trial results the potential approval and commercial launch of it product candidates and the timing of the closing of the business combination and expected first day of trading of topco s securities on the nasdaq stock market llc and the nasdaq first north growth market in some cases you can identify forward looking statements by terminology such as may should expect intend will estimate anticipate believe predict potential or continue or the negatives of these terms or variations of them or similar terminology such forward looking statements are subject to risks uncertainties and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements these forward looking statements are based upon estimates and assumptions that while considered reasonable by oacb and its management and alvotech and its management as the case may be are inherently uncertain and are inherently subject to risks variability and contingencies many of which are beyond oacb s and alvotech s control factors that may cause actual results to differ materially from current expectations include but are not limited to 1 the occurrence of any event change or other circumstances that could give rise to the termination of negotiations and any subsequent definitive agreements with respect to the business combination 2 the outcome of any legal proceedings that may be instituted against oacb the combined company or others following this announcement of the business combination and any definitive agreements with respect thereto 3 the inability to complete the business combination due to the failure to satisfy conditions to closing 4 the inability to execute final agreement with respect to the loan facility with sculptor on acceptable terms or at all 5 the inability to consummate the transactions contemplated by the sepa 6 the ability to meet or maintain stock exchange listing standards following the consummation of the business combination 7 the risk that the business combination disrupts current plans and operations of alvotech 8 the ability to recognize the anticipated benefits of the business combination which may be affected by among other things competition the ability of the combined company to grow and manage growth profitably maintain key relationships and retain its management and key employees 9 costs related to the business combination 10 changes in applicable laws or regulations 11 the possibility that alvotech or the combined company may be adversely affected by other economic business and or competitive factors 12 alvotech s estimates of expenses and profitability 13 alvotech s ability to develop manufacture and commercialize the product candidates in its pipeline 14 actions of regulatory authorities which may affect the initiation timing and progress of clinical trials or future regulatory approvals or marketing authorizations 15 alvotech s ability to obtain and maintain regulatory approval or authorizations of its product candidates including the timing or likelihood of expansion into additional markets or geographies 16 the success of alvotech s current and future collaborations joint ventures partnerships or licensing arrangements 17 alvotech s ability and that of its commercial partners to execute their commercialization strategy for approved products 18 alvotech s ability to manufacture sufficient commercial supply of its approved products 19 the outcome of ongoing and future litigation regarding alvotech s products and product candidates 20 the potential impact of the ongoing covid 19 pandemic on the fda s review timelines including its ability to complete timely inspection of manufacturing sites and 21 other risks and uncertainties set forth in the section entitled risk factors and cautionary note regarding forward looking statements in oacb s annual report on form 10 k for the fiscal year ended december 31 2021 in the registration statement or in other documents filed by oacb with the sec there may be additional risks that neither oacb nor alvotech presently know or that oacb and alvotech currently believe are immaterial that could also cause actual results to differ from those contained in the forward looking statements nothing in this communication should be regarded as a representation by any person that the forward looking statements set forth herein will be achieved or that any of the contemplated results of such forward looking statements will be achieved you should not place undue reliance on forward looking statements which speak only as of the date they are made neither oacb nor alvotech undertakes any duty to update these forward looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication alvotech and oacb disclaim any and all liability for any loss or damage whether foreseeable or not suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed the recipient agrees that it shall not seek to sue or otherwise hold alvotech oacb or any of their respective directors officers employees affiliates agents advisors or representatives liable in any respect for the provision of this communication the information contained in this communication or the omission of any information from this communication no offer this communication is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities pursuant to the proposed transaction or otherwise nor shall there be any sale of any such securities in any state or jurisdiction in which such offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction no offer of securities shall be made except by means of a prospectus meeting the requirements of the securities act of 1933 as amended alvotech holdings s a investor relations stephanie carrington icr westwicke stephanie carrington westwicke com 646 277 1282 media relations sean leous icr westwicke sean leous westwicke com 646 866 4012 corporate communications alvotech media alvotech com oaktree acquisition corp ii investor relations info oaktreeacquisitioncorp com media relations mediainquiries oaktreecapital com
vrnt earnings call for the period ending march 31 2022 verint systems vrnt 3 04 q1 2023 earnings call 4 30 p m et contents prepared remarks questions and answers call participants prepared remarks operator hello thank you for standing by and welcome to the verint systems inc first quarter 2023 earnings conference call please be advised that today s conference may be recorded i would now like to hand the conference over to your speaker today matthew frankel investor relations and corporate development director matthew frankel investor relations thank you operator good afternoon and thank you for joining our conference call today i m here with dan bodner verint s ceo doug robinson verint s cfo and alan roden verint s chief corporate development officer before getting started i d like to mention that accompanying our call today is a webex slide if you d like to view these slides in real time during the call please use the ir section of our website at verint com click on the investor relations tab and click on the webcast link and select today s conference call i d also like to draw your attention to the fact that certain matters discussed on this call may contain forward looking statements within the meaning of the private securities litigation reform act of 1995 and other provisions of federal securities laws these forward looking statements are based on management s current expectations and are not guarantees of future performance actual results could differ materially from those expressed in or implied by these forward looking statements 10 stocks we like better than verint systems when our award winning analyst team has a stock tip it can pay to listen after all the newsletter they have run for over a decade motley fool stock advisor has tripled the market they just revealed what they believe are the ten best stocks for investors to buy right now and verint systems wasn t one of them that s right they think these 10 stocks are even better buys see the 10 stocks stock advisor returns as of june 2 2022 the forward looking statements are made as of the date of this call and as except as required by law verint s no obligation to update or revise them investors are cautioned not to place undue reliance on these forward looking statements for more detailed discussion on how these and other risks and uncertainties could cause verint s actual results to differ materially from those indicated in these forward looking statements please see our form 10 k for the fiscal year ended jan 31 2022 our form 10 q for the quarter ended april 30 2022 when filed and other filings we make with the sec the financial measures discussed today include non gaap measures as we believe investors focus on those measures in comparing results between periods and among our peer companies please see today s webex slides our earnings release and the investor relations section of our website of verint com for a reconciliation of non gaap financial measures to gaap measures non gaap financial information should not be considered in isolation from as a substitute for or superior to gaap financial information but is included because management believes it provides meaningful supplemental information regarding our operating results when assessing our business and is useful to investors for informational and comparative purposes the non gaap financial measures the company uses have limitations and may differ from those used by other companies now i d like to turn the call over to dan dan dan bodner chief executive officer thank you matt i m pleased to report strong cloud momentum in q1 with non gaap revenue and diluted earnings per share coming in ahead of our guidance in fact q1 was strong across all key metrics including new ple bookings growth and mix as the bookings continue to shift to saas looking ahead we expect strong cloud momentum and are raising our annual guidance to cloud revenue growth by 200 basis points to a range of 32 to 34 behind our strong momentum is our focus on helping brands close the engagement capacity gap with a highly differentiated customer engagement cloud platform we believe that closing the capacity gap has become more urgent for brands as a result of recent macroeconomic conditions including wage inflation challenges in hiring as well as post pandemic hybrid workforce dynamics on thursday this week we will hold our annual investor day and we will discuss this new workforce reality and dive deeper into our platform differentiation which helps brands reduce costs and elevate the customer experience today let s take a closer look at our q1 results including key cloud kpis our journey to the cloud continues to progress ahead of the plan that we outlined a little over a year ago at the time of the spin off of our security business let s take a closer look at our q1 cloud kpis first cloud revenue increased by 38 year over year driven by new logos customer expansions and strong cloud conversions second our booking mix continue to shift to the cloud with 58 of our new ple bookings coming from saas compared to 51 in q1 of the prior year the continued mix shift suggests strong market adoption for our cloud platform third new ple bookings increased 27 year over year a great start to the year and well ahead of our annual target of low double digit growth fourth we had 26 cloud orders in excess of 1 million tcv as the number of large enterprise customers shifting to the cloud continues to increase our 1 million cloud order included some of the more notable brands in the world such as wells fargo comcast marriott and zillow and finally during q1 we continued to win many new customers and added more than 100 new logos including eastman chemical kindercare education and sun jones university let s take a closer look at some of our competitive wins i would like to highlight three q1 wins the first order for 15 million was from a leading insurance company that expanded its relationship with us by consolidating applications for multiple vendors onto the verint cloud platform and also converted its perpetual licenses with very into the cloud verint was selected to help this customer close the engagement capacity gap we believe that this large order was due to our strong relationship differentiated ai capabilities and our ability to drive significant roi the second order for 3 million was for a customer in the healthcare industry that is expanding its relationship with us by replacing another vendor with additional solutions in the verint cloud platform we believe our open partnership strategy differentiated ai capabilities and platform scalability were key reasons we want this opportunity and the third win is a new logo for verint typically new logos start small and expand over time this win was relatively large for 2 million from a new customer in the banking industry the customer conducted a competitive process and we believe we were selected due to our leading ai capabilities and the open scalable architecture of our cloud platform behind these wins and our strong momentum is a cloud platform differentiation our investor day on thursday will focus on what makes our platform differentiated you will hear from multiple variant executives and we will cover the following topics recent market trends and the burnt opportunity to help brands close the engagement capacity gap our strategy to increase differentiation and deliver even more our eye to customers a cloud platform and a deep dive into da vinci ai and finally our financial model we think it will be a very informative session and hope that you can attend this event next week we will hold our annual engage customer conference which is also open for investors at engage we will unveil numerous innovations across the platform and i would like to briefly touch on two examples of our recent innovation to help brands close the engagement capacity gap the first one we call one workforce one workforce enables the entire customer engagement workforce across the enterprise to engage with customers in the right way at the right time by connecting workforce silos and automating business processes with one workforce we are helping people and bots work together as a unified workforce to increase efficiency and elevate customer sentiment the second one is very in da vinci ai which is at the core of the verint platform we are introducing very da vinci ai capabilities as api services this means our developer community consisting of customers and partners can now leverage verite to develop unique functionality with our cloud platform we are able to accelerate our pace of innovation which we will showcase at engage before concluding my prepared remarks i would like to briefly discuss our approach to guidance and investments in the current environment we are pleased with our strong start to the year with strength across all key cloud metrics we expect the cloud momentum to continue throughout the year and are pleased to be raising our annual outlook for cloud revenue growth behind our guidance is our strong start to the year combined with our cloud momentum and our recurring revenue visibility we plan to continue hiring and investing for the remainder of the year to support this growth guidance beyond this year we believe we are uniquely positioned to grow long term as we help brands close the engagement capacity gap and deliver strong roi now let me turn the call over to doug to discuss our financial results in more detail doug doug robinson chief financial officer yes thanks dan good afternoon everyone our discussion today will include non gaap financial measures a reconciliation between our gaap and non gaap financial measures is available as matt mentioned in our earnings release and in the ir section of our website differences between our gaap and non gaap financial measures include adjustments related to acquisitions including fair value revenue adjustments amortization of acquisition related intangibles certain other acquisition related expenses stock based compensation expenses separation related expenses accelerated lease costs as well as certain other items that can vary significantly in amount and frequency from period to period for certain metrics it also includes adjustments related to foreign exchange rates as dan mentioned our q1 results came in ahead of expectations revenue growth came in around 8 5 or 218 million on a gaap basis and 219 million on a non gaap basis non gaap diluted eps came in at 0 52 up 18 year over year we generated 54 million of cash from operations during the quarter up 43 year over year regarding our stock buyback i d like to mention that we completed our previously announced approximately 100 million buyback program repurchasing 2 million shares the maximum amount were permitted to repurchase this year due to the tax free nature of the spin off in q1 our cloud metrics came in strong across the board cloud revenue increased 38 year over year we saw strength in both customers buying new cloud solutions as well as maintenance customers converting to the cloud new ple bookings increased 27 year over year well above our 10 to 12 target for the year 58 of our new ple bookings came from saas compared to 51 in q1 last year as our customers continue to shift to the cloud and the percentage of our software revenue that was recurring came in at 83 in q1 turning to guidance for the current year ending january 31st 2023 let me start with three key metrics we re raising our cloud revenue guidance again we now expect cloud revenue growth of 32 to 34 up from our initial guidance of 30 we expect 940 million of revenue for the year reflecting 7 growth year over year at the midpoint of our guidance and we expect non gaap diluted eps of 2 50 reflecting 10 year over year growth at the midpoint of our revenue guidance i d also like to mention that while the dollar has been strengthening we ve been able to absorb this within our guidance now let me provide you with some additional information for modeling purposes for the year starting with bookings we expect double digit new ple bookings growth in the range of 10 to 12 with approximately 65 coming from saas with respect to perpetual revenue as we transition to the cloud we expect it to decline to around 120 million this year compared to 138 million last year and with respect to or approximately 250 million maintenance base we assume 15 to 20 will convert to the cloud this year relative to margins we see some modest growth margin and operating margin expansion for the full year additionally we expect our cash flow from operations to grow more than 20 this year last year cash flow from operations was 180 million excluding nonrecurring items and this year we expect more than 215 million on the same basis this should drive our cash balance to around 400 million at year end and a net debt position close to zero as a reminder we have 45 million of debt comprised of 350 million of convertible notes at a fixed 0 25 interest rate and a 100 million term loan which is our only floating interest rate exposure in a rising interest rate environment based on our current cash position we expect the incremental interest income from our cash balances will be more than the increased cost of our floating rate debt now let s discuss some below the line assumptions for the remainder of the year we expect around 1 5 million per quarter of interest and other expense we expect about 300 000 per quarter of net income from the noncontrolling interest we have in a small joint venture we expect an approximately 11 5 cash tax rate for each quarter and for the year and we expect around 76 million of fully diluted shares flat with last year reflecting the effect of our stock buyback program for modeling purposes in q2 we assumed 225 million of revenue and 0 52 of diluted eps our q2 outlook reflects a gradual increase in gross margin and operating expenses we believe that our q2 outlook combined with our strong q1 results give us a great start to the year looking beyond this year we believe we are well positioned for long term growth and at our investor day on thursday we ll discuss some of our assumptions our long term financial model let me give you a summary of what we ll discuss first we ll discuss our opportunity to gradually improve gross margins over time we ll review how we re targeting non gaap gross margins to reach the mid 70s this is driven by an increase in recurring revenue which in fiscal 22 carried a 76 gross margin compared to 50 for nonrecurring revenue we ll discuss our expectation that gross margins will increase modestly over the next few years and then increase faster as recurring revenue crosses 90 of total revenue and we ll also discuss cash flow from operations and why we expect strong cash flow generation over the next few years in summary we re pleased with our strong cloud momentum we re tracking ahead of our three year plan we laid out last year and we re raising our annual outlook for cloud revenue growth we expect total revenue growth to accelerate we expect our margins to gradually expand and we re generating strong cash flow and have a strong balance sheet most importantly we believe our cloud and ai differentiation positions us well for long term growth and with that operator let s open up the lines for questions questions answers operator thank you our first question comes from peter levin with evercore you may proceed peter burkly evercore isi analyst hi guys this is actually peter burkly on for peter levine thanks for taking the questions here you guys mentioned a couple of nice wins i think for an insurance company and a healthcare company so there might be actually some overlap here but just curious five9 on their last call highlighted that verint was a part of one of our largest deals to date with an insurance company so just curious specific to i wonder if you could share with us how long it took to close that deal whether you gave away any concessions with that and how many of those seats that you end up getting dan bodner chief executive officer ok sure regarding the five9 40 million in non scale so none of this was booked by verint in q1 so the numbers we reported do not include that deal and this is not the win that we discussed we expect to book this deal over time i m unable to discuss the specific scope and time line of the deal but i can say that this particular customer is already a variant customer and we did five9 win variant is expanding also the application relationship with the customer consolidating a number of different variant competitors into the verint platform peter burkly evercore isi analyst that s really helpful i appreciate that color maybe if i could just sneak in one more just given the stronger usd just curious how much of an impact fx is having on your guide and then maybe if you can just remind us how you price your contracts for customers outside the u s dan bodner chief executive officer yes so i ll start and doug if you want to give some more data but the guidance we gave today basically absorbs the fx changes that we saw in q1 so it reflects everything that we know today and we are predominantly doing business in u s dollars but we do have some exposure to revenue but also we have a hedge because where a lot of our resources are outside of the u s as well doug would you want to would you like to give more data on the mix the mix of our currencies doug robinson chief financial officer yeah sure about three quarters of our revenue is in u s dollars so that leaves a quarter in other currencies primarily euro pound to australian dollar are the big ones so as the dollar strengthened from a translation purposes it s going to hurt our top line and at current rates it s probably about close to 15 million of headwind which we ve absorbed it into our guidance from a currency perspective but as dan mentioned since we operate internationally we have a lot of expenses in those currencies as well so that 15 million of headwind translates to between 0 5 million and 1 million maybe of op income in the year if things were to play out at current rates so i think from an earnings perspective we re ok with respect to the foreign exchange movements but it just creates a little bit of a kind of a top line reporting headwind for us peter burkly evercore isi analyst that s helpful color thank you both dan bodner chief executive officer sure operator thank you our next question comes from samad samana with jefferies you may proceed samad samana jefferies analyst hi good evening it s good to see the solid results maybe first one just doug i think you mentioned in terms of the outlook for conversions being 15 to 20 can you maybe just help us understand how much visibility you have into that is that based on the company s efforts is that based on interest or indications from customers just how should we think about that range that you gave dan bodner chief executive officer yeah let me give the strategy for conversion and then you can give the numbers because i think it s important to understand how we drive conversions with our customer base so our strategy is to provide our customers the flexibility to move to the very cloud regardless of the conversion of the legacy solution so what does it mean it means basically that customers can buy new functionality that we have in the verint platform they can buy that in the cloud regardless of whether they want to maintain the legacy solutions on prem or they are ready to move their legacy solutions to the cloud so the architecture of the platform allows them to consumed a new functionality and obviously everyone is interested in moving up so they can consume new functionality already in cloud and when you look at our 38 growth in cloud revenue last year two thirds came from selling new functionality but also some of it to customers that didn t want to move to the cloud with their legacy and so a third came from customers actually are taking legacy solutions and moving them to be hosted by verint cloud and two thirds came from expansions new logos anything to do with innovation and not worried about whether the legacy is on prem doug anything you want to add doug robinson chief financial officer yes no i think you covered it i ll just say that through last year about 20 of our maintenance base had converted and this year we re kind of dialing in maybe another 15 or so in our numbers samad samana jefferies analyst yeah i mean i guess just the follow up again is that when you of the 15 that you re dialing up is that because the customers have like i guess why that number right are the customers indicating that they re willing to move or is that just kind of the estimate based on what you ve already seen doug robinson chief financial officer it s really based on dan bodner chief executive officer it s on discussions with customers that some of them are indicating that they re going to move this year some are looking for next year or even the year after so far customers have a multiyear strategy that is based on strategy that is bigger than what verint deliver what s their overall strategy to move to the cloud in phases so we are part of their strategy and we re able to kind of dial that into our outlook but you can see that for what doug said we have 65 of our new bookings will be in saas this year that s our projection 55 of our revenue will be in saas in cloud and only 35 will be as a result of conversion the 20 as doug mentioned we already have last year and the 15 we expect this year so that lagging the fact that customers don t really feel like they need to rush with variants because they re not dependent on the conversion in order to benefit from innovation we have the modules that they re buying the cloud and the modules they keep on prem are networked and they have all the integrations they need to run them as one platform so i guess in the way you would need to understand that our strategy is not to put pressure on customers to convert something that already works but to offer them innovation so they can move into the future with verint and obviously the future is more ai automation of business processes samad samana jefferies analyst great and then maybe just a follow up building on the prior analyst i know you guys talked about the guidance reflects what you re currently seeing but i m curious are you seeing any change in deal cycles or the number of people involved in approvals just anything in real time that reflects maybe the greater volatility that at least that we re hearing about in the world just curious what customer feedback is and what you re seeing dan bodner chief executive officer yeah i don t think we see any change at this point we saw more than 100 new logos also in q1 so there s clearly customers that are buying something that they need and it s very obviously new logos are competitive so we re able to win not any material change in terms of the buying pattern but clearly focus when it comes to our category which is business applications the focus has been and state is roi and that s how we sell and i want to remind you that we did talk i think it was a couple of quarters ago we had a forrester study on varying customers that they interviewed our customers and concluded that the roi was 391 and the payback was less than six months so we ve always been kind of focusing on our e driven sale process and i think now perhaps customers are even more focused on roi but it s not a major change from our perspective samad samana jefferies analyst great thanks for taking my questions operator thank you our next question comes from ryan macdonald with needham you may proceed ryan macdonald needham and company analyst hi thanks for taking my question dan i d be curious as you re looking at the environment currently you talked about expectation for 15 to 20 migration but when you talk to customers are you seeing a sort of a shift in demand or a preference for full migration given the current state of the market versus just a continuation of bolting on additional cloud applications onto their existing legacy infrastructure dan bodner chief executive officer i think what customers tell us that look what we have is working and as long as our data centers are not fully depreciated we don t have to invest in building a new data center this is not a priority we re not going to get tremendous some are sometimes when they move to the cloud with legacy just saving their it personnel and so on but there s not a bigger eye such as what they re looking to get from innovation so usually focus is we ve been disrupted the customers say look we ve been disrupted by digital there s clearly more interactions we can hire because the labor spend is huge and also it s hard to find people and train them and then there s attrition and remote and hybrid workforce dynamics so everything is kind of getting very challenging for our customers in managing this very large labor so they definitely want to increase automation by introducing more bots but then they defined that the bots are operating as a silo so they really need one workforce of people and bots working together so that s more automation in terms of the business processes to get knowledge shared between people and box and get in than automation so that when the bad gets stacked the person can take over and continue all these things we didn t have in our legacy solutions so for customers to benefit from all this innovation that we offer to the market today they know they have to go to the cloud because we don t offer it on prem we only offer the new innovation in saas but as long as we are able to connect what they have on prem with what they buy is new we take the pressure off i need a big project i need to disrupt myself and i have to move everything or else i can t move forward so this is a big plus especially for very large customers they want innovation but they also cannot afford to disrupt their operations and we allow them to do that in a more organized and planned way so it s been working well for us i don t know if there s going to be acceleration in conversion i don t see a reason because there s no pressure but we do see acceleration in cloud overall both in terms of booking in q1 we had tremendous 27 growth in new booking and shift to saas so clearly there is a strong demand for saas solutions but not necessarily take the legacy into saas with urgency ryan macdonald needham and company analyst that s really helpful color and then maybe as a follow up great to see another quarter of 100 new logos onto the platform can you talk about what modules are driving the continued strong new logo adoption and whether they weight toward sort of some of the wfo solutions versus the cx solutions thanks dan bodner chief executive officer yeah no that s very interesting and we are obviously monitoring that very carefully because what we see and we talk about it is the engagement capacity gap so let me just kind of quickly explain why the important to respond to your question the capacity gap is based on the fact that with the increase in the number of channels and the number of interactions and the complexity around the workforce clearly they need more capacity and the capacity can be either in terms of hiring people or in terms of buying new ai based solutions those are the two options that customers have if they don t increase capacity they re going to start to lose customers because of poor customer experience and very low customer sentiment so our cx portfolio is very much integrated with our wfe portfolio into one platform which means you have to continuously measure the customer experience because as you make changes in operation it affects the customer experience and you need to really in real time figure out what was the good changes and what were the bad changes and make adjustments and that s the only way you can introduce changes which will reduce costs but at the same time ensure that your customer experience stay high so both are very much together and we see new logos are very excited about our ability to connect the two things because as you know mostly we compete with port solutions that are not connected into one platform and there are solutions that measure customer experience and provide you a indication of customers plant were up or nps go went up but why is it going up why is it going down and how do you can effect change and how can you change things in real time in your workforce processes that s not connected to the workforce solutions so new logos are interested in that combination that we have in the platform because that s the best way to actually close the capacity gap which is reduced cost but also at the same time elevate the customer experience ryan macdonald needham and company analyst thanks for the color congrats again operator thank you our next question comes from tim horan with oppenheimer you may proceed tim horan oppenheimer and company analyst thanks guys two qualitative questions i know that you won t have definitive answers but can you just talk about the quality of the product and the ai and ability to implement ai and your customers i guess ability to take advantage of it now versus maybe where you were a year ago or two years ago like how much of an improvement have we seen and then secondly on the bookings front can you just characterize your overall demand environment i know the bookings are up really really strong but have you seen this type of growth before and maybe is that continuing into the quarter this quarter thank you dan bodner chief executive officer yeah so ai is clearly in our view the future of customer engagement when you think about the technology spend and customer engagement it s 65 billion a year that s a big number clearly customer engagement industry knowledge technology is critical but in addition to the 65 billion that spend on technology the industry is spending 2 trillion on labor so now when you think about that 97 of the investment is in labor and 3 is in technology and with incremental ai that can obviously reduce the 97 of cost that s a tremendous opportunity for the industry and that s why verint is very passionate about closing the capacity gaps and this is our very focused objective after the spin is really we are focusing on this one thing introducing an ai powered platform to help customers close this gap and not have to deal with the 97 of the cost keep increasing because industry the industry needs to hire more people so that s the role of ai and why it s important now what s the state of ai i think that what many brands are trying to do now is to deploy in a very poor way and it s not to blame the ai it s really how it s deployed and how it s connected or not connected to the rest of the workforce because i cannot be a silo my own personal experience i tried to call vendor and i got a bot and the bot asked me 20 different questions which i answered very patiently and then bot got stuck so i try to ask for an agent which i didn t get and after several attempts to bot basically responded this service is now available in this channel which means that the bot doesn t even want to acknowledge that they are not able to respond and connect me to a person that s not a good implementation of ai the bot may be as smart as they wanted to bought to be but i will need to call an agent and i will need to answer the same to any questions again which will be a waste of time and definitely a source of frustration so the real issue with ai cannot be deployed in silos and what we did with the platform and i mentioned that as one workforce and we ll go through more details obviously on thursday in our investor day and also during the engage next week a customer conference and introduce what is one workforce how we actually break down the silos and create a unified workforce which is a huge source for increased capacity flexibility and agility and that s the correct way to implement ai which is to infuse ai through the business processes to automate business processes and companies need to really focus on this as customer engagement specific ai it s not a generic ai that can be implemented in finance in hr rpa type of solution because the customer engagement industry have very unique processes that need to be automated and we re able to do that by putting da vinci which is our ai engine at the core of the platform so we can infuse their eyes through every application that we sell and customers can actually benefit from ai not just when they implement the bot but in every business process when they schedule when they hire when they do quality monitoring any of the business processes needs to be infused with ai and that s what they have in the verint platform tim horan oppenheimer and company analyst great i m looking forward to thursday and this just qualitatively on the overall demand environment dan bodner chief executive officer so at this point we definitely are looking and monitoring the macro environment to see if there is an impact on the customer engagement industry we haven t seen any impact that we can report at this point we as variant we live through recessions before we definitely have the experience how to manage the company recession we know we have very sticky software so renewal rates are pretty high during recessions and customers continue to focus on roi and sometimes even more so we definitely already are very focused on roi and using ai to automate but we haven t seen any signs other than what does reported is fx moved in q1 but we absorbed that into our guidance and our guidance reflecting the current spot rates we haven t seen anything that we can report today tim horan oppenheimer and company analyst very helpful thank you operator thank you our next question comes from brian essex with goldman sachs you may proceed unknown speaker this is on for brian i was hoping you can talk about spending patterns across your verticals what are where are you seeing the most traction thanks dan bodner chief executive officer so we don t have a vertical strategy but because we have the leading vendors in almost in every vertical that has customer service we have developed over time all kind of specific offering for verticals so just to recap for everyone verint has 10 of the top 10 banks as customers nine of the top 10 insurance companies with customers eight of the top healthcare companies as our customers and so on in retail and so we are the leaders in each vertical and the reason why this is important to your question is a lot of the ais to my previous ai discussion ai is as good as the data that you have to develop the ai models and we have been working with these customers for two decades and have been enjoying we have access to that data and developing ai models and those animals are perfected ongoing in our cloud as we get more data and new data we have machine learning that learn those patterns and improve the ai and what we noticed is that in different verticals there is some differences in ai sorry in the data that drives different ai models so and that s interesting because you would think that customer service is customer service it doesn t really matter which industry but in each industry there are nuances there is some difference in language models in terminology and sometimes in service offering so we are able working with the leading companies in each industry and using that data we re able to continuously refine our offering to the different industries unknown speaker great thanks and then have you seen any impact from wage inflation are people looking to you all to try to bridge that capacity gap or do you think it s more a future capacity gap that you could ultimately fell dan bodner chief executive officer yes our customers really are struggling now with wage inflation combined with high attrition difficulty to hire they really are looking for hiring tools and we introduced last quarter a new hiring ai based hiring tools to improve the hiring process and also people working from home in the new hybrid environment and they need coaching they need real time assistance at home so there s a lot of changes that the pandemic and now the wage inflation combined are causing to our customers wage inflation is one of them and that s what causing people to want to deploy more bits right because they feel like they can deal with the growth in interaction by hiring more people it s expensive and it s hard so bots are really very much in favor but as i mentioned before as some of our customers deploy many boss they start to see that they are working in silos and now they re looking for tools to connect the bottom people into one workforce unknown speaker great thank you so much operator thank you and i m not showing any further questions at this time i would now like to turn the call back over to matthew frankel for any closing remarks matthew frankel investor relations thank you operator and thank you to everyone for joining us today as a reminder we ll hold our virtual investor day on thursday and then next week on the 14th we invite you to come down to orlando florida for our ngh conference for more information on that please feel free to reach out to me and i ll get to the information you need thanks again for joining us and have a good night operator duration 45 minutes call participants matthew frankel investor relations dan bodner chief executive officer doug robinson chief financial officer peter burkly evercore isi analyst samad samana jefferies analyst ryan macdonald needham and company analyst tim horan oppenheimer and company analyst unknown speaker more vrnt analysis all earnings call transcripts
nimbleness and adaptability are needed to be able to scale production up quickly within the dynamic aerospace and defense sectors changes to part specifications and quantities are frequent and often unpredictable as a result clients require a machining partner who can nimbly and quickly adapt to design and production changes as they occur and be capable to scale up to lights out manufacturing when needed aerospace and defense customers may prefer large machining operations said tony doan ceo of halcyon manufacturing an advanced itar registered and as 9100 is 9001 certified machining shop based in san jose california but size alone does not equate to capacity smaller shops can have an advantage when a client needs a machining partner to also be nimble and flexible for our clients the ability to adapt and problem solve is incredibly important as complex manufacturing requirements frequently evolve and change aerospace machining involves a lot of low volume high mix work the reality is not every machine shop wants to take on small orders or highly complex jobs a client needs a machining partner who really embraces this kind of work in addition to the high volume orders when evaluating the capacity of a precision machine shop the capability to respond to changes in specifications and production quickly becomes a key factor nowhere is this more acute than when an aerospace client has a priority aircraft on the ground aog machining order until the aog gets filled an aircraft will not be able to operate making response time incredibly important unfortunately an aog order is never predictable and can happen at any time halcyon manufacturing building capacity through cross training staff cross training is one way a machine shop can improve their ability to respond to unexpected and time sensitive machining needs such as aogs while today s machine shops are filled with a mix of high tech precision cnc equipment each requires trained staff to manage maintain and operate a lot of aerospace machine shops will assign an operator to a specific cnc machine said doan this can create a situation where a particular operator has to be available and not working on other orders to operate a given machine having the ability to move people from machine to machine as well as from line to line and from shift to shift without interruption enables a machine shop to respond to changes in demand more quickly at halcyon where they machine bar grade 6061 aluminum brass copper titanium stainless steel and plastics they have cross trained their entire staff to work across all their equipment to maximize their capability for scale up we have not only cross trained our team but we all work multiple shifts and we have the same controls throughout our shop said doan it makes it easy for our people to be able to move around as needed so when a client needs something over a weekend we don t have to completely rethink how we re going to schedule we can easily plug in people for surge hours or to increase our manpower as needed the company made the decision to further enhance their cross training through their selection of machining equipment unlike shops that purchase a variety of types and brands of cnc equipment over time halcyon intentionally purchases the same model of high end 5 axis cnc machine from doosan machine tools with fanuc controls as they expand this further reduces the learning curve for their staff halcyon manufacturing lights out manufacturing capability nimbleness and adaptability are also needed to be able to scale production up quickly some machine shops such as halcyon operate on a 24 7 basis enabling customers to connect with them outside of traditional office hours lights out manufacturing takes scaling up production to the next level said doan cnc operators can set up the equipment to run on its own without supervision overnight this lights out capability means smaller shops can maximize their capacity without adding more staff it starts with culture the mindset that a machining partner brings to precision aerospace machining is also critically important it starts with the culture of the shop and the problem solving mindset they bring to a project particularly for complex precision parts explained doan you also need a machining partner to be proactive by engaging early in the process an aerospace machine shop can anticipate and resolve machining issues before any parts are produced in a recent example halcyon had a customer bring them what appeared to be a simple part but could not find a machine shop that wanted to take the job the part had a 6 threaded shaft with a hex head there was an 832 thread across the outside diameter od of the shaft most lathes aren t able to cut those threads across six inches said doan we had to get creative since we could not use round stock which is generally used when cutting od threads the team determined how to form the threads while accounting for the growth that occurs when threads are formed on plate steel to meet the tight requirements for it to run on a cnc machine they also had to create a modified thread using a cut die to create a formed thread we took the challenge on and were able to meet the client s deadlines with parts that met spec when no one else could do it said doan it takes more than the equipment and know how it also means really having an appetite to take on these kinds of complex challenges nimbleness and adaptability in precision machining represents a key consideration for aerospace clients as they seek partners to provide solutions to their complex design problems and production scale up needs through cross training lights out manufacturing and a problem solving proactive mindset smaller machine shops are well equipped to meet the demand halcyonmfg com
new york june 07 2022 globe newswire cynergistek inc nyse ctek lifshitz law pllc announces investigation into possible breach of fiduciary duties in connection with the sale of ctek to clearwater compliance llc for 1 25 per share in cash if you are an investor and would like information about our investigation please complete the information request form or contact joshua lifshitz esq by telephone at 516 493 9780 or e mail at info jlclasslaw com mantech international corporation nasdaqgs mant lifshitz law pllc announces investigation into possible breach of fiduciary duties in connection with the sale of mant to a private equity consortium led by the carlyle group inc for 96 00 in cash per share of mant owned if you are an investor and would like information about our investigation please complete the information request form or contact joshua lifshitz esq by telephone at 516 493 9780 or e mail at info jlclasslaw com entasis therapeutics holdings inc nasdaq ettx lifshitz law pllc announces investigation into possible breach of fiduciary duties in connection with the sale of ettx to innoviva inc for 2 20 per share in cash if you are an investor and would like information about our investigation please complete the information request form or contact joshua lifshitz esq by telephone at 516 493 9780 or e mail at info jlclasslaw com vmware inc nyse vmw lifshitz law pllc announces investigation into possible breach of fiduciary duties in connection with the sale of vmw to broadcom inc under the terms of the proposed transaction shareholders of vmw will elect to receive either 142 50 in cash or 0 2520 shares of broadcom common stock for each share of vmw they own if you are an investor and would like additional information about our investigation please complete the information request form or contact joshua lifshitz esq by telephone at 516 493 9780 or e mail at info jlclasslaw com attorney advertising 2022 lifshitz law pllc the law firm responsible for this advertisement is lifshitz law pllc 1190 broadway hewlett new york 11557 tel 516 493 9780 prior results do not guarantee or predict a similar outcome with respect to any future matter contact
new york june 07 2022 globe newswire hemisphere media group inc nasdaq hmtv lifshitz law pllc announces investigation into possible breach of fiduciary duties in connection with the sale of hmtv to a subsidiary of gato investments lp for 7 00 in cash per share of hmtv owned if you are an investor and would like additional information about our investigation please complete the information request form or contact joshua lifshitz esq by telephone at 516 493 9780 or e mail at info jlclasslaw com pcsb financial corporation pcsb lifshitz law pllc announces investigation into possible breach of fiduciary duties in connection with the sale of pcsb to brookline bancorp inc brookline for either 22 00 in cash consideration or 1 3284 shares of brookline common stock subject to allocation procedures to ensure that 60 of the outstanding shares of pcsb common stock will be converted to brookline common stock if you are an investor and would like additional information about our investigation please complete the information request form or contact joshua lifshitz esq by telephone at 516 493 9780 or e mail at info jlclasslaw com servicesource international inc nasdaq srev lifshitz law pllc announces investigation into possible breach of fiduciary duties in connection with the sail of srev to concentrix corporation for 1 50 in cash per share of srev owned if you are an investor and would like information about our investigation please complete the information request form or contact joshua lifshitz esq by telephone at 516 493 9780 or e mail at info jlclasslaw com terminix global holdings inc nyse tmx lifshitz law pllc announces investigation into possible breach of fiduciary duties in connection with the sale of tmx to rentokil initial plc if you are an investor and would like information about our investigation please complete the information request form or contact joshua lifshitz esq by telephone at 516 493 9780 or e mail at info jlclasslaw com attorney advertising 2022 lifshitz law pllc the law firm responsible for this advertisement is lifshitz law pllc 1190 broadway hewlett new york 11557 tel 516 493 9780 prior results do not guarantee or predict a similar outcome with respect to any future matter contact
the governor s office says it is considering portland s request that it form a task force on homelessness but also is thinking about whether existing state agencies could play a greater role in addressing the issue the portland city council on monday unanimously approved a resolution calling for the creation of a task force to look at ways to respond to homelessness which the council hopes might include changes to general assistance law and the creation of a state resettlement office and statewide shelter system the governor is committed to addressing emergency housing needs in maine and the administration has engaged with the city of portland other municipalities the legislature maine s congressional delegation and community based organizations consistently over the past several months to that end lindsay crete a spokesperson for mills said in an email with respect to the portland city council s resolution the administration is considering its request and is evaluating whether existing entities like the statewide homeless council and built for zero initiative can be further empowered to serve as the appropriate venue to address the broader problem of homelessness in maine crete said the statewide homeless council is an advisory committee whose members include appointees of the governor state officials and appointees chosen jointly by the president of the maine senate and the speaker of the house its job is to coordinate information assess statewide needs and provide leadership on ways to end homelessness built for zero is a national initiative that is working to end homelessness through the nonprofit community solutions maine first got involved in the program about a year ago and in february announced contracts for nine service hub coordinators to engage with local officials and coordinate homelessness services in nine geographic areas of the state advertisement portland mayor kate snyder said tuesday that while there already are state efforts to address homelessness and increase housing stock the city s resolution is also focused on the unique and immediate crisis of an influx of asylum seekers it s sort of a new factor and not something we were thinking about a year ago at this time snyder said in her email crete listed other efforts the administration has undertaken in recent months to address emergency housing needs such as including 22 million in the governor s supplemental budget to address homelessness in part by providing rental assistance or appropriate housing for people staying in hotels and making 750 000 in grant funding available for wraparound services the governor also worked with the congressional delegation to secure 100 percent reimbursement from the federal government for eligible general assistance expenses including housing during the covid 19 pandemic crete said adding that after july 1 municipalities will still be reimbursed 90 percent of their eligible costs indefinitely the state also has made 10 million available to municipalities and tribes to help them offset potential reductions in federal financial support crete said mills has instructed greg payne her senior housing adviser and the maine department of health and human services to work closely with community leaders to help individuals and families struggling with housing and services on behalf of the administration greg has led a coordinated effort to locate and finance emergency housing for people experiencing homelessness including those seeking asylum crete said this work remains ongoing send questions comments to the editors previous next filed under
shares in asia pacific were higher on wednesday with hong kong leading gains regionally the reserve bank of india will raise the policy repo rate by 50 basis points to 4 9 with immediate effect governor shaktikanta das announced wednesday the repo rate refers to the rate at which the central bank lends to commercial banks japan s economy shrank an annualized 0 5 in the first quarter revised government data showed wednesday an improvement over the initial estimate of a 1 contraction singapore shares in asia pacific were higher on wednesday with hong kong leading gains regionally the hang seng index in hong kong jumped 2 24 to close at 22 014 59 as chinese tech stocks listed in the city soared alibaba surged 10 12 while tencent climbed 6 47 and netease gained 5 66 the shanghai composite in mainland china closed 0 68 higher at 3 263 79 while the shenzhen component climbed 0 818 to 12 033 26 get connecticut local news weather forecasts and entertainment stories to your inbox sign up for nbc connecticut newsletters rbi announces rate hike the reserve bank of india on wednesday raised a key interest rate the rbi will raise the policy repo rate by 50 basis points to 4 9 with immediate effect governor shaktikanta das said the repo rate refers to the rate at which the central bank lends to commercial banks economists in a reuters poll had predicted a rate hike of between 25 to 75 basis points it may be noted in this context that the repo rate still remains below its pre pandemic level the indian central bank chief said following the announcement both the nifty 50 and bse sensex in india rose close to 0 4 each as of 1 44 p m local time the indian rupee traded at 77 763 per dollar weaker as compared with levels below 77 4 seen against the greenback last week the rbi s decision comes after the reserve bank of australia s surprise 50 basis point rate hike on tuesday in other markets the nikkei 225 in japan advanced 1 04 to close at 28 234 29 while the topix index climbed 1 18 to 1 969 98 japan s economy shrank an annualized 0 5 in the first quarter revised government data showed wednesday an improvement over the initial estimate of a 1 contraction south korea s kospi closed little changed at 2 626 15 the s p asx 200 in australia rose 0 36 to finish the trading day at 7 121 10 msci s broadest index of asia pacific shares outside japan gained 1 13 the world bank on tuesday cut its global growth forecast to 2 9 for 2022 and warned of the world economy slipping into a period of stagflation reminiscent of the 1970s these sort of headlines around risk of stagflation slower growth these are things the market has been you know trading on for most of the year already kieran calder head of equity research for asia at ubp told cnbc s street signs asia on wednesday calder described the world bank s expectation for 4 3 growth in 2022 for china as pretty aggressive given that multiple banks have cut their outlook for the country ubp is looking for below 4 gdp growth in china this year he said currencies and oil the u s dollar index which tracks the greenback against a basket of its peers was at 102 619 after seeing an earlier low of 102 387 the japanese yen traded at 133 62 per dollar weaker than levels below 132 seen against the dollar yesterday the australian dollar was at 0 7189 off an earlier high of 0 7235 oil prices were higher in the afternoon of asia trading hours with international benchmark brent crude futures up 0 39 to 121 04 per barrel u s crude futures gained 0 55 to 120 07 per barrel
shares in asia pacific were higher on wednesday with hong kong leading gains regionally the reserve bank of india will raise the policy repo rate by 50 basis points to 4 9 with immediate effect governor shaktikanta das announced wednesday the repo rate refers to the rate at which the central bank lends to commercial banks japan s economy shrank an annualized 0 5 in the first quarter revised government data showed wednesday an improvement over the initial estimate of a 1 contraction singapore shares in asia pacific were higher on wednesday with hong kong leading gains regionally the hang seng index in hong kong jumped 2 24 to close at 22 014 59 as chinese tech stocks listed in the city soared alibaba surged 10 12 while tencent climbed 6 47 and netease gained 5 66 the shanghai composite in mainland china closed 0 68 higher at 3 263 79 while the shenzhen component climbed 0 818 to 12 033 26 get san diego local news weather forecasts sports and lifestyle stories to your inbox sign up for nbc san diego newsletters rbi announces rate hike the reserve bank of india on wednesday raised a key interest rate the rbi will raise the policy repo rate by 50 basis points to 4 9 with immediate effect governor shaktikanta das said the repo rate refers to the rate at which the central bank lends to commercial banks economists in a reuters poll had predicted a rate hike of between 25 to 75 basis points it may be noted in this context that the repo rate still remains below its pre pandemic level the indian central bank chief said following the announcement both the nifty 50 and bse sensex in india rose close to 0 4 each as of 1 44 p m local time the indian rupee traded at 77 763 per dollar weaker as compared with levels below 77 4 seen against the greenback last week the rbi s decision comes after the reserve bank of australia s surprise 50 basis point rate hike on tuesday in other markets the nikkei 225 in japan advanced 1 04 to close at 28 234 29 while the topix index climbed 1 18 to 1 969 98 japan s economy shrank an annualized 0 5 in the first quarter revised government data showed wednesday an improvement over the initial estimate of a 1 contraction south korea s kospi closed little changed at 2 626 15 the s p asx 200 in australia rose 0 36 to finish the trading day at 7 121 10 msci s broadest index of asia pacific shares outside japan gained 1 13 the world bank on tuesday cut its global growth forecast to 2 9 for 2022 and warned of the world economy slipping into a period of stagflation reminiscent of the 1970s these sort of headlines around risk of stagflation slower growth these are things the market has been you know trading on for most of the year already kieran calder head of equity research for asia at ubp told cnbc s street signs asia on wednesday calder described the world bank s expectation for 4 3 growth in 2022 for china as pretty aggressive given that multiple banks have cut their outlook for the country ubp is looking for below 4 gdp growth in china this year he said currencies and oil the u s dollar index which tracks the greenback against a basket of its peers was at 102 619 after seeing an earlier low of 102 387 the japanese yen traded at 133 62 per dollar weaker than levels below 132 seen against the dollar yesterday the australian dollar was at 0 7189 off an earlier high of 0 7235 oil prices were higher in the afternoon of asia trading hours with international benchmark brent crude futures up 0 39 to 121 04 per barrel u s crude futures gained 0 55 to 120 07 per barrel
this morning sucked it sucked because of montana s labor shortage it sucked because i was put in an awkward position as a customer but it wasn t anyone s fault to be very clear my words and frustration stated here are not at all directed to the nice young man who was working alone the entire front register area today he was assisting several people at once who were using the self check out island which i m sure is no easy task i went grocery shopping at 10am on a tuesday thinking it was an ideal time seriously these days we have to think about when and how we shop for things is the store likely to be staffed am i avoiding peak hours well apparently i was wrong about it being an ideal time not that it matters but i shop at various stores depending on where in town i am how much stuff i need and who has decent sales i try to plan my shopping trips to save time and money because frankly i despise grocery shopping and always have i had a list felt organized and didn t need to do a search and destroy but i did need a full small cart of groceries by the time i was ready to check out that small cart was packed and it ended up being about 200 worth of stuff and my receipt says i purchased 41 items grocery cart michelle wolfe so i m ready to check out with my 41 items some of which are manager s special meat packages that have a special coupon on them and i know they require a checker to scan the discount there are no actual check out lines open only the small self check out islands me hi there i need to get checked out with a cart full hi there i need to get checked out with a cart full guy we don t have anybody right now we don t have anybody right now me glancing at cart full of items so what am i supposed to do i have a bunch of stuff glancing at cart full of items so what am i supposed to do i have a bunch of stuff guy just use one of the self check outs just use one of the self check outs me awkwardly smiling are you joking awkwardly smiling are you joking guy no sorry it s just me here until 11 no sorry it s just me here until 11 me awkwardly still smiling and silently getting super pissed off that i have to deal with an entire cartload of groceries by myself okee dokie in this day and age of staffing shortages everywhere i do not mind being super patient i don t mind waiting in line i don t mind things being out of stock i don t mind self service for that matter as long as i m prepared for it had i known they didn t have any check out staff i wouldn t have bought so many items obviously i m not a complete idiot i know how to use the self check out kiosks but i didn t expect to be forced into using one with a stupid number of items phot michelle wolfe did i get it done yes was the young guy super helpful when i needed him to scan a few special discounted items yes did i make a disaster area out of my check out space yes did the machine beep and chirp at me incessantly about where i put my loaded bags yes did i feel like kind of an a hole yes but i assure you by the time i was done there were far more bags on the floor waiting for me to load them back into my cart somehow i felt like the problem that sucks as a customer and i can only imagine how that must feel for a manager of a store desperately trying to hire minimal staff to keep the doors open we all wish we had a magic wand to help ease the staffing shortages that are affecting so many businesses i don t have a solution to offer but i do offer my sympathy to the young guy busting his ass at the grocery store today he did his best as did i first world problem perhaps but it was weird awkward and inconvenient for all parties involved
it s that time again mad money host jim cramer rings the lightning round bell which means he s giving his answers to callers stock questions at rapid speed blackline inc they re losing money we can just not go with it enbridge inc that is exactly what you should be buying axogen inc it s a medical device and i think you have to stick with tried and true johnson johnson get connecticut local news weather forecasts and entertainment stories to your inbox sign up for nbc connecticut newsletters metlife inc i m going to have to say yes to that even as i m not a great fan of the insurers that is too cheap a stock bridge investment group holdings we don t really know what they do pass because there s too much room for error farfetch ltd i say buy target down here disclosure cramer s charitable trust owns shares of johnson johnson sign up now for the cnbc investing club to follow jim cramer s every move in the market disclaimer questions for cramer call cramer 1 800 743 cnbc want to take a deep dive into cramer s world hit him up mad money twitter jim cramer twitter facebook instagram questions comments suggestions for the mad money website madcap cnbc com
new york june 07 2022 globe newswire pomerantz llp is investigating claims on behalf of investors of verrica pharmaceuticals inc verrica or the company nasdaq vrca such investors are advised to contact robert s willoughby at newaction pomlaw com or 888 476 6529 ext 7980 the investigation concerns whether verrica and certain of its officers and or directors have engaged in securities fraud or other unlawful business practices in december 2020 verrica submitted its new drug application nda to the u s food and drug administration fda seeking regulatory approval of vp 102 for the treatment of molluscum then on september 20 2021 after the market closed verrica announced receipt of a complete response letter crl due to deficiencies at a facility of verrica s contract manufacturer in connection with the company s nda on this news the company s stock price fell 1 00 per share or 8 3 to close at 11 03 per share on september 21 2021 in november 2021 verrica resubmitted the nda for vp 102 claiming he resubmission addresses the successful resolution of inspection deficiencies at the manufacturing facility finally on may 24 2022 after the market closed verrica announced receipt of another complete response letter regarding the vp 102 nda citing deficiencies identified during a general reinspection of sterling pharmaceuticals services llc sterling the contract manufacturing organization cmo that manufacture s verrica s bulk solution drug product on this news verrica s stock price fell 3 55 per share or 63 8 to close at 2 01 per share on may 25 2022 pomerantz llp with offices in new york chicago los angeles paris and tel aviv is acknowledged as one of the premier firms in the areas of corporate securities and antitrust class litigation founded by the late abraham l pomerantz known as the dean of the class action bar pomerantz pioneered the field of securities class actions today more than 85 years later pomerantz continues in the tradition he established fighting for the rights of the victims of securities fraud breaches of fiduciary duty and corporate misconduct the firm has recovered numerous multimillion dollar damages awards on behalf of class members see www pomlaw com
stocks fell on wednesday as investors monitored signs of a potential economic slowdown and kept an eye on the bond market the dow jones industrial average shed 269 24 points or 0 81 to close at 32 910 90 the s p 500 slid 1 08 to finish at 4 115 77 while nasdaq composite dropped 0 73 to 12 086 27 the moves came as investors weighed updates from major companies and signs that economic growth may be slowing get connecticut local news weather forecasts and entertainment stories to your inbox sign up for nbc connecticut newsletters the u s traded shares of credit suisse fell 1 after the bank issued a profit warning for the second quarter citing tighter monetary policy and the war in ukraine intel dropped more than 5 after management warned of weakening demand for semiconductors at an industry conference meanwhile the atlanta federal reserve s gdpnow tracker shows a growth rate of just 0 9 for the second quarter down from 1 3 last week mortgage demand hit its lowest level in 22 years last week according to the mortgage bankers association deutsche bank chief u s economist matthew luzzetti who previously called for a recession by the end of 2023 said in a note to clients on wednesday that the odds for a recession are likely to rise in the coming months our main conclusion is that forward looking recession probabilities are likely to look far more sinister later this year as financial conditions tighten luzzetti wrote as the fed continues to tighten monetary conditions the concerns about economic growth and corporate earnings could have a bigger impact on stocks allianz chief economic advisor mohamed el erian said on cnbc s squawk box the markets have been taking this news much better than they would have otherwise but if i were fully invested right now i d take some chips off the table i would wait for more value to be created el erian said action in the bond market may have hurt investor sentiment on wednesday as the 10 year treasury yield jumped back above 3 the price of oil also rose with u s benchmark west texas intermediate crude pushing well above 120 per barrel energy was a bright spot for the market as the sector closed at its highest level since august 2014 chinese tech stocks provided some support to the nasdaq with the u s traded shares of jd com and pinduoduo rising about 7 7 and 9 7 respectively elsewhere shares of robinhood fell 3 9 after securities and exchange commission chair gary gensler detailed potential rule changes around trade execution such as possibly requiring retail orders to be routed into auctions moderna rose nearly 2 2 after its modified covid 19 booster shot showed a stronger response to new variants on the earnings front campbell soup moved higher by about 1 5 after a stronger than expected quarterly report investors are looking toward friday s consumer price index reading for may many believe the print will be crucial for the path of fed policy and whether the central bank will keep raising rates in half point increments we believe equity markets would likely rally at any hint of a pause in the expected rate hike cycle positive consumer data could also help relieve some growth fears but in some circumstances could also further concerns that the fed needs to get more aggressive to cool demand wells fargo strategist scott wren said in a note to clients stock market rallies at this point will likely see headwinds and not meaningful follow through until there are clear signs the fed is succeeding in controlling inflation wren added the stock market has had a roller coaster year as the fed s aggressive rate hikes stoked recession fears the s p 500 is off about 14 from its all time high reached in january the equity benchmark briefly dipped into bear market territory on an intraday basis last month the tech heavy nasdaq meanwhile is down roughly 25 from its record high lea la cobertura del mercado de hoy en espaol aqu
rttnews the malaysia stock market has moved lower in four straight sessions sinking more than 40 points or 2 8 percent along the way the kuala lumpur composite index now rests just above the 1 525 point plateau although it s due for support on wednesday the global forecast for the asian markets is mixed to higher with support expected from the oil and technology sectors the european markets were down and the u s bourses were up and the asian markets figure to follow the latter lead the klci finished modestly lower on tuesday as losses from the financials telecoms and plantations were mitigated by support from the glove makers for the day the index shed down 11 90 points or 0 77 percent to finish at 1 525 93 after trading between 1 525 93 and 1 541 43 volume was 2 619 billion shares worth 1 776 billion ringgit there were 592 decliners and 365 gainers among the actives axiata skidded 0 95 percent while cimb group dropped 0 78 percent dialog group plunged 3 40 percent digi com slumped 1 20 percent genting gained 0 77 percent genting malaysia added 0 33 percent hartalega holdings advanced 1 27 percent inari tumbled 2 11 percent ioi corporation sank 0 71 percent kuala lumpur kepong surrendered 2 08 percent maybank lost 0 45 percent maxis shed 0 56 percent misc spiked 2 08 percent petronas chemicals stumbled 1 30 percent ppb group jumped 1 47 percent press metal tanked 3 36 percent public bank retreated 1 31 percent rhb capital and tenaga nasional both fell 0 34 percent sime darby climbed 1 35 percent sime darby plantations plummeted 4 28 percent telekom malaysia declined 1 32 percent top glove improved 0 81 percent and ihh healthcare mrdiy and hong leong financial were unchanged the lead from wall street is upbeat as the major averages shook off a lower open on tuesday picking up steam as the session progressed to end firmly in the green the dow jumped 264 36 points or 0 80 percent to finish at 33 180 14 while the nasdaq spiked 113 86 points or 0 94 percent to end at 12 175 23 and the s p 500 gained 39 25 points or 0 95 percent to close at 4 160 68 worries about slowing growth a weak margin guidance from target and a sell off in the technology space contributed to wall street s weakness in early trades however top technology stocks soon recovered and the broad market too started climbing higher as well in u s economic news the commerce department said the u s trade deficit narrowed significantly in the month of april to 87 1 billion in april from 107 7 billion in march crude oil prices climbed higher on tuesday as prospects of increased demand from china and supply concerns outweighed concerns about growth west texas intermediate crude oil futures for july ended higher by 0 91 or 0 8 percent at 119 41 a barrel
washington ap state officials across the nation have taken on big tech companies in the courts and state legislatures and federal regulators have nipped at twitter over alleged violations of users data privacy now one state attorney general with an outsize personality and edge skating stance nearly in the league of elon musk is striding into the maelstrom of musk s 44 billion now tenuous bid for twitter he is launching an investigation of twitter for potential false reporting of bots on its platform to bolster complaints musk himself made this week in threatening to walk away from the deal texas attorney general ken paxton announced his investigation of twitter on monday just hours after musk the billionaire tesla and spacex ceo accused twitter of refusing to disclose the extent of its spam bot and fake accounts the unexpected turn in the months long drama of musk and twitter sent that company s shares down 1 5 likely angering shareholders who had filed suit against musk last month accusing him of deflating the stock price twitter s shares have tumbled more than 20 in the last month they closed at 40 13 tuesday up 57 cents paxton s unusual move struck observers as singular and possibly inappropriate though he likely has the legal authority to pursue it in launching his investigation paxton suggested that twitter might have violated texas deceptive trade practices act the state attorney general s move against twitter is far different from the growing legal actions taken by groups of states that have joined to target alleged anticompetitive practices by google and meta for example or to investigate tiktok and its possible harmful effects on young users mental health individual state attorneys general don t normally investigate a major publicly traded company over its regulatory filings in twitter s case the data it submitted to the u s securities and exchange commission involve complex federal law the sec has the resources and the expertise and the legal remedies for this and i doubt that texas has any of these marc fagel a securities law expert who was the regional director of the sec s san francisco office said in an interview it s a headline based investigation as far as i can tell johnny koremenos a spokesman for the republican attorneys general association told the associated press that he s unaware of any other state attorney general who might be planning to launch a similar investigation into twitter james tierney a former maine attorney general who teaches at harvard was critical of paxton s probe which he sees as aiding musk whose electric car maker tesla recently opened a plant in texas capital of austin consumer laws exist to protect consumers from real harm tierney said they do not exist to allow a government official to meddle in ongoing corporate transactions on behalf of a constituent paxton notes that twitter had said in its filings with the sec that fewer than 5 of all users are bots when paxton asserts they may in fact comprise as much as 20 or more of the 229 million total accounts musk contended in a may tweet without providing evidence that 20 or more are bogus paxton demanded that twitter turn over documents by june 27 to show how it calculates and manages its user data the difference could dramatically affect the cost to texas consumers and businesses who transact with twitter such as advertisers paxton contended in his announcement he asserted that the disparity may inflate the value of twitter now estimated at 30 5 billion and raise the costs of doing business with it twitter spokespeople declined comment tuesday on paxton s announcement the company said in a statement monday that it has been cooperatively sharing information with musk in accordance with the terms of the merger agreement the texas attorney general who has long carved out a distinctive public persona isn t likely to mind any criticism a republican currently running for a third term as the state s top lawyer paxton has yet to have his day in court after being indicted on securities fraud charges in 2015 and his career has upended what it means to be a compromised officeholder in texas his critics say paxton has become an example of how powerful public figures can drag out even normally career threatening criminal charges and defy predictions of their political demise conservative republicans who accuse social media like twitter of anti conservative bias and censoring views of those opposed to abortion and others have embraced musk s bid for twitter because of his advocacy of free speech in place of the platform s content moderation paxton s fellow texan u s sen ted cruz has called musk s move the biggest development for free speech in decades associated press writers geoff mulvihill in new jersey and acacia coronado in texas contributed to this report __ follow marcy gordon at
shares in asia pacific were higher on wednesday with hong kong leading gains regionally the reserve bank of india will raise the policy repo rate by 50 basis points to 4 9 with immediate effect governor shaktikanta das announced wednesday the repo rate refers to the rate at which the central bank lends to commercial banks japan s economy shrank an annualized 0 5 in the first quarter revised government data showed wednesday an improvement over the initial estimate of a 1 contraction singapore shares in asia pacific were higher on wednesday with hong kong leading gains regionally the hang seng index in hong kong jumped 2 24 to close at 22 014 59 as chinese tech stocks listed in the city soared alibaba surged 10 12 while tencent climbed 6 47 and netease gained 5 66 the shanghai composite in mainland china closed 0 68 higher at 3 263 79 while the shenzhen component climbed 0 818 to 12 033 26 get south florida local news weather forecasts and entertainment stories to your inbox sign up for nbc south florida newsletters rbi announces rate hike the reserve bank of india on wednesday raised a key interest rate the rbi will raise the policy repo rate by 50 basis points to 4 9 with immediate effect governor shaktikanta das said the repo rate refers to the rate at which the central bank lends to commercial banks economists in a reuters poll had predicted a rate hike of between 25 to 75 basis points it may be noted in this context that the repo rate still remains below its pre pandemic level the indian central bank chief said following the announcement both the nifty 50 and bse sensex in india rose close to 0 4 each as of 1 44 p m local time the indian rupee traded at 77 763 per dollar weaker as compared with levels below 77 4 seen against the greenback last week the rbi s decision comes after the reserve bank of australia s surprise 50 basis point rate hike on tuesday in other markets the nikkei 225 in japan advanced 1 04 to close at 28 234 29 while the topix index climbed 1 18 to 1 969 98 japan s economy shrank an annualized 0 5 in the first quarter revised government data showed wednesday an improvement over the initial estimate of a 1 contraction south korea s kospi closed little changed at 2 626 15 the s p asx 200 in australia rose 0 36 to finish the trading day at 7 121 10 msci s broadest index of asia pacific shares outside japan gained 1 13 the world bank on tuesday cut its global growth forecast to 2 9 for 2022 and warned of the world economy slipping into a period of stagflation reminiscent of the 1970s these sort of headlines around risk of stagflation slower growth these are things the market has been you know trading on for most of the year already kieran calder head of equity research for asia at ubp told cnbc s street signs asia on wednesday calder described the world bank s expectation for 4 3 growth in 2022 for china as pretty aggressive given that multiple banks have cut their outlook for the country ubp is looking for below 4 gdp growth in china this year he said currencies and oil the u s dollar index which tracks the greenback against a basket of its peers was at 102 619 after seeing an earlier low of 102 387 the japanese yen traded at 133 62 per dollar weaker than levels below 132 seen against the dollar yesterday the australian dollar was at 0 7189 off an earlier high of 0 7235 oil prices were higher in the afternoon of asia trading hours with international benchmark brent crude futures up 0 39 to 121 04 per barrel u s crude futures gained 0 55 to 120 07 per barrel
cnbc s jim cramer on tuesday gave investors his blessing to consider purchasing beaten down tech stocks after target s latest quarter indicated good news for the federal reserve s fight against inflation the real greenlight here is on the beaten down tech they might deserve a bit of a resurgence if they have profits and a total romp if they have buybacks and dividends he said cnbc s jim cramer on tuesday gave investors his blessing to consider purchasing beaten down tech stocks after target s latest quarter indicated good news for the federal reserve s fight against inflation the real greenlight here is on the beaten down tech they might deserve a bit of a resurgence if they have profits and a total romp if they have buybacks and dividends he said this is not a subtle market i don t want you to overthink it because sometimes it can be easy he added get connecticut local news weather forecasts and entertainment stories to your inbox sign up for nbc connecticut newsletters cramer s comments come after target said in its latest quarter that it will need to shed its excess inventory which will in turn constrain the company s profits the mad money host who the day before advised investors to buy the dip only on oil stocks said that target s news suggests that inflation is peaking this opens up the door for investors to buy stocks that were previously untouchable in a high interest rate environment he said listing servicenow broadcom and salesforce as names that are more attractive after target s news cramer said he s still staying away from retail stocks short term he also warned investors that this change in the market could go away as fast as it came due to the economy s volatility of course this market s so darned fickle that this whole move could reverse when we get the big consumer price index number at the end of the week that could drive long term interest rates higher again putting this whole move on ice he said disclosure cramer s charitable trust owns shares of salesforce sign up now for the cnbc investing club to follow jim cramer s every move in the market disclaimer questions for cramer call cramer 1 800 743 cnbc want to take a deep dive into cramer s world hit him up mad money twitter jim cramer twitter facebook instagram questions comments suggestions for the mad money website madcap cnbc com
the speed at which americans pivoted away from pandemic spending was laid bare in the most recent quarterly financial filings from a number of major retailers new york target is canceling orders from suppliers particularly for home goods and clothing and it s slashing prices further to clear out amassed inventory ahead of the critical fall and holiday shopping seasons the actions come after a pronounced spending shift by americans from investments in their homes to money spent on travel nights out for dinner and dressier clothes a change that arrived much faster than major retailers had anticipated the speed at which americans pivoted away from pandemic spending was laid bare in the most recent quarterly financial filings from a number of major retailers target reported last month its profit for the fiscal first quarter tumbled 52 compared with the same period last year sales of big tvs and small kitchen appliances that americans loaded up on during the pandemic have faded leaving target with a bloated inventory that it said must be marked down to sell target declined to give a dollar amount of merchandise orders that are being canceled and depths of the discounts in aggressively clearing out unwanted goods target wants to make room for what is now in demand including groceries and makeup products but target is also facing sharply higher costs for everything from labor to transportation and shipping and it will offset price cuts where it can with higher prices for goods now in demand retail inventories are elevated michael fiddelke target s chief financial officer told the associated press in a phone interview monday and they certainly are for us in some of the categories that we misforecast we determined that acting aggressively was the right way to continue to fuel the business target is working with suppliers to cover costs for their vendors whose orders are being cancelled in some cases some of the raw materials that were meant for some goods will instead be used for other products in higher demand fiddelke said many of the orders for products being canceled have a long production lead time of nine months he said target also announced that it will add five distribution centers over the next two fiscal years target said the costs related to the moves will hurt the bottom line in the current quarter target now expects its second quarter operating margin rate will be roughly 2 down from around 5 3 it had expected last month for the second half of the year target expects an operating margin rate in a range around 6 a rate it said would exceed the company s average fall season performance in the years leading up to the pandemic last month target forecast its full year operating income margin rate would be in the 6 range target didn t give a new full range prediction it also said it secured additional space near u s ports to hold merchandise to allow for more flexibility target however continues to expect full year revenue growth in the low to mid single digit range and expects to maintain or gain market share for the year
new york new york u s stocks advanced on tuesday despite concerns from the u s treasury about unacceptable inflation we currently face macroeconomic challenges including unacceptable levels of inflation as well as the headwinds associated with the disruptions caused by the pandemic s effect on supply chains and the effects of supply side disturbances to oil and food markets resulting from russia s war in ukraine treasury secretary janet yellen told a senate finance committee hearing tuesday the dow jones industrials rallied 264 36 points or 0 80 percent to 33 180 14 the nasdaq composite finished with a 113 86 points or 0 94 percent gain to 12 175 23 the standard and poor s advanced 39 24 points or 0 95 percent to 4 160 67 the u s dollar was sold off the euro cruised higher to 1 0709 around the new york close tuesday the british pound strengthened to 1 2598 the canadian dollar jumped to 1 2525 the australian dollar on the back of an rba 50 basis points rate hike accelerated to 0 7237 the new zealand dollar was slightly higher at 0 6497 the japanese yen went against the trend crumbling to a more than a two decade low of 132 62 the swiss franc too weakened last trading at 0 9728 equity markets overseas mostly finished in the red in london the ftse 100 fell 0 12 percent the german dax declined 0 66 percent the cac 40 in paris france was off 0 74 percent the australian all ordinaries tumbled 114 50 points or 1 54 percent to 7 318 60 in new zealand the s p nzx 50 sank 151 64 points or 1 33 percent to 11 265 70 south korea s kospi composite dived 44 31 points or 1 66 percent to 2 626 30 hong kong s hang seng declined 122 23 points or 0 56 percent to 21 531 67 in tokyo the nikkei 225 going against the trend added 28 06 points or 0 10 percent to close at 27 943 95 china s shanghai composite finished a little better than flat up 5 39 points or 0 17 percent at 3 241 76
washington a panel of experts convened by the us drug regulator on tuesday recommended the novavax covid 19 shot a late runner in the fight against the virus that could nonetheless play a role in overcoming vaccine hesitancy three vaccines are currently approved in the united states pfizer and moderna which are based on messenger rna and johnson and johnson which recently received a recommendation against broad use becase of links to a serious form of clotting experts voted 21 in favour of the novavax vaccine with none against and one abstention despite some concerns it may be linked to rare cases of heart inflammation the food and drug administration which called the meeting is expected to issue an emergency use authorization soon then another agency the centers for disease control and prevention will weigh in with guidance on how it should best be used maryland based novavax was an early frontrunner in the global vaccine race but fell behind after being hit by manufacturing and regulatory delays the us was one of the few major markets where it hasn t yet received authorization while the eu uk canada australia are among many that have already given it the green light officials hope that the shot which is based on lab grown viral proteins could provide an alternative for people still hesitant of the mrna technology it also doesn t have the same cold storage requirements as pfizer and moderna s shots there really is a population of patients who are willing to take this and not going to take existing vaccines i think it s pretty compelling said eric rubin an infectious disease specialist who participated in the meeting explaining his vote in favour of the various vaccine technologies mrna has been subject to the most misinformation efforts possible myocarditis link novavax s vaccine was found to be more than 90 per cent effective against symptomatic cases of the disease but its trial was conducted long before the currently circulating sub variants of omicron were dominant and the company may yet have to add a booster or update its shot what s more six cases of myocarditis an inflammation of the heart muscle were detected in the group that received the vaccine against one case in the placebo group in a trial of around 40 000 people novavax says there is insufficient evidence to establish a causal relationship between the cases of myocarditis and the vaccine such a link has been established with mrna vaccines but it only became apparent when they were used on millions of people in the real world rather than tens of thousands in a trial the fda voiced concern over the myocarditis link on friday and a warning is likely to be included on the eventual label earlier trading in novavax shares on nasdaq was halted pending the meeting known as a protein subunit vaccine novavax is administered in two doses it is based on a lab created version of the spikes that dot the surface of the coronavirus to evoke an immune response the company uses a modified spike gene inserted into another kind of virus called a baculovirus which is used to infect moth cells which then produce the spikes on their surface these spikes are harvested and assembled into nanoparticles which are injected into patients
new york new york u s stocks advanced on tuesday despite concerns from the u s treasury about unacceptable inflation we currently face macroeconomic challenges including unacceptable levels of inflation as well as the headwinds associated with the disruptions caused by the pandemic s effect on supply chains and the effects of supply side disturbances to oil and food markets resulting from russia s war in ukraine treasury secretary janet yellen told a senate finance committee hearing tuesday the dow jones industrials rallied 264 36 points or 0 80 percent to 33 180 14 the nasdaq composite finished with a 113 86 points or 0 94 percent gain to 12 175 23 the standard and poor s advanced 39 24 points or 0 95 percent to 4 160 67 the u s dollar was sold off the euro cruised higher to 1 0709 around the new york close tuesday the british pound strengthened to 1 2598 the canadian dollar jumped to 1 2525 the australian dollar on the back of an rba 50 basis points rate hike accelerated to 0 7237 the new zealand dollar was slightly higher at 0 6497 the japanese yen went against the trend crumbling to a more than a two decade low of 132 62 the swiss franc too weakened last trading at 0 9728 equity markets overseas mostly finished in the red in london the ftse 100 fell 0 12 percent the german dax declined 0 66 percent the cac 40 in paris france was off 0 74 percent the australian all ordinaries tumbled 114 50 points or 1 54 percent to 7 318 60 in new zealand the s p nzx 50 sank 151 64 points or 1 33 percent to 11 265 70 south korea s kospi composite dived 44 31 points or 1 66 percent to 2 626 30 hong kong s hang seng declined 122 23 points or 0 56 percent to 21 531 67 in tokyo the nikkei 225 going against the trend added 28 06 points or 0 10 percent to close at 27 943 95 china s shanghai composite finished a little better than flat up 5 39 points or 0 17 percent at 3 241 76
it s that time again mad money host jim cramer rings the lightning round bell which means he s giving his answers to callers stock questions at rapid speed blackline inc they re losing money we can just not go with it enbridge inc that is exactly what you should be buying axogen inc it s a medical device and i think you have to stick with tried and true johnson johnson get san diego local news weather forecasts sports and lifestyle stories to your inbox sign up for nbc san diego newsletters metlife inc i m going to have to say yes to that even as i m not a great fan of the insurers that is too cheap a stock bridge investment group holdings we don t really know what they do pass because there s too much room for error farfetch ltd i say buy target down here disclosure cramer s charitable trust owns shares of johnson johnson sign up now for the cnbc investing club to follow jim cramer s every move in the market disclaimer questions for cramer call cramer 1 800 743 cnbc want to take a deep dive into cramer s world hit him up mad money twitter jim cramer twitter facebook instagram questions comments suggestions for the mad money website madcap cnbc com
in a quieter session on tuesday natural gas futures failed to sustain early gains as traders took profits the july nymex gas futures contract settled at 9 293 mmbtu off 2 9 cents on the day august futures slipped 2 8 cents to 9 278 at a glance production falls to 97 bcf d forecasts for mixed demand ngi models draw of 41 bcf spot gas prices moved higher again with triple digit temperatures creeping across texas and much of the south ngi s spot gas national avg rose 30 0 cents to 8 865 despite a late sell off along the nymex futures curve the background state remained supportive and trended slightly more bullish based on the latest data on the weather front the forecast trended slightly hotter for the june 14 17 period boosting national gas demand as strong
it s that time again mad money host jim cramer rings the lightning round bell which means he s giving his answers to callers stock questions at rapid speed blackline inc they re losing money we can just not go with it enbridge inc that is exactly what you should be buying axogen inc it s a medical device and i think you have to stick with tried and true johnson johnson get south florida local news weather forecasts and entertainment stories to your inbox sign up for nbc south florida newsletters metlife inc i m going to have to say yes to that even as i m not a great fan of the insurers that is too cheap a stock bridge investment group holdings we don t really know what they do pass because there s too much room for error farfetch ltd i say buy target down here disclosure cramer s charitable trust owns shares of johnson johnson sign up now for the cnbc investing club to follow jim cramer s every move in the market disclaimer questions for cramer call cramer 1 800 743 cnbc want to take a deep dive into cramer s world hit him up mad money twitter jim cramer twitter facebook instagram questions comments suggestions for the mad money website madcap cnbc com
suzhou china and rockville md june 7 2022 prnewswire ascentage pharma 6855 hk a global biopharmaceutical company engaged in developing novel therapies for cancers chronic hepatitis b chb and age related diseases today announced that it has released the results from its phase i first in human fih study of the company s novel fak inhibitor and third generation alk ros1 tyrosine kinase inhibitor tki apg 2449 in patients with second generation tki resistant alk ros1 non small cell lung cancer nsclc or mesothelioma in a poster presentation at the 58th american society of clinical oncology asco annual meeting apg 2449 is the first china developed third generation alk inhibitor entering clinical studies entering the fifth consecutive year in which its abstracts were selected for presentations by the asco annual meeting ascentage pharma showcased results from multiple clinical trials of its five drug candidates including the first time results of apg 2449 highlighting the company s promising pipeline in solid tumors apg 2449 demonstrated preliminary efficacy in tki nave patients or those whose disease was resistant to second generation tkis with 4 partial responses prs observed in the 14 patients with second generation tki resistant and alk positive nsclc in the 10 tki nave alk ros1 patients the objective response rate orr was 80 and the disease control rate dcr was 100 discovered and developed by ascentage pharma apg 2449 is a novel orally available fak alk ros1 inhibitor and the first china developed third generation alk inhibitor entering clinical studies prof hongyun zhao of sun yat sen university cancer center who is the principal investigator of this study said apg 2449 is a potent fak alk ros1 inhibitor that can address drug resistance to second generation alk tkis in this fih study apg 2449 demonstrated favorable safety and antitumor activity in patients with advanced nsclc and showed on target pharmacodynamic effects building on results from this phase i study we look forward to further evaluate apg 2449 s efficacy in advanced nsclc patients resistant to second generation alk inhibitor dr yifan zhai chief medical officer of ascentage pharma commented apg 2449 is one of our key drug candidates outside our pipeline of apoptosis targeting assets the data presented at this year s asco annual meeting demonstrated apg 2449 s therapeutic potential in patients with advanced nsclc and are indicative of our progress in the field of solid tumors we will continue to take firm steps to advance this clinical development program furthermore we are proud to be able to present clinical development progress for a number of ascentage pharma s drug candidates at this year s asco annual meeting which highlight our capabilities in global innovation honoring our mission of addressing unmet clinical needs in china and around the world we are now accelerating our clinical programs to bring more safe and effective therapeutics to patients in need the highlights of this abstract on apg 2449 are as follows first in human phase i results of apg 2449 a novel fak and third generation alk ros1 tyrosine kinase inhibitor tki in patients pts with second generation tki resistant alk ros1 non small cell lung cancer nsclc or mesothelioma abstract 9071 this dose escalation and dose expansion study was designed to assess the safety tolerability recommended phase ii dose rp2d pharmacokinetics pk pharmacodynamics pd and efficacy of apg 2449 in patients with second generation tki resistant alk ros1 nsclc or mesothelioma as of december 30 2021 84 chinese patients with nsclc or mesothelioma enrolled were treated with apg 2449 at doses ranging from 150 to 1 500 mg apg 2449 was administered orally once daily on a 28 day cycle using a 3 3 dose escalation design 84 chinese patients with nsclc or mesothelioma enrolled were treated with apg 2449 at doses ranging from 150 to 1 500 mg apg 2449 was administered orally once daily on a 28 day cycle using a 3 3 dose escalation design 4 prs were observed in 14 alk patients resistant to second generation tkis treated at the rp2d among 8 patients with brain metastases 1 complete response cr and 3 prs were observed intracranially in 10 tki nave patients the orr was 80 alk 6 8 ros1 2 2 and the dcr was 100 in addition agp 2449 demonstrated a favorable safety profile the preliminary biomarker data showed decreased fak phosphorylation in peripheral blood mononuclear cells and increased ifn  levels in serum after multiple doses of apg 2449 conclusions apg 2449 has a favorable safety and pk profile preliminary efficacy was observed in patients whose disease was resistant to second generation or tki nave biomarker data indicated potential target engagement on fak and the immunomodulatory effects of apg 2449 appendix a list of ascentage pharma s abstracts selected by this year s asco annual meeting drug candidate abstract title abstract format olverembatinib hqp1351 promising antitumor activity of olverembatinib hqp1351 in patients pts with tyrosine kinase inhibitor tki resistant succinate dehydrogenase sdh deficient gastrointestinal stromal tumor gist 11513 poster discussion lisaftoclax apg 2575 a phase ib ii study of lisaftoclax apg 2575 a novel bcl 2 inhibitor bcl 2i in patients pts with relapsed refractory chronic lymphocytic leukemia or small lymphocytic lymphoma r r cll sll 7543 poster presentation phase ib ii study of bcl 2 inhibitor lisaftoclax apg 2575 safety and tolerability when administered alone or combined with a cyclin dependent kinase 4 6 cdk4 6 inhibitor in patients with estrogen receptor positive er breast cancer or advanced solid tumors tps1122 poster presentation alrizomadlin apg 115 newly updated activity results of alrizomadlin apg 115 a novel mdm2 p53 inhibitor plus pembrolizumab phase 2 study in adults and children with various solid tumors 9517 poster discussion apg 2449 first in human phase i results of apg 2449 a novel fak and third generation alk ros1 tyrosine kinase inhibitor tki in patients pts with second generation tki resistant alk ros1 non small cell lung cancer nsclc or mesothelioma 9071 poster presentation pelcitoclax apg 1252 updated study results of pelcitoclax apg 1252 in combination with osimertinib in patients pts with egfr mutant non small cell lung cancer nsclc 9116 poster presentation first in human study of pelcitoclax apg 1252 in combination with paclitaxel in patients pts with relapsed refractory small cell lung cancer r r sclc e20612 publication only about ascentage pharma ascentage pharma 6855 hk is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers chronic hepatitis b and age related diseases on october 28 2019 ascentage pharma was listed on the main board of the stock exchange of hong kong limited with the stock code 6855 hk ascentage pharma focuses on developing therapeutics that inhibit protein protein interactions to restore apoptosis or programmed cell death the company has built a pipeline of eight clinical drug candidates including novel highly potent bcl 2 and dual bcl 2 bcl xl inhibitors as well as candidates aimed at iap and mdm2 p53 pathways and next generation tyrosine kinase inhibitors tkis ascentage pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators the company is conducting more than 50 phase i ii clinical trials in the us australia europe and china olverembatinib the company s core drug candidate developed for the treatment of drug resistant chronic myeloid leukemia cml was granted priority review status and a breakthrough therapy designation btd by the center for drug evaluation cde of the china national medical products administration nmpa and is already approved for the indication in addition olverembatinib was also granted an orphan drug designation odd and a fast track designation ftd by the us fda and an orphan designation by the eu to date ascentage pharma has obtained a total of 15 odds 2 ftds and 2 rare pediatric disease rpd designations from the fda and 1 odd from the eu for four of the company s investigational drug candidates ascentage pharma has been designated for multiple major national r d projects including 5 national major new drug discovery and manufacturing projects 1 new drug incubator status 4 innovative drug programs and 1 major project for the prevention and treatment of infectious diseases leveraging its robust r d capabilities ascentage pharma has built a portfolio of global intellectual property rights and entered into global partnerships with numerous renowned biotechnology and pharmaceutical companies and research institutes such as unity biotechnology md anderson cancer center mayo clinic dana farber cancer institute merck astrazeneca and pfizer the company has built a talented team with global experience in discovering developing launching and commercializing innovative drugs and is setting up world class commercial manufacturing and sales marketing teams one pivotal aim of ascentage pharma is to continuously strengthen its r d capabilities and accelerate its clinical development programs in order to fulfil its mission of addressing unmet clinical needs in china and around the world for the benefit of more patients forward looking statements the forward looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article except as required by law ascentage pharma undertakes no obligation to update or revise publicly any forward looking statements whether as a result of new information future events or otherwise after the date on which the statements are made or to reflect the occurrence of unanticipated events you should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect in this article statements of or references to our intentions or those of any of our directors or our company are made as of the date of this article any of these intentions may alter in light of future development source ascentage pharma
san francisco and suzhou china june 7 2022 prnewswire innovent biologics inc innovent hkex 01801 a world class biopharmaceutical company that develops manufactures and commercializes high quality medicines for the treatment of oncology autoimmune metabolic ophthalmology and other major diseases announces that the primary and all key secondary endpoints were met in a randomized double blind placebo controlled phase 2 study of mazdutide r d code ibi362 a glucagon like peptide 1 receptor glp 1r glucagon receptor gcgr dual agonist in chinese participants with overweight or obesity this study clinicaltrials gov nct04904913 was designed to evaluate the efficacy and safety of mazdutide in chinese participants with overweight or obesity a total of 248 subjects were randomized to receive 1 5 3 0 mg 1 5 3 0 4 5 mg or 2 0 4 0 6 0 mg of mazdutide or placebo subcutaneously and once weekly for 24 weeks the primary endpoint was the percentage change from baseline in body weight at week 24 a total of 230 participants 92 7 completed week 24 mazdutide demonstrated superior weight loss efficacy in chinese participants with overweight or obesity compared with placebo in a dose dependent manner after 24 weeks of treatment the least squares ls mean percent change absolute change from baseline in body weight were 7 21 6 35 kg on 3 0 mg 10 56 9 07 kg on 4 5 mg and 11 57 9 85 kg on 6 0 mg with mazdutide compared with 1 05 1 08 kg with placebo the treatment difference versus placebo in ls mean percent change from baseline were 8 26 on 3 0 mg 11 60 on 4 5 mg and 12 62 on 6 0 mg p 0 0001 for all comparisons the proportion of participants with 5 body weight loss from baseline was 58 1 3 0 mg 82 5 4 5 mg and 80 3 6 0 mg with mazdutide compared with 4 8 with placebo the proportion of participants with 10 body weight loss from baseline was 19 4 3 0 mg 49 2 4 5 mg and 50 8 6 0 mg with mazdutide compared with 0 with placebo meanwhile mazdutide markedly reduced body mass index waist circumference liver fat content and blood pressure lowered lipid transaminase and serum uric acid levels and improved insulin sensitivity delivering comprehensive metabolic benefits for participants with overweight or obesity in terms of safety mazdutide was well tolerated only one participant discontinued the treatment due to an adverse event which was not related to mazdutide as judged by the investigator the overall safety profile was similar to those observed in early phase development and with other glp 1 based agonists and co agonists the most frequently reported treatment emergent adverse events were diarrhea nausea and upper respiratory tract infection mostly mild or moderate in severity and transient professor linong ji the principal investigator of the study peking university people s hospital stated in recent years the prevalence of obesity in china has increased rapidly and resulted in the increase of the prevalence of diabetes fatty liver sleep disorders and cardiovascular diseases therefore effective and safe weight loss drugs are urgently needed we are pleased to see the exciting results of the phase 2 study of mazdutide in chinese participants with overweight or obesity suggesting that mazdutide could potentially be the best in class agent the half year treatment of mazdutide achieved on average 12 6 weight reduction from baseline compared with placebo which was comparable to the most cutting edge weight loss drugs under development in the world the excellent efficacy of mazdutide in weight loss and multiple metabolic parameters truly reflects the advantages of weekly formulation based on dual incretin receptor agonists i am confident and looking forward to the success of mazdutide in the upcoming phase 3 study dr lei qian vice president of clinical development of innovent stated the phase 2 study of mazdutide in chinese participants with overweight or obesity achieved the primary and all key secondary endpoints while showing improvement on multiple metabolic parameters including blood pressure lipids transaminase and serum uric acid these results demonstrate the great utility value of glp 1r gcgr dual agonist further demonstrating the potential to be the best in class agent and paving solid foundation for further clinical development of note the auto injector has been used in the phase 2 studies greatly improving the quality of life and compliance of participants while demonstrating the quality and capability of domestic enterprises in device development and manufacturing we will actively promote the development of phase 3 clinical study of mazdutide and anticipate more clinical data later this year striving to provide more convenient user friendly effective and safe drug for overweight and obese population as soon as possible due to the outbreak of covid 19 the data are being collected and under further analysis the data disclosed in this press release may have some deviation from the final results about obesity china has the largest obese population in the world with obesity rate likely to increase obesity can lead to a range of complications or related diseases that impact life expectancy and lead to a decrease in quality of life in more severely obese patients the incidence and mortality of cardiovascular disease diabetes and certain tumors increase significantly obesity is a chronic disease that requires long term management and there is a lack of long term effective and safe treatments lifestyle intervention is the first choice and basic treatment for patients with overweight or obesity however a considerable percentage of patients fail to achieve the desired weight loss goal upon lifestyle intervention due to various reasons and may require pharmacological intervention traditional anti obesity drugs have limited weight loss effects and are associated with safety issues about mazdutide ibi362 innovent entered into a licensing agreement with eli lilly and company lilly for the development and potential commercialization of oxm3 also known as mazdutide a glp 1r and gcgr dual agonist in china in parallel lilly is developing oxm3 outside china mazdutide is a long acting synthetic peptide related to mammalian oxyntomodulin oxm which uses a fatty acid side chain to prolong the duration of action and allow once weekly administration mazdutide is thought to exert its biological effects by activating glp 1 receptor and glucagon receptor in human beings which improves glucose tolerance and induces weight loss mimicking the effects of endogenous oxyntomodulin in addition to the effects of glp 1 receptor agonists on promoting insulin secretion lowering blood glucose and reducing body weight mazdutide may also increase energy expenditure and improve hepatic fat metabolism through the activation of glucagon receptor the treatment of metabolic diseases by activating multiple metabolism related targets simultaneously is currently the worldwide trend in drug development about innovent inspired by the spirit of start with integrity succeed through action innovent s mission is to develop manufacture and commercialize high quality biopharmaceutical products that are affordable to ordinary people established in 2011 innovent is committed to developing manufacturing and commercializing high quality innovative medicines for the treatment of cancer autoimmune metabolic ophthalmology and other major diseases on october 31 2018 innovent was listed on the main board of the stock exchange of hong kong limited with the stock code 01801 hk since its inception innovent has developed a fully integrated multi functional platform which includes r d cmc chemistry manufacturing and controls clinical development and commercialization capabilities leveraging the platform the company has built a robust pipeline of 32 valuable assets in the fields of cancer autoimmune metabolic ophthalmology and other major therapeutic areas with 7 products approved for marketing in china tyvyt sintilimab injection byvasda bevacizumab biosimilar injection sulinno adalimumab biosimilar injection halpryza rituximab biosimilar injection pemazyre pemigatinib oral inhibitor and olverembatinib bcr abl tki and cyramza ramucirumab 2 asset under nmpa nda review 4 assets in phase 3 or pivotal clinical trials and an additional 19 molecules in clinical studies innovent has built an international team with advanced talent in high end biological drug development and commercialization including many global experts the company has also entered into strategic collaborations with eli lilly and company adimab incyte md anderson cancer center hanmi and other international partners innovent strives to work with many collaborators to help advance china s biopharmaceutical industry improve drug availability and enhance the quality of the patients lives for more information please visit www innoventbio com and www linkedin com company innovent biologics note tyvyt sintilimab injection is not an approved product in the united states byvasda bevacizumab biosimilar injection sulinno and halpryza rituximab biosimilar injection are not approved products in the united states tyvyt sintilimab injection innovent byvasda bevacizumab biosimilar injection innovent halpryza rituximab biosimilar injection innovent sulinno adalimumab biosimilar injection innovent pemazyre pemigatinib oral inhibitor incyte corporation pemazyre was discovered by incyte corporation and licensed to innovent for development and commercialization in mainland china hong kong macau and taiwan cyramza ramucirumab eli lilly cyramza was discovered by eli lilly and licensed to innovent for commercialization in mainland china disclaimer 1 this indication is still under clinical study which hasn t been approved in china 2 innovent does not recommend any off label usage forward looking statement this news release may contain certain forward looking statements that are by their nature subject to significant risks and uncertainties the words anticipate believe estimate expect intend and similar expressions as they relate to innovent biologics innovent are intended to identify certain of such forward looking statements the company does not intend to update these forward looking statements regularly these forward looking statements are based on the existing beliefs assumptions expectations estimates projections and understandings of the management of the company with respect to future events at the time these statements are made these statements are not a guarantee of future developments and are subject to risks uncertainties and other factors some of which are beyond the company s control and are difficult to predict consequently actual results may differ materially from information contained in the forward looking statements as a result of future changes or developments in our business the company s competitive environment and political economic legal and social conditions the company the directors and the employees of the company assume a no obligation to correct or update the forward looking statements contained in this site and b no liability in the event that any of the forward looking statements does not materialise or turn out to be incorrect source innovent biologics
washington a former member of donald trump s cabinet will attempt a return to the u s congress in montana and california democrats concerned about crime may oust one of their own as voters head to the polls in midterm primary elections in seven states on tuesday voters in south dakota new jersey iowa mississippi and new mexico will also cast ballots in nominating contests that will set the competitive field for nov 8 s elections which will determine control of congress for the next two years with president joe biden slumping in the polls and soaring inflation souring voters moods republicans are expected to win control of the house of representatives and possibly the senate which would bring biden s legislative agenda to a halt and give republicans the power to launch distracting and possibly politically damaging investigations in montana ryan zinke who served as interior secretary under republican former president trump is running for a newly created house seat that the state gained thanks to population growth and the once a decade redistricting process zinke who served in congress previously faces four republican challengers some of whom claim that he is too liberal or lacks commitment to the state because his wife s residence is in california advertisement zinke was accused in an inspector general report this year of using is position as head of the interior department to advance a development project in his hometown and lying to an ethics investigator he has denied wrongdoing south dakota s conservative republican governor kristi noem faces a challenge by steven haugaard a member of the south dakota house of representatives noem has been mentioned as a possible vice presidential running mate if former president donald trump seeks election again in 2024 or as a white house candidate in her own right if he does not the winners of each of those republican primaries are favored to win in november california shakeout a pair of races in california will also illustrate liberal leaning voters frustrations with spikes in homicides and gun violence polls show that san francisco s progressive district attorney chesa boudin is likely to be pushed out of office in a recall vote a replacement would be chosen by the city s mayor london breed a democrat who has criticized boudin but has not taken a stance on the recall in los angeles rick caruso a billionaire developer and former republican is battling u s representative karen bass and a host of other liberal candidates in the mayoral election caruso who has spent more than 30 million of his own money in the campaign made crime the centerpiece of his candidacy in a city that saw homicides reach a 15 year high in 2021 that forced bass a longtime progressive champion in congress to move to the center and pledge to put more police on the streets caruso and bass could be headed to a runoff polls show advertisement new jersey iowa challenges republicans in new jersey and iowa will also be picking challengers to embattled incumbent house democrats representatives tom malinowski in new jersey and cindy axne in iowa former state senate republican leader tom kean jr the son of popular two time governor thomas kean leads a crowded republican field to challenge malinowski malinowski a two term incumbent who entered congress by flipping a republican seat in 2018 won reelection by defeating kean by 1 2 percentage points in 2020 since then his prospects have been weakened by redistricting and by a house ethics investigation after reports that he failed to disclose hundreds of thousands of dollars in stock trades it was a nail biter in 2020 and his district has become a little more favorable for republicans so it s going to be a significant challenge said benjamin dworkin director of the rowan university institute of public policy citizenship in iowa three republicans are vying for the chance to challenge axne businesswoman nicole hasso construction consultant gary leffler and former state senator zach nunn nunn the only republican contender who has held elective office boasts a string of endorsements from high profile party luminaries including trump s former secretary of state mike pompeo and several sitting house republicans
washington a panel of experts convened by the us drug regulator yesterday recommended the novavax covid 19 shot a late runner in the fight against the virus that could nonetheless play a role in overcoming vaccine hesitancy three vaccines are currently approved in the us pfizer and moderna which are based on messenger rna and johnson and johnson which recently received a recommendation against broad use because of links to a serious form of clotting experts voted 21 in favour of the novavax vaccine with none against and one abstention despite some concerns it may be linked to rare cases of heart inflammation the food and drug administration which called the meeting is expected to issue an emergency use authorisation soon then another agency the centers for disease control and prevention will weigh in with guidance on how it should best be used maryland based novavax was an early frontrunner in the global vaccine race but fell behind after being hit by manufacturing and regulatory delays the us was one of the few major markets where it hasn t yet received authorisation while the eu uk canada australia are among many that have already given it the green light officials hope that the shot which is based on lab grown viral proteins could provide an alternative for people still hesitant of the mrna technology it also doesn t have the same cold storage requirements as pfizer and moderna s shots  there really is a population of patients who are willing to take this and not going to take existing vaccines i think it s pretty compelling  said eric rubin an infectious disease specialist who participated in the meeting explaining his vote in favour of the various vaccine technologies mrna has been subject to the most misinformation efforts possible myocarditis link novavax s vaccine was found to be more than 90 effective against symptomatic cases of the disease but its trial was conducted long before the currently circulating sub variants of omicron were dominant and the company may yet have to add a booster or update its shot what s more six cases of myocarditis an inflammation of the heart muscle were detected in the group that received the vaccine against one case in the placebo group in a trial of around 40 000 people novavax says there is insufficient evidence to establish a causal relationship between the cases of myocarditis and the vaccine such a link has been established with mrna vaccines but it only became apparent when they were used on millions of people in the real world rather than tens of thousands in a trial the fda voiced concern over the myocarditis link on friday and a warning is likely to be included on the eventual label earlier trading in novavax shares on nasdaq was halted pending the meeting known as a protein subunit vaccine novavax is administered in two doses it is based on a lab created version of the spikes that dot the surface of the coronavirus to evoke an immune response the company uses a modified spike gene inserted into another kind of virus called a baculovirus which is used to infect moth cells which then produce the spikes on their surface these spikes are harvested and assembled into nanoparticles which are injected into patients a compound of soapbark tree is added to the vaccine to heighten the response  afp
shanghai and hong kong june 7 2022 prnewswire antengene corporation limited antengene sehk 6996 hk a leading innovative commercial stage global biopharmaceutical company dedicated to discovering developing and commercializing first in class and or best in class therapeutics in hematology and oncology today announced that the first patient has been dosed in the phase i stamina 001 trial to evaluate atg 037 as a monotherapy or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors in australia the primary objective of the study is to evaluate the safety tolerability recommended phase ii dose and preliminary antitumor efficacy of atg 037 as a monotherapy and in combination with pembrolizumab secondary objectives include characterization of the pharmacology of atg 037 atg 037 is an orally available small molecule cd73 inhibitor cd73 is an immune checkpoint mediator 1 that interferes with anti tumor immune responses by generating adenosine which leads to immunosuppression in the tumor microenvironment atg 037 can reverse adenosine mediated immunosuppression2 it has demonstrated promising preclinical efficacy as a monotherapy and in combination with icis and chemotherapy agents in preclinical studies this compound overcomes the hook effect that is common in anti cd73 antibodies in addition glp toxicology studies indicate the compound has a potentially wide therapeutic window while icis are widely used in the treatment of various cancers many patients have resistant or refractory disease which has created a large unmet need said dr ganessan kichenadasse principal investigator southern oncology clinical research unit in adelaide australia mounting evidence suggests that adenosine plays a critical role in suppressing anti tumor immunoactivity cd73 can convert adenosine monophosphate amp to adenosine atg 037 an orally available small molecule cd73 inhibitor can block the generation of adenosine we are excited to be a part of the stamina 001 trial this phase i study brings together a group of highly experienced australian investigators to collaborate with antengene we are excited to assess the therapeutic potential of atg 037 for patients with solid tumors as a single agent as well the exploring the opportunity for benefit with the addition of an icis developing agents that can act in the tumor microenvironment to reverse immunosuppression is one of the key focus areas for antengene said dr kevin lynch antengene s chief medical officer preclinical data presented at the 2022 american association of cancer research annual meeting aacr 2022 showed that atg 037 had a stronger ability to restore t cell function in higher amp environments compared with anti cd73 monoclonal antibodies these data highlighted the potential therapeutic advantages of small molecule inhibitors of cd73 over blocking antibodies either as a monotherapy or in combination with other immune oncological treatments we have been very pleased with the drug s performance in preclinical studies and are hopeful that in this phase i study atg 037 can demonstrate the tolerability and signals of activity that will allow us to move forward into a broader development program we are very excited about the start of this first in human clinical trial and look forward to next steps with atg 037 about the stamina 001 trial the stamina 001 trial is a phase i multi center open label dose finding study of atg 037 monotherapy or combination therapy with pembrolizumab in patients with locally advanced and metastatic solid tumors subjects will begin with two monotherapy cycles and then be allowed to receive the addition of pembrolizumab the primary objective of the study is to evaluate the safety and tolerability of atg 037 and to determine the maximum tolerated dose mtd and or recommended phase ii dose rp2d and or optimal biological dose of atg 037 monotherapy and preliminary efficacy secondary objectives include characterization of the pharmacology of atg 037 as a phase i study there will be intensive safety monitoring throughout the trial about atg 037 atg 037 is an orally available highly selective small molecule that completely blocks the activity of cd73 cd73 an ecto 5 nucleotidase catalyzes the conversion of adenosine monophosphate amp to adenosine adenosine production leads to significant immunosuppression in the tumor microenvironment now recognized as one of the most important immunomodulatory pathways in the tumor microenvironment many human tumors overexpress cd73 and this expression is frequently associated with poor prognosis blocking cd73 has been shown to be effective in controlling tumor growth and metastases and cd73 inhibitors may increase the therapeutic activity of icis and chemotherapy agents clinical data so far indicate that cd73 inhibitors add little additional toxicity to standard of care treatments about antengene antengene corporation limited antengene sehk 6996 hk is a leading commercial stage r d driven global biopharmaceutical company focused on the discovery development manufacturing and commercialization of innovative first in class best in class therapeutics for the treatment of hematologic malignancies and solid tumors in realizing its vision of treating patients beyond borders since 2017 antengene has a built broad and expanding pipeline of 15 clinical and preclinical assets of which 10 are global rights assets and 5 came with rights for asia pacific markets including the greater china region to date antengene has obtained 24 investigational new drug ind approvals in the u s and asia and submitted 6 new drug applications ndas in multiple asia pacific markets with the nda for xpovio selinexor already approved in mainland china south korea singapore and australia forward looking statements the forward looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article except as required by law we undertake no obligation to update or revise publicly any forward looking statements whether as a result of new information future events or otherwise after the date on which the statements are made or to reflect the occurrence of unanticipated events you should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect in this article statements of or references to our intentions or those of any of our directors or our company are made as of the date of this article any of these intentions may alter in light of future development for a further discussion of these and other factors that could cause future results to differ materially from any forward looking statement see the section titled risk factors in our periodic reports filed with the hong kong stock exchange and the other risks and uncertainties described in the company s annual report for year end december 31 2021 and subsequent filings with the hong kong stock exchange references 1 allard b longhi ms robson sc stagg j the ectonucleotidases cd39 and cd73 novel checkpoint inhibitor targets immunol rev 2017 276 1 121 144 doi 10 1111 imr 12528 2 antengene r d day 2021 for more information please contact investor contacts donald lung e mail mobile 86 18420672158 pr contacts peter qian e mail mobile 86 13062747000 source antengene corporation limited
suzhou china and rockville md june 7 2022 prnewswire ascentage pharma 6855 hk a global biopharmaceutical company engaged in developing novel therapies for cancers chronic hepatitis b chb and age related diseases today announced that it has released the updated results from a phase ib ii study of the bcl 2 inhibitor lisaftoclax apg 2575 in patients with relapsed refractory chronic lymphocytic leukemia small lymphocytic lymphoma r r cll sll in a poster presentation at the 58th american society of clinical oncology asco annual meeting entering the fifth consecutive year in which company s abstracts were selected for presentations by the asco annual meeting ascentage pharma showcased results from multiple clinical trials of its five drug candidates including favorable data of lisaftoclax a key drug candidate of the company s apoptosis targeted pipeline in chinese patients with r r cll sll showing an objective response rate orr of 67 4 lisaftoclax was well tolerated and all adverse events were manageable no dose limiting toxicity dlt were observed at up to 800 mg day the risk of clinical tumor lysis syndrome tls in patients on daily dose ramp up was minimal prof jianyong li director of the hematology department jiangsu people s hospital and the principal investigator of this study said lisaftoclax is a bcl 2 selective inhibitor that can induce apoptosis and suppress the growth of tumor cells in this phase ib ii study lisaftoclax as a single agent showed favorable preliminary efficacy and safety and a daily ramp up schedule that is patients friendly we look forward to further evaluating the efficacy of lisaftoclax as a single agent and in combinations in patients with r r cll sll dr yifan zhai chief medical officer of ascentage pharma commented lisaftoclax is the first china developed bcl 2 inhibitor entering clinical development in china also the world s second and china s first bcl 2 inhibitor being investigated in pivotal trials data released at this year s asco annual meeting suggest that lisaftoclax may offer an effective safe and more user friendly treatment alternative to patients with r r cll sll we are taking firm steps forward with this clinical development program to allow patients to benefit from this novel therapeutic as soon as possible meanwhile we are also evaluating lisaftoclax monotherapy and combinations in patients with solid tumors dr zhai continued furthermore we are proud to be able to present clinical development progress for a number of ascentage pharma s drug candidates which highlight our capabilities in global innovation honoring our mission of addressing unmet clinical needs in china and around the world we are now accelerating our clinical programs to bring more safe and effective therapeutics to patients in need the highlights of this abstract on lisaftoclax are as follows a phase ib ii study of lisaftoclax apg 2575 a novel bcl 2 inhibitor bcl 2i in patients pts with relapsed refractory chronic lymphocytic leukemia or small lymphocytic lymphoma r r cll sll abstract 7543 the aim of this multicenter open label study was to evaluate the safety antitumor activity pk and pharmacodynamics pd of lisaftoclax in chinese patients with r r cll sll as of january 25 2022 45 patients had been enrolled lisaftoclax was administered orally once daily at 3 dose cohorts 400 600 or 800 mg in 28 day cycles with 15 patients in each cohort 45 patients had been enrolled lisaftoclax was administered orally once daily at 3 dose cohorts 400 600 or 800 mg in 28 day cycles with 15 patients in each cohort lisaftoclax monotherapy demonstrated favorable safety profiles in all three dose cohorts and no dlt was observed during the phase i study the risk of tls in patients on daily dose ramp up was extremely low which was consistent with the observations of the phase i study the median duration of treatment was 7 cycles and the orr in the 43 efficacy evaluable patients with r r cll sll was 67 4 including 1 complete response cr and 28 partial responses prs bcl 2i lisaftoclax was well tolerated up to 800 mg day there were no significant new or unmanageable safety findings the recommended phase ii dose rp2d of lisaftoclax was determined as 600 mg lisaftoclax may offer a treatment alternative for patients with r r cll sll with a daily ramp up schedule that may be more convenient and user friendly appendix a list of ascentage pharma s abstracts selected by this year s asco annual meeting drug candidate abstract title abstract format olverembatinib hqp1351 promising antitumor activity of olverembatinib hqp1351 in patients pts with tyrosine kinase inhibitor tki resistant succinate dehydrogenase sdh deficient gastrointestinal stromal tumor gist 11513 poster discussion lisaftoclax apg 2575 a phase ib ii study of lisaftoclax apg 2575 a novel bcl 2 inhibitor bcl 2i in patients pts with relapsed refractory chronic lymphocytic leukemia or small lymphocytic lymphoma r r cll sll 7543 poster presentation phase ib ii study of bcl 2 inhibitor lisaftoclax apg 2575 safety and tolerability when administered alone or combined with a cyclin dependent kinase 4 6 cdk4 6 inhibitor in patients with estrogen receptor positive er breast cancer or advanced solid tumors tps1122 poster presentation alrizomadlin apg 115 newly updated activity results of alrizomadlin apg 115 a novel mdm2 p53 inhibitor plus pembrolizumab phase 2 study in adults and children with various solid tumors 9517 poster discussion apg 2449 first in human phase i results of apg 2449 a novel fak and third generation alk ros1 tyrosine kinase inhibitor tki in patients pts with second generation tki resistant alk ros1 non small cell lung cancer nsclc or mesothelioma 9071 poster presentation pelcitoclax apg 1252 updated study results of pelcitoclax apg 1252 in combination with osimertinib in patients pts with egfr mutant non small cell lung cancer nsclc 9116 poster presentation first in human study of pelcitoclax apg 1252 in combination with paclitaxel in patients pts with relapsed refractory small cell lung cancer r r sclc e20612 publication only about ascentage pharma ascentage pharma 6855 hk is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers chronic hepatitis b and age related diseases on october 28 2019 ascentage pharma was listed on the main board of the stock exchange of hong kong limited with the stock code 6855 hk ascentage pharma focuses on developing therapeutics that inhibit protein protein interactions to restore apoptosis or programmed cell death the company has built a pipeline of eight clinical drug candidates including novel highly potent bcl 2 and dual bcl 2 bcl xl inhibitors as well as candidates aimed at iap and mdm2 p53 pathways and next generation tyrosine kinase inhibitors tkis ascentage pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators the company is conducting more than 50 phase i ii clinical trials in the us australia europe and china olverembatinib the company s core drug candidate developed for the treatment of drug resistant chronic myeloid leukemia cml was granted priority review status and a breakthrough therapy designation btd by the center for drug evaluation cde of the china national medical products administration nmpa and is already approved for the indication in addition olverembatinib was also granted an orphan drug designation odd and a fast track designation ftd by the us fda and an orphan designation by the eu to date ascentage pharma has obtained a total of 15 odds 2 ftds and 2 rare pediatric disease rpd designations from the fda and 1 odd from the eu for four of the company s investigational drug candidates ascentage pharma has been designated for multiple major national r d projects including 5 national major new drug discovery and manufacturing projects 1 new drug incubator status 4 innovative drug programs and 1 major project for the prevention and treatment of infectious diseases leveraging its robust r d capabilities ascentage pharma has built a portfolio of global intellectual property rights and entered into global partnerships with numerous renowned biotechnology and pharmaceutical companies and research institutes such as unity biotechnology md anderson cancer center mayo clinic dana farber cancer institute merck astrazeneca and pfizer the company has built a talented team with global experience in discovering developing launching and commercializing innovative drugs and is setting up world class commercial manufacturing and sales marketing teams one pivotal aim of ascentage pharma is to continuously strengthen its r d capabilities and accelerate its clinical development programs in order to fulfil its mission of addressing unmet clinical needs in china and around the world for the benefit of more patients forward looking statements the forward looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article except as required by law ascentage pharma undertakes no obligation to update or revise publicly any forward looking statements whether as a result of new information future events or otherwise after the date on which the statements are made or to reflect the occurrence of unanticipated events you should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect in this article statements of or references to our intentions or those of any of our directors or our company are made as of the date of this article any of these intentions may alter in light of future development source ascentage pharma
suzhou china and rockville md june 7 2022 prnewswire ascentage pharma 6855 hk a global biopharmaceutical company engaged in developing novel therapies for cancers chronic hepatitis b chb and age related diseases today announced that it has released the results from its phase i first in human fih study of the company s novel fak inhibitor and third generation alk ros1 tyrosine kinase inhibitor tki apg 2449 in patients with second generation tki resistant alk ros1 non small cell lung cancer nsclc or mesothelioma in a poster presentation at the 58th american society of clinical oncology asco annual meeting apg 2449 is the first china developed third generation alk inhibitor entering clinical studies entering the fifth consecutive year in which its abstracts were selected for presentations by the asco annual meeting ascentage pharma showcased results from multiple clinical trials of its five drug candidates including the first time results of apg 2449 highlighting the company s promising pipeline in solid tumors apg 2449 demonstrated preliminary efficacy in tki nave patients or those whose disease was resistant to second generation tkis with 4 partial responses prs observed in the 14 patients with second generation tki resistant and alk positive nsclc in the 10 tki nave alk ros1 patients the objective response rate orr was 80 and the disease control rate dcr was 100 discovered and developed by ascentage pharma apg 2449 is a novel orally available fak alk ros1 inhibitor and the first china developed third generation alk inhibitor entering clinical studies prof hongyun zhao of sun yat sen university cancer center who is the principal investigator of this study said apg 2449 is a potent fak alk ros1 inhibitor that can address drug resistance to second generation alk tkis in this fih study apg 2449 demonstrated favorable safety and antitumor activity in patients with advanced nsclc and showed on target pharmacodynamic effects building on results from this phase i study we look forward to further evaluate apg 2449 s efficacy in advanced nsclc patients resistant to second generation alk inhibitor dr yifan zhai chief medical officer of ascentage pharma commented apg 2449 is one of our key drug candidates outside our pipeline of apoptosis targeting assets the data presented at this year s asco annual meeting demonstrated apg 2449 s therapeutic potential in patients with advanced nsclc and are indicative of our progress in the field of solid tumors we will continue to take firm steps to advance this clinical development program furthermore we are proud to be able to present clinical development progress for a number of ascentage pharma s drug candidates at this year s asco annual meeting which highlight our capabilities in global innovation honoring our mission of addressing unmet clinical needs in china and around the world we are now accelerating our clinical programs to bring more safe and effective therapeutics to patients in need the highlights of this abstract on apg 2449 are as follows first in human phase i results of apg 2449 a novel fak and third generation alk ros1 tyrosine kinase inhibitor tki in patients pts with second generation tki resistant alk ros1 non small cell lung cancer nsclc or mesothelioma abstract 9071 this dose escalation and dose expansion study was designed to assess the safety tolerability recommended phase ii dose rp2d pharmacokinetics pk pharmacodynamics pd and efficacy of apg 2449 in patients with second generation tki resistant alk ros1 nsclc or mesothelioma as of december 30 2021 84 chinese patients with nsclc or mesothelioma enrolled were treated with apg 2449 at doses ranging from 150 to 1 500 mg apg 2449 was administered orally once daily on a 28 day cycle using a 3 3 dose escalation design 4 prs were observed in 14 alk patients resistant to second generation tkis treated at the rp2d among 8 patients with brain metastases 1 complete response cr and 3 prs were observed intracranially in 10 tki nave patients the orr was 80 alk 6 8 ros1 2 2 and the dcr was 100 in addition agp 2449 demonstrated a favorable safety profile the preliminary biomarker data showed decreased fak phosphorylation in peripheral blood mononuclear cells and increased ifn  levels in serum after multiple doses of apg 2449 conclusions apg 2449 has a favorable safety and pk profile preliminary efficacy was observed in patients whose disease was resistant to second generation or tki nave biomarker data indicated potential target engagement on fak and the immunomodulatory effects of apg 2449 appendix a list of ascentage pharma s abstracts selected by this year s asco annual meeting drug candidate abstract title abstract format olverembatinib hqp1351 promising antitumor activity of olverembatinib hqp1351 in patients pts with tyrosine kinase inhibitor tki resistant succinate dehydrogenase sdh deficient gastrointestinal stromal tumor gist 11513 poster discussion lisaftoclax apg 2575 a phase ib ii study of lisaftoclax apg 2575 a novel bcl 2 inhibitor bcl 2i in patients pts with relapsed refractory chronic lymphocyticleukemia or small lymphocytic lymphoma r rcll sll 7543 posterpresentation phase ib ii study of bcl 2 inhibitor lisaftoclax apg 2575 safety and tolerability when administered alone or combined with a cyclin dependent kinase 4 6 cdk4 6 inhibitor in patients with estrogen receptor positive er breast cancer or advanced solid tumors tps1122 poster presentation alrizomadlin apg 115 newly updated activity results of alrizomadlin apg 115 a novel mdm2 p53 inhibitor plus pembrolizumab phase 2 study in adults and children with various solid tumors 9517 posterdiscussion apg 2449 first in human phase i results of apg 2449 a novel fak and third generation alk ros1 tyrosine kinase inhibitor tki in patients pts with second generation tki resistant alk ros1non small cell lung cancer nsclc ormesothelioma 9071 posterpresentation pelcitoclax apg 1252 updated study results of pelcitoclax apg 1252 incombination with osimertinib in patients pts with egfr mutant non small cell lung cancer nsclc 9116 poster presentation first in human study of pelcitoclax apg 1252 in combination with paclitaxel in patients pts with relapsed refractory small cell lung cancer r r sclc e20612 publication only about ascentage pharma ascentage pharma 6855 hk is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers chronic hepatitis b and age related diseases on october 28 2019 ascentage pharma was listed on the main board of the stock exchange of hong kong limited with the stock code 6855 hk ascentage pharma focuses on developing therapeutics that inhibit protein protein interactions to restore apoptosis or programmed cell death the company has built a pipeline of eight clinical drug candidates including novel highly potent bcl 2 and dual bcl 2 bcl xl inhibitors as well as candidates aimed at iap and mdm2 p53 pathways and next generation tyrosine kinase inhibitors tkis ascentage pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators the company is conducting more than 50 phase i ii clinical trials in the us australia europe and china olverembatinib the company s core drug candidate developed for the treatment of drug resistant chronic myeloid leukemia cml was granted priority review status and a breakthrough therapy designation btd by the center for drug evaluation cde of the china national medical products administration nmpa and is already approved for the indication in addition olverembatinib was also granted an orphan drug designation odd and a fast track designation ftd by the us fda and an orphan designation by the eu to date ascentage pharma has obtained a total of 15 odds 2 ftds and 2 rare pediatric disease rpd designations from the fda and 1 odd from the eu for four of the company s investigational drug candidates ascentage pharma has been designated for multiple major national r d projects including 5 national major new drug discovery and manufacturing projects 1 new drug incubator status 4 innovative drug programs and 1 major project for the prevention and treatment of infectious diseases leveraging its robust r d capabilities ascentage pharma has built a portfolio of global intellectual property rights and entered into global partnerships with numerous renowned biotechnology and pharmaceutical companies and research institutes such as unity biotechnology md anderson cancer center mayo clinic dana farber cancer institute merck astrazeneca and pfizer the company has built a talented team with global experience in discovering developing launching and commercializing innovative drugs and is setting up world class commercial manufacturing and sales marketing teams one pivotal aim of ascentage pharma is to continuously strengthen its r d capabilities and accelerate its clinical development programs in order to fulfil its mission of addressing unmet clinical needs in china and around the world for the benefit of more patients forward looking statements the forward looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article except as required by law ascentage pharma undertakes no obligation to update or revise publicly any forward looking statements whether as a result of new information future events or otherwise after the date on which the statements are made or to reflect the occurrence of unanticipated events you should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect in this article statements of or references to our intentions or those of any of our directors or our company are made as of the date of this article any of these intentions may alter in light of future development view original content to download multimedia source ascentage pharma
shares in asia pacific were higher on wednesday with hong kong leading gains regionally the reserve bank of india will raise the policy repo rate by 50 basis points to 4 9 with immediate effect governor shaktikanta das announced wednesday the repo rate refers to the rate at which the central bank lends to commercial banks japan s economy shrank an annualized 0 5 in the first quarter revised government data showed wednesday an improvement over the initial estimate of a 1 contraction singapore shares in asia pacific were higher on wednesday with hong kong leading gains regionally the hang seng index in hong kong jumped 2 24 to close at 22 014 59 as chinese tech stocks listed in the city soared alibaba surged 10 12 while tencent climbed 6 47 and netease gained 5 66 the shanghai composite in mainland china closed 0 68 higher at 3 263 79 while the shenzhen component climbed 0 818 to 12 033 26 get tri state area news and weather forecasts to your inbox sign up for nbc new york newsletters rbi announces rate hike the reserve bank of india on wednesday raised a key interest rate the rbi will raise the policy repo rate by 50 basis points to 4 9 with immediate effect governor shaktikanta das said the repo rate refers to the rate at which the central bank lends to commercial banks economists in a reuters poll had predicted a rate hike of between 25 to 75 basis points it may be noted in this context that the repo rate still remains below its pre pandemic level the indian central bank chief said following the announcement both the nifty 50 and bse sensex in india rose close to 0 4 each as of 1 44 p m local time the indian rupee traded at 77 763 per dollar weaker as compared with levels below 77 4 seen against the greenback last week the rbi s decision comes after the reserve bank of australia s surprise 50 basis point rate hike on tuesday in other markets the nikkei 225 in japan advanced 1 04 to close at 28 234 29 while the topix index climbed 1 18 to 1 969 98 japan s economy shrank an annualized 0 5 in the first quarter revised government data showed wednesday an improvement over the initial estimate of a 1 contraction south korea s kospi closed little changed at 2 626 15 the s p asx 200 in australia rose 0 36 to finish the trading day at 7 121 10 msci s broadest index of asia pacific shares outside japan gained 1 13 the world bank on tuesday cut its global growth forecast to 2 9 for 2022 and warned of the world economy slipping into a period of stagflation reminiscent of the 1970s these sort of headlines around risk of stagflation slower growth these are things the market has been you know trading on for most of the year already kieran calder head of equity research for asia at ubp told cnbc s street signs asia on wednesday calder described the world bank s expectation for 4 3 growth in 2022 for china as pretty aggressive given that multiple banks have cut their outlook for the country ubp is looking for below 4 gdp growth in china this year he said currencies and oil the u s dollar index which tracks the greenback against a basket of its peers was at 102 619 after seeing an earlier low of 102 387 the japanese yen traded at 133 62 per dollar weaker than levels below 132 seen against the dollar yesterday the australian dollar was at 0 7189 off an earlier high of 0 7235 oil prices were higher in the afternoon of asia trading hours with international benchmark brent crude futures up 0 39 to 121 04 per barrel u s crude futures gained 0 55 to 120 07 per barrel
suzhou china and rockville md june 7 2022 prnewswire ascentage pharma 6855 hk a global biopharmaceutical company engaged in developing novel therapies for cancers chronic hepatitis b chb and age related diseases today announced that it has released the results from its phase i first in human fih study of the company s novel fak inhibitor and third generation alk ros1 tyrosine kinase inhibitor tki apg 2449 in patients with second generation tki resistant alk ros1 non small cell lung cancer nsclc or mesothelioma in a poster presentation at the 58th american society of clinical oncology asco annual meeting apg 2449 is the first china developed third generation alk inhibitor entering clinical studies entering the fifth consecutive year in which its abstracts were selected for presentations by the asco annual meeting ascentage pharma showcased results from multiple clinical trials of its five drug candidates including the first time results of apg 2449 highlighting the company s promising pipeline in solid tumors apg 2449 demonstrated preliminary efficacy in tki nave patients or those whose disease was resistant to second generation tkis with 4 partial responses prs observed in the 14 patients with second generation tki resistant and alk positive nsclc in the 10 tki nave alk ros1 patients the objective response rate orr was 80 and the disease control rate dcr was 100 discovered and developed by ascentage pharma apg 2449 is a novel orally available fak alk ros1 inhibitor and the first china developed third generation alk inhibitor entering clinical studies prof hongyun zhao of sun yat sen university cancer center who is the principal investigator of this study said apg 2449 is a potent fak alk ros1 inhibitor that can address drug resistance to second generation alk tkis in this fih study apg 2449 demonstrated favorable safety and antitumor activity in patients with advanced nsclc and showed on target pharmacodynamic effects building on results from this phase i study we look forward to further evaluate apg 2449 s efficacy in advanced nsclc patients resistant to second generation alk inhibitor dr yifan zhai chief medical officer of ascentage pharma commented apg 2449 is one of our key drug candidates outside our pipeline of apoptosis targeting assets the data presented at this year s asco annual meeting demonstrated apg 2449 s therapeutic potential in patients with advanced nsclc and are indicative of our progress in the field of solid tumors we will continue to take firm steps to advance this clinical development program furthermore we are proud to be able to present clinical development progress for a number of ascentage pharma s drug candidates at this year s asco annual meeting which highlight our capabilities in global innovation honoring our mission of addressing unmet clinical needs in china and around the world we are now accelerating our clinical programs to bring more safe and effective therapeutics to patients in need the highlights of this abstract on apg 2449 are as follows first in human phase i results of apg 2449 a novel fak and third generation alk ros1 tyrosine kinase inhibitor tki in patients pts with second generation tki resistant alk ros1 non small cell lung cancer nsclc or mesothelioma abstract 9071 this dose escalation and dose expansion study was designed to assess the safety tolerability recommended phase ii dose rp2d pharmacokinetics pk pharmacodynamics pd and efficacy of apg 2449 in patients with second generation tki resistant alk ros1 nsclc or mesothelioma as of december 30 2021 84 chinese patients with nsclc or mesothelioma enrolled were treated with apg 2449 at doses ranging from 150 to 1 500 mg apg 2449 was administered orally once daily on a 28 day cycle using a 3 3 dose escalation design 84 chinese patients with nsclc or mesothelioma enrolled were treated with apg 2449 at doses ranging from 150 to 1 500 mg apg 2449 was administered orally once daily on a 28 day cycle using a 3 3 dose escalation design 4 prs were observed in 14 alk patients resistant to second generation tkis treated at the rp2d among 8 patients with brain metastases 1 complete response cr and 3 prs were observed intracranially in 10 tki nave patients the orr was 80 alk 6 8 ros1 2 2 and the dcr was 100 in addition agp 2449 demonstrated a favorable safety profile the preliminary biomarker data showed decreased fak phosphorylation in peripheral blood mononuclear cells and increased ifn  levels in serum after multiple doses of apg 2449 conclusions apg 2449 has a favorable safety and pk profile preliminary efficacy was observed in patients whose disease was resistant to second generation or tki nave biomarker data indicated potential target engagement on fak and the immunomodulatory effects of apg 2449 appendix a list of ascentage pharma s abstracts selected by this year s asco annual meeting drug candidate abstract title abstract format olverembatinib hqp1351 promising antitumor activity of olverembatinib hqp1351 in patients pts with tyrosine kinase inhibitor tki resistant succinate dehydrogenase sdh deficient gastrointestinal stromal tumor gist 11513 poster discussion lisaftoclax apg 2575 a phase ib ii study of lisaftoclax apg 2575 a novel bcl 2 inhibitor bcl 2i in patients pts with relapsed refractory chronic lymphocytic leukemia or small lymphocytic lymphoma r r cll sll 7543 poster presentation phase ib ii study of bcl 2 inhibitor lisaftoclax apg 2575 safety and tolerability when administered alone or combined with a cyclin dependent kinase 4 6 cdk4 6 inhibitor in patients with estrogen receptor positive er breast cancer or advanced solid tumors tps1122 poster presentation alrizomadlin apg 115 newly updated activity results of alrizomadlin apg 115 a novel mdm2 p53 inhibitor plus pembrolizumab phase 2 study in adults and children with various solid tumors 9517 poster discussion apg 2449 first in human phase i results of apg 2449 a novel fak and third generation alk ros1 tyrosine kinase inhibitor tki in patients pts with second generation tki resistant alk ros1 non small cell lung cancer nsclc or mesothelioma 9071 poster presentation pelcitoclax apg 1252 updated study results of pelcitoclax apg 1252 in combination with osimertinib in patients pts with egfr mutant non small cell lung cancer nsclc 9116 poster presentation first in human study of pelcitoclax apg 1252 in combination with paclitaxel in patients pts with relapsed refractory small cell lung cancer r r sclc e20612 publication only about ascentage pharma ascentage pharma 6855 hk is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers chronic hepatitis b and age related diseases on october 28 2019 ascentage pharma was listed on the main board of the stock exchange of hong kong limited with the stock code 6855 hk ascentage pharma focuses on developing therapeutics that inhibit protein protein interactions to restore apoptosis or programmed cell death the company has built a pipeline of eight clinical drug candidates including novel highly potent bcl 2 and dual bcl 2 bcl xl inhibitors as well as candidates aimed at iap and mdm2 p53 pathways and next generation tyrosine kinase inhibitors tkis ascentage pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators the company is conducting more than 50 phase i ii clinical trials in the us australia europe and china olverembatinib the company s core drug candidate developed for the treatment of drug resistant chronic myeloid leukemia cml was granted priority review status and a breakthrough therapy designation btd by the center for drug evaluation cde of the china national medical products administration nmpa and is already approved for the indication in addition olverembatinib was also granted an orphan drug designation odd and a fast track designation ftd by the us fda and an orphan designation by the eu to date ascentage pharma has obtained a total of 15 odds 2 ftds and 2 rare pediatric disease rpd designations from the fda and 1 odd from the eu for four of the company s investigational drug candidates ascentage pharma has been designated for multiple major national r d projects including 5 national major new drug discovery and manufacturing projects 1 new drug incubator status 4 innovative drug programs and 1 major project for the prevention and treatment of infectious diseases leveraging its robust r d capabilities ascentage pharma has built a portfolio of global intellectual property rights and entered into global partnerships with numerous renowned biotechnology and pharmaceutical companies and research institutes such as unity biotechnology md anderson cancer center mayo clinic dana farber cancer institute merck astrazeneca and pfizer the company has built a talented team with global experience in discovering developing launching and commercializing innovative drugs and is setting up world class commercial manufacturing and sales marketing teams one pivotal aim of ascentage pharma is to continuously strengthen its r d capabilities and accelerate its clinical development programs in order to fulfil its mission of addressing unmet clinical needs in china and around the world for the benefit of more patients forward looking statements the forward looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article except as required by law ascentage pharma undertakes no obligation to update or revise publicly any forward looking statements whether as a result of new information future events or otherwise after the date on which the statements are made or to reflect the occurrence of unanticipated events you should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect in this article statements of or references to our intentions or those of any of our directors or our company are made as of the date of this article any of these intentions may alter in light of future development source ascentage pharma
san francisco and suzhou china june 7 2022 prnewswire innovent biologics inc innovent hkex 01801 a world class biopharmaceutical company that develops manufactures and commercializes high quality medicines for the treatment of oncology autoimmune metabolic ophthalmology and other major diseases announces that the primary and all key secondary endpoints were met in a randomized double blind placebo controlled phase 2 study of mazdutide r d code ibi362 a glucagon like peptide 1 receptor glp 1r glucagon receptor gcgr dual agonist in chinese participants with overweight or obesity this study clinicaltrials gov nct04904913 was designed to evaluate the efficacy and safety of mazdutide in chinese participants with overweight or obesity a total of 248 subjects were randomized to receive 1 5 3 0 mg 1 5 3 0 4 5 mg or 2 0 4 0 6 0 mg of mazdutide or placebo subcutaneously and once weekly for 24 weeks the primary endpoint was the percentage change from baseline in body weight at week 24 a total of 230 participants 92 7 completed week 24 mazdutide demonstrated superior weight loss efficacy in chinese participants with overweight or obesity compared with placebo in a dose dependent manner after 24 weeks of treatment the least squares ls mean percent change absolute change from baseline in body weight were 7 21 6 35 kg on 3 0 mg 10 56 9 07 kg on 4 5 mg and 11 57 9 85 kg on 6 0 mg with mazdutide compared with 1 05 1 08 kg with placebo the treatment difference versus placebo in ls mean percent change from baseline were 8 26 on 3 0 mg 11 60 on 4 5 mg and 12 62 on 6 0 mg p 0 0001 for all comparisons the proportion of participants with 5 body weight loss from baseline was 58 1 3 0 mg 82 5 4 5 mg and 80 3 6 0 mg with mazdutide compared with 4 8 with placebo the proportion of participants with 10 body weight loss from baseline was 19 4 3 0 mg 49 2 4 5 mg and 50 8 6 0 mg with mazdutide compared with 0 with placebo meanwhile mazdutide markedly reduced body mass index waist circumference liver fat content and blood pressure lowered lipid transaminase and serum uric acid levels and improved insulin sensitivity delivering comprehensive metabolic benefits for participants with overweight or obesity in terms of safety mazdutide was well tolerated only one participant discontinued the treatment due to an adverse event which was not related to mazdutide as judged by the investigator the overall safety profile was similar to those observed in early phase development and with other glp 1 based agonists and co agonists the most frequently reported treatment emergent adverse events were diarrhea nausea and upper respiratory tract infection mostly mild or moderate in severity and transient professor linong ji the principal investigator of the study peking university people s hospital stated in recent years the prevalence of obesity in china has increased rapidly and resulted in the increase of the prevalence of diabetes fatty liver sleep disorders and cardiovascular diseases therefore effective and safe weight loss drugs are urgently needed we are pleased to see the exciting results of the phase 2 study of mazdutide in chinese participants with overweight or obesity suggesting that mazdutide could potentially be the best in class agent the half year treatment of mazdutide achieved on average 12 6 weight reduction from baseline compared with placebo which was comparable to the most cutting edge weight loss drugs under development in the world the excellent efficacy of mazdutide in weight loss and multiple metabolic parameters truly reflects the advantages of weekly formulation based on dual incretin receptor agonists i am confident and looking forward to the success of mazdutide in the upcoming phase 3 study dr lei qian vice president of clinical development of innovent stated the phase 2 study of mazdutide in chinese participants with overweight or obesity achieved the primary and all key secondary endpoints while showing improvement on multiple metabolic parameters including blood pressure lipids transaminase and serum uric acid these results demonstrate the great utility value of glp 1r gcgr dual agonist further demonstrating the potential to be the best in class agent and paving solid foundation for further clinical development of note the auto injector has been used in the phase 2 studies greatly improving the quality of life and compliance of participants while demonstrating the quality and capability of domestic enterprises in device development and manufacturing we will actively promote the development of phase 3 clinical study of mazdutide and anticipate more clinical data later this year striving to provide more convenient user friendly effective and safe drug for overweight and obese population as soon as possible due to the outbreak of covid 19 the data are being collected and under further analysis the data disclosed in this press release may have some deviation from the final results about obesity china has the largest obese population in the world with obesity rate likely to increase obesity can lead to a range of complications or related diseases that impact life expectancy and lead to a decrease in quality of life in more severely obese patients the incidence and mortality of cardiovascular disease diabetes and certain tumors increase significantly obesity is a chronic disease that requires long term management and there is a lack of long term effective and safe treatments lifestyle intervention is the first choice and basic treatment for patients with overweight or obesity however a considerable percentage of patients fail to achieve the desired weight loss goal upon lifestyle intervention due to various reasons and may require pharmacological intervention traditional anti obesity drugs have limited weight loss effects and are associated with safety issues about mazdutide ibi362 innovent entered into a licensing agreement with eli lilly and company lilly for the development and potential commercialization of oxm3 also known as mazdutide a glp 1r and gcgr dual agonist in china in parallel lilly is developing oxm3 outside china mazdutide is a long acting synthetic peptide related to mammalian oxyntomodulin oxm which uses a fatty acid side chain to prolong the duration of action and allow once weekly administration mazdutide is thought to exert its biological effects by activating glp 1 receptor and glucagon receptor in human beings which improves glucose tolerance and induces weight loss mimicking the effects of endogenous oxyntomodulin in addition to the effects of glp 1 receptor agonists on promoting insulin secretion lowering blood glucose and reducing body weight mazdutide may also increase energy expenditure and improve hepatic fat metabolism through the activation of glucagon receptor the treatment of metabolic diseases by activating multiple metabolism related targets simultaneously is currently the worldwide trend in drug development about innovent inspired by the spirit of start with integrity succeed through action innovent s mission is to develop manufacture and commercialize high quality biopharmaceutical products that are affordable to ordinary people established in 2011 innovent is committed to developing manufacturing and commercializing high quality innovative medicines for the treatment of cancer autoimmune metabolic ophthalmology and other major diseases on october 31 2018 innovent was listed on the main board of the stock exchange of hong kong limited with the stock code 01801 hk since its inception innovent has developed a fully integrated multi functional platform which includes r d cmc chemistry manufacturing and controls clinical development and commercialization capabilities leveraging the platform the company has built a robust pipeline of 32 valuable assets in the fields of cancer autoimmune metabolic ophthalmology and other major therapeutic areas with 7 products approved for marketing in china tyvyt sintilimab injection byvasda bevacizumab biosimilar injection sulinno adalimumab biosimilar injection halpryza rituximab biosimilar injection pemazyre pemigatinib oral inhibitor and olverembatinib bcr abl tki and cyramza ramucirumab 2 asset under nmpa nda review 4 assets in phase 3 or pivotal clinical trials and an additional 19 molecules in clinical studies innovent has built an international team with advanced talent in high end biological drug development and commercialization including many global experts the company has also entered into strategic collaborations with eli lilly and company adimab incyte md anderson cancer center hanmi and other international partners innovent strives to work with many collaborators to help advance china s biopharmaceutical industry improve drug availability and enhance the quality of the patients lives for more information please visit www innoventbio com and www linkedin com company innovent biologics note tyvyt sintilimab injection is not an approved product in the united states byvasda bevacizumab biosimilar injection sulinno and halpryza rituximab biosimilar injection are not approved products in the united states tyvyt sintilimab injection innovent byvasda bevacizumab biosimilar injection innovent halpryza rituximab biosimilar injection innovent sulinno adalimumab biosimilar injection innovent pemazyre pemigatinib oral inhibitor incyte corporation pemazyre was discovered by incyte corporation and licensed to innovent for development and commercialization in mainland china hong kong macau and taiwan cyramza ramucirumab eli lilly cyramza was discovered by eli lilly and licensed to innovent for commercialization in mainland china disclaimer 1 this indication is still under clinical study which hasn t been approved in china 2 innovent does not recommend any off label usage forward looking statement this news release may contain certain forward looking statements that are by their nature subject to significant risks and uncertainties the words anticipate believe estimate expect intend and similar expressions as they relate to innovent biologics innovent are intended to identify certain of such forward looking statements the company does not intend to update these forward looking statements regularly these forward looking statements are based on the existing beliefs assumptions expectations estimates projections and understandings of the management of the company with respect to future events at the time these statements are made these statements are not a guarantee of future developments and are subject to risks uncertainties and other factors some of which are beyond the company s control and are difficult to predict consequently actual results may differ materially from information contained in the forward looking statements as a result of future changes or developments in our business the company s competitive environment and political economic legal and social conditions the company the directors and the employees of the company assume a no obligation to correct or update the forward looking statements contained in this site and b no liability in the event that any of the forward looking statements does not materialise or turn out to be incorrect source innovent biologics
cityzenith is partnering with the los angeles branch of the u s department of energy s better buildings challenge to help construct a digital twin or virtual replica of a section of the city to help make its buildings more sustainable and reduce carbon emissions the endeavor will initially focus on los angeles downtown neighborhood bunker hill the partnership will also help los angeles work toward its green new deal goal to achieve zero net emissions by 2050 across its building sector which accounts for 43 of the city s emissions how do you start figuring out what tech your offices shops or warehouses need when there are thousands of startups in the industry placetech spoke to jll spark s raj singh for his advice on getting it right among his tips singh suggests that firms 1 hire people who understand tech or face financial consequences 2 build a framework 3 remember best in class might not be best for you and 4 recognize the value of occupancy data the future of coworking spaces looked uncertain during the pandemic but the ceo of regus and spaces parent company says huge opportunities lie in the industry s near future iwg is preparing to open between 500 and 700 new coworking spaces in the u s in the next 12 months founder and ceo mark dixon told the washington business journal as businesses navigate their future relationships with office spaces many are looking to coworking spaces as options to bring shared workplaces closer to employees homes
jpmorgan s marko kolanovic predicts oil is surging higher but so are stocks kolanovic who serves as the firm s chief global markets strategist and co head of global research believes the u s economy is strong enough to handle oil prices as high as 150 a barrel there could be some potential further spikes in oil especially given the situation in europe and the war so we wouldn t be surprised he told cnbc s fast money on tuesday but it could be a short lived spike and eventually sort of normalize get tri state area news and weather forecasts to your inbox sign up for nbc new york newsletters wti crude is trading around three month highs settling up 0 77 to 119 41 a barrel on tuesday brent crude closed at the 120 57 mark the bullish move came as shanghai reopened from a two month covid 19 lockdown opening the door for higher demand and more upside we think the consumer can handle oil at 130 135 because we had that back in 2010 to 2014 inflation adjusted that was basically the level so we think the consumer can handle that said kolanovic who has earned top honors from institutional investor for accurate forecasts multiple years in a row his base case is the u s and global economy will avoid a recession but at a financial conference last week jpmorgan chase chairman and ceo jamie dimon told investors he s preparing for an economic hurricane which could be a minor one or superstorm sandy kolanovic contends it s vital to be ready for all possibilities we do forecast some slow down he said nobody is saying that there are no problems his firm s official s p 500 year end target is 4 900 but in a recent note kolanovic speculated the index would end the year around 4 800 still on par with all time highs hit on jan 4 right now the s p is 16 below its record high we don t think investors will stick in cash we don t think investors will stick in cash for the next 12 months you know waiting for this recession kolanovic said if we continue to see consumer especially on the services side holding up which we do expect then we think investors will gradually come back into equity markets kolanovic s top call remains energy a group he has been bullish on since 2019 actually valuations went lower despite the stock price appreciation kolanovic said earnings grow faster so multiples are actually lower now in energy than they were a year ago he s also bullish on small caps and high beta technology stocks that have gotten crushed this year disclaimer
suzhou china and rockville md june 7 2022 prnewswire ascentage pharma 6855 hk a global biopharmaceutical company engaged in developing novel therapies for cancers chronic hepatitis b chb and age related diseases today announced that it has released the updated results from a phase ib ii study of the bcl 2 inhibitor lisaftoclax apg 2575 in patients with relapsed refractory chronic lymphocytic leukemia small lymphocytic lymphoma r r cll sll in a poster presentation at the 58th american society of clinical oncology asco annual meeting entering the fifth consecutive year in which company s abstracts were selected for presentations by the asco annual meeting ascentage pharma showcased results from multiple clinical trials of its five drug candidates including favorable data of lisaftoclax a key drug candidate of the company s apoptosis targeted pipeline in chinese patients with r r cll sll showing an objective response rate orr of 67 4 lisaftoclax was well tolerated and all adverse events were manageable no dose limiting toxicity dlt were observed at up to 800 mg day the risk of clinical tumor lysis syndrome tls in patients on daily dose ramp up was minimal prof jianyong li director of the hematology department jiangsu people s hospital and the principal investigator of this study said lisaftoclax is a bcl 2 selective inhibitor that can induce apoptosis and suppress the growth of tumor cells in this phase ib ii study lisaftoclax as a single agent showed favorable preliminary efficacy and safety and a daily ramp up schedule that is patients friendly we look forward to further evaluating the efficacy of lisaftoclax as a single agent and in combinations in patients with r r cll sll dr yifan zhai chief medical officer of ascentage pharma commented lisaftoclax is the first china developed bcl 2 inhibitor entering clinical development in china also the world s second and china s first bcl 2 inhibitor being investigated in pivotal trials data released at this year s asco annual meeting suggest that lisaftoclax may offer an effective safe and more user friendly treatment alternative to patients with r r cll sll we are taking firm steps forward with this clinical development program to allow patients to benefit from this novel therapeutic as soon as possible meanwhile we are also evaluating lisaftoclax monotherapy and combinations in patients with solid tumors dr zhai continued furthermore we are proud to be able to present clinical development progress for a number of ascentage pharma s drug candidates which highlight our capabilities in global innovation honoring our mission of addressing unmet clinical needs in china and around the world we are now accelerating our clinical programs to bring more safe and effective therapeutics to patients in need the highlights of this abstract on lisaftoclax are as follows a phase ib ii study of lisaftoclax apg 2575 a novel bcl 2 inhibitor bcl 2i in patients pts with relapsed refractory chronic lymphocytic leukemia or small lymphocytic lymphoma r r cll sll abstract 7543 the aim of this multicenter open label study was to evaluate the safety antitumor activity pk and pharmacodynamics pd of lisaftoclax in chinese patients with r r cll sll as of january 25 2022 45 patients had been enrolled lisaftoclax was administered orally once daily at 3 dose cohorts 400 600 or 800 mg in 28 day cycles with 15 patients in each cohort 45 patients had been enrolled lisaftoclax was administered orally once daily at 3 dose cohorts 400 600 or 800 mg in 28 day cycles with 15 patients in each cohort lisaftoclax monotherapy demonstrated favorable safety profiles in all three dose cohorts and no dlt was observed during the phase i study the risk of tls in patients on daily dose ramp up was extremely low which was consistent with the observations of the phase i study the median duration of treatment was 7 cycles and the orr in the 43 efficacy evaluable patients with r r cll sll was 67 4 including 1 complete response cr and 28 partial responses prs bcl 2i lisaftoclax was well tolerated up to 800 mg day there were no significant new or unmanageable safety findings the recommended phase ii dose rp2d of lisaftoclax was determined as 600 mg lisaftoclax may offer a treatment alternative for patients with r r cll sll with a daily ramp up schedule that may be more convenient and user friendly appendix a list of ascentage pharma s abstracts selected by this year s asco annual meeting drug candidate abstract title abstract format olverembatinib hqp1351 promising antitumor activity of olverembatinib hqp1351 in patients pts with tyrosine kinase inhibitor tki resistant succinate dehydrogenase sdh deficient gastrointestinal stromal tumor gist 11513 poster discussion lisaftoclax apg 2575 a phase ib ii study of lisaftoclax apg 2575 a novel bcl 2 inhibitor bcl 2i in patients pts with relapsed refractory chronic lymphocytic leukemia or small lymphocytic lymphoma r r cll sll 7543 poster presentation phase ib ii study of bcl 2 inhibitor lisaftoclax apg 2575 safety and tolerability when administered alone or combined with a cyclin dependent kinase 4 6 cdk4 6 inhibitor in patients with estrogen receptor positive er breast cancer or advanced solid tumors tps1122 poster presentation alrizomadlin apg 115 newly updated activity results of alrizomadlin apg 115 a novel mdm2 p53 inhibitor plus pembrolizumab phase 2 study in adults and children with various solid tumors 9517 poster discussion apg 2449 first in human phase i results of apg 2449 a novel fak and third generation alk ros1 tyrosine kinase inhibitor tki in patients pts with second generation tki resistant alk ros1 non small cell lung cancer nsclc or mesothelioma 9071 poster presentation pelcitoclax apg 1252 updated study results of pelcitoclax apg 1252 in combination with osimertinib in patients pts with egfr mutant non small cell lung cancer nsclc 9116 poster presentation first in human study of pelcitoclax apg 1252 in combination with paclitaxel in patients pts with relapsed refractory small cell lung cancer r r sclc e20612 publication only about ascentage pharma ascentage pharma 6855 hk is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers chronic hepatitis b and age related diseases on october 28 2019 ascentage pharma was listed on the main board of the stock exchange of hong kong limited with the stock code 6855 hk ascentage pharma focuses on developing therapeutics that inhibit protein protein interactions to restore apoptosis or programmed cell death the company has built a pipeline of eight clinical drug candidates including novel highly potent bcl 2 and dual bcl 2 bcl xl inhibitors as well as candidates aimed at iap and mdm2 p53 pathways and next generation tyrosine kinase inhibitors tkis ascentage pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators the company is conducting more than 50 phase i ii clinical trials in the us australia europe and china olverembatinib the company s core drug candidate developed for the treatment of drug resistant chronic myeloid leukemia cml was granted priority review status and a breakthrough therapy designation btd by the center for drug evaluation cde of the china national medical products administration nmpa and is already approved for the indication in addition olverembatinib was also granted an orphan drug designation odd and a fast track designation ftd by the us fda and an orphan designation by the eu to date ascentage pharma has obtained a total of 15 odds 2 ftds and 2 rare pediatric disease rpd designations from the fda and 1 odd from the eu for four of the company s investigational drug candidates ascentage pharma has been designated for multiple major national r d projects including 5 national major new drug discovery and manufacturing projects 1 new drug incubator status 4 innovative drug programs and 1 major project for the prevention and treatment of infectious diseases leveraging its robust r d capabilities ascentage pharma has built a portfolio of global intellectual property rights and entered into global partnerships with numerous renowned biotechnology and pharmaceutical companies and research institutes such as unity biotechnology md anderson cancer center mayo clinic dana farber cancer institute merck astrazeneca and pfizer the company has built a talented team with global experience in discovering developing launching and commercializing innovative drugs and is setting up world class commercial manufacturing and sales marketing teams one pivotal aim of ascentage pharma is to continuously strengthen its r d capabilities and accelerate its clinical development programs in order to fulfil its mission of addressing unmet clinical needs in china and around the world for the benefit of more patients forward looking statements the forward looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article except as required by law ascentage pharma undertakes no obligation to update or revise publicly any forward looking statements whether as a result of new information future events or otherwise after the date on which the statements are made or to reflect the occurrence of unanticipated events you should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect in this article statements of or references to our intentions or those of any of our directors or our company are made as of the date of this article any of these intentions may alter in light of future development source ascentage pharma
san francisco and suzhou china june 7 2022 prnewswire innovent biologics inc innovent hkex 01801 a world class biopharmaceutical company that develops manufactures and commercializes high quality medicines for the treatment of oncology autoimmune metabolic ophthalmology and other major diseases announces that the primary and all key secondary endpoints were met in a randomized double blind placebo controlled phase 2 study of mazdutide r d code ibi362 a glucagon like peptide 1 receptor glp 1r glucagon receptor gcgr dual agonist in chinese participants with overweight or obesity this study clinicaltrials gov nct04904913 was designed to evaluate the efficacy and safety of mazdutide in chinese participants with overweight or obesity a total of 248 subjects were randomized to receive 1 5 3 0 mg 1 5 3 0 4 5 mg or 2 0 4 0 6 0 mg of mazdutide or placebo subcutaneously and once weekly for 24 weeks the primary endpoint was the percentage change from baseline in body weight at week 24 a total of 230 participants 92 7 completed week 24 mazdutide demonstrated superior weight loss efficacy in chinese participants with overweight or obesity compared with placebo in a dose dependent manner after 24 weeks of treatment the least squares ls mean percent change absolute change from baseline in body weight were 7 21 6 35 kg on 3 0 mg 10 56 9 07 kg on 4 5 mg and 11 57 9 85 kg on 6 0 mg with mazdutide compared with 1 05 1 08 kg with placebo the treatment difference versus placebo in ls mean percent change from baseline were 8 26 on 3 0 mg 11 60 on 4 5 mg and 12 62 on 6 0 mg p the proportion of participants with 5 body weight loss from baseline was 58 1 3 0 mg 82 5 4 5 mg and 80 3 6 0 mg with mazdutide compared with 4 8 with placebo the proportion of participants with 10 body weight loss from baseline was 19 4 3 0 mg 49 2 4 5 mg and 50 8 6 0 mg with mazdutide compared with 0 with placebo meanwhile mazdutide markedly reduced body mass index waist circumference liver fat content and blood pressure lowered lipid transaminase and serum uric acid levels and improved insulin sensitivity delivering comprehensive metabolic benefits for participants with overweight or obesity in terms of safety mazdutide was well tolerated only one participant discontinued the treatment due to an adverse event which was not related to mazdutide as judged by the investigator the overall safety profile was similar to those observed in early phase development and with other glp 1 based agonists and co agonists the most frequently reported treatment emergent adverse events were diarrhea nausea and upper respiratory tract infection mostly mild or moderate in severity and transient professor linong ji the principal investigator of the study peking university people s hospital stated in recent years the prevalence of obesity in china has increased rapidly and resulted in the increase of the prevalence of diabetes fatty liver sleep disorders and cardiovascular diseases therefore effective and safe weight loss drugs are urgently needed we are pleased to see the exciting results of the phase 2 study of mazdutide in chinese participants with overweight or obesity suggesting that mazdutide could potentially be the best in class agent the half year treatment of mazdutide achieved on average 12 6 weight reduction from baseline compared with placebo which was comparable to the most cutting edge weight loss drugs under development in the world the excellent efficacy of mazdutide in weight loss and multiple metabolic parameters truly reflects the advantages of weekly formulation based on dual incretin receptor agonists i am confident and looking forward to the success of mazdutide in the upcoming phase 3 study dr lei qian vice president of clinical development of innovent stated the phase 2 study of mazdutide in chinese participants with overweight or obesity achieved the primary and all key secondary endpoints while showing improvement on multiple metabolic parameters including blood pressure lipids transaminase and serum uric acid these results demonstrate the great utility value of glp 1r gcgr dual agonist further demonstrating the potential to be the best in class agent and paving solid foundation for further clinical development of note the auto injector has been used in the phase 2 studies greatly improving the quality of life and compliance of participants while demonstrating the quality and capability of domestic enterprises in device development and manufacturing we will actively promote the development of phase 3 clinical study of mazdutide and anticipate more clinical data later this year striving to provide more convenient user friendly effective and safe drug for overweight and obese population as soon as possible due to the outbreak of covid 19 the data are being collected and under further analysis the data disclosed in this press release may have some deviation from the final results about obesity china has the largest obese population in the world with obesity rate likely to increase obesity can lead to a range of complications or related diseases that impact life expectancy and lead to a decrease in quality of life in more severely obese patients the incidence and mortality of cardiovascular disease diabetes and certain tumors increase significantly obesity is a chronic disease that requires long term management and there is a lack of long term effective and safe treatments lifestyle intervention is the first choice and basic treatment for patients with overweight or obesity however a considerable percentage of patients fail to achieve the desired weight loss goal upon lifestyle intervention due to various reasons and may require pharmacological intervention traditional anti obesity drugs have limited weight loss effects and are associated with safety issues about mazdutide ibi362 innovent entered into a licensing agreement with eli lilly and company lilly for the development and potential commercialization of oxm3 also known as mazdutide a glp 1r and gcgr dual agonist in china in parallel lilly is developing oxm3 outside china mazdutide is a long acting synthetic peptide related to mammalian oxyntomodulin oxm which uses a fatty acid side chain to prolong the duration of action and allow once weekly administration mazdutide is thought to exert its biological effects by activating glp 1 receptor and glucagon receptor in human beings which improves glucose tolerance and induces weight loss mimicking the effects of endogenous oxyntomodulin in addition to the effects of glp 1 receptor agonists on promoting insulin secretion lowering blood glucose and reducing body weight mazdutide may also increase energy expenditure and improve hepatic fat metabolism through the activation of glucagon receptor the treatment of metabolic diseases by activating multiple metabolism related targets simultaneously is currently the worldwide trend in drug development about innovent inspired by the spirit of start with integrity succeed through action innovent s mission is to develop manufacture and commercialize high quality biopharmaceutical products that are affordable to ordinary people established in 2011 innovent is committed to developing manufacturing and commercializing high quality innovative medicines for the treatment of cancer autoimmune metabolic ophthalmology and other major diseases on october 31 2018 innovent was listed on the main board of the stock exchange of hong kong limited with the stock code 01801 hk since its inception innovent has developed a fully integrated multi functional platform which includes r d cmc chemistry manufacturing and controls clinical development and commercialization capabilities leveraging the platform the company has built a robust pipeline of 32 valuable assets in the fields of cancer autoimmune metabolic ophthalmology and other major therapeutic areas with 7 products approved for marketing in china tyvyt sintilimab injection byvasda bevacizumab biosimilar injection sulinno adalimumab biosimilar injection halpryza rituximab biosimilar injection pemazyre pemigatinib oral inhibitor and olverembatinib bcr abl tki and cyramza ramucirumab 2 asset under nmpa nda review 4 assets in phase 3 or pivotal clinical trials and an additional 19 molecules in clinical studies innovent has built an international team with advanced talent in high end biological drug development and commercialization including many global experts the company has also entered into strategic collaborations with eli lilly and company adimab incyte md anderson cancer center hanmi and other international partners innovent strives to work with many collaborators to help advance china s biopharmaceutical industry improve drug availability and enhance the quality of the patients lives for more information please visit www innoventbio com and www linkedin com company innovent biologics note tyvyt sintilimab injection is not an approved product in the united states byvasda bevacizumab biosimilar injection sulinno and halpryza rituximab biosimilar injection are not approved products in the united states tyvyt sintilimab injection innovent byvasda bevacizumab biosimilar injection innovent halpryza rituximab biosimilar injection innovent sulinno adalimumab biosimilar injection innovent pemazyre pemigatinib oral inhibitor incyte corporation pemazyre was discovered by incyte corporation and licensed to innovent for development and commercialization in mainland china hong kong macau and taiwan cyramza ramucirumab eli lilly cyramza was discovered by eli lilly and licensed to innovent for commercialization in mainland china disclaimer 1 this indication is still under clinical study which hasn t been approved in china 2 innovent does not recommend any off label usage forward looking statement this news release may contain certain forward looking statements that are by their nature subject to significant risks and uncertainties the words anticipate believe estimate expect intend and similar expressions as they relate to innovent biologics innovent are intended to identify certain of such forward looking statements the company does not intend to update these forward looking statements regularly these forward looking statements are based on the existing beliefs assumptions expectations estimates projections and understandings of the management of the company with respect to future events at the time these statements are made these statements are not a guarantee of future developments and are subject to risks uncertainties and other factors some of which are beyond the company s control and are difficult to predict consequently actual results may differ materially from information contained in the forward looking statements as a result of future changes or developments in our business the company s competitive environment and political economic legal and social conditions the company the directors and the employees of the company assume a no obligation to correct or update the forward looking statements contained in this site and b no liability in the event that any of the forward looking statements does not materialise or turn out to be incorrect view original content source innovent biologics
suzhou china and rockville md june 7 2022 prnewswire ascentage pharma 6855 hk a global biopharmaceutical company engaged in developing novel therapies for cancers chronic hepatitis b chb and age related diseases today announced that it has released the updated results from a phase ib ii study of the bcl 2 inhibitor lisaftoclax apg 2575 in patients with relapsed refractory chronic lymphocytic leukemia small lymphocytic lymphoma r r cll sll in a poster presentation at the 58th american society of clinical oncology asco annual meeting entering the fifth consecutive year in which company s abstracts were selected for presentations by the asco annual meeting ascentage pharma showcased results from multiple clinical trials of its five drug candidates including favorable data of lisaftoclax a key drug candidate of the company s apoptosis targeted pipeline in chinese patients with r r cll sll showing an objective response rate orr of 67 4 lisaftoclax was well tolerated and all adverse events were manageable no dose limiting toxicity dlt were observed at up to 800 mg day the risk of clinical tumor lysis syndrome tls in patients on daily dose ramp up was minimal prof jianyong li director of the hematology department jiangsu people s hospital and the principal investigator of this study said lisaftoclax is a bcl 2 selective inhibitor that can induce apoptosis and suppress the growth of tumor cells in this phase ib ii study lisaftoclax as a single agent showed favorable preliminary efficacy and safety and a daily ramp up schedule that is patients friendly we look forward to further evaluating the efficacy of lisaftoclax as a single agent and in combinations in patients with r r cll sll dr yifan zhai chief medical officer of ascentage pharma commented lisaftoclax is the first china developed bcl 2 inhibitor entering clinical development in china also the world s second and china s first bcl 2 inhibitor being investigated in pivotal trials data released at this year s asco annual meeting suggest that lisaftoclax may offer an effective safe and more user friendly treatment alternative to patients with r r cll sll we are taking firm steps forward with this clinical development program to allow patients to benefit from this novel therapeutic as soon as possible meanwhile we are also evaluating lisaftoclax monotherapy and combinations in patients with solid tumors dr zhai continued furthermore we are proud to be able to present clinical development progress for a number of ascentage pharma s drug candidates which highlight our capabilities in global innovation honoring our mission of addressing unmet clinical needs in china and around the world we are now accelerating our clinical programs to bring more safe and effective therapeutics to patients in need the highlights of this abstract on lisaftoclax are as follows a phase ib ii study of lisaftoclax apg 2575 a novel bcl 2 inhibitor bcl 2i in patients pts with relapsed refractory chronic lymphocytic leukemia or small lymphocytic lymphoma r r cll sll abstract 7543 the aim of this multicenter open label study was to evaluate the safety antitumor activity pk and pharmacodynamics pd of lisaftoclax in chinese patients with r r cll sll as of january 25 2022 45 patients had been enrolled lisaftoclax was administered orally once daily at 3 dose cohorts 400 600 or 800 mg in 28 day cycles with 15 patients in each cohort lisaftoclax monotherapy demonstrated favorable safety profiles in all three dose cohorts and no dlt was observed during the phase i study the risk of tls in patients on daily dose ramp up was extremely low which was consistent with the observations of the phase i study the median duration of treatment was 7 cycles and the orr in the 43 efficacy evaluable patients with r r cll sll was 67 4 including 1 complete response cr and 28 partial responses prs bcl 2i lisaftoclax was well tolerated up to 800 mg day there were no significant new or unmanageable safety findings the recommended phase ii dose rp2d of lisaftoclax was determined as 600 mg lisaftoclax may offer a treatment alternative for patients with r r cll sll with a daily ramp up schedule that may be more convenient and user friendly appendix a list of ascentage pharma s abstracts selected by this year s asco annual meeting drug candidate abstract title abstract format olverembatinib hqp1351 promising antitumor activity of olverembatinib hqp1351 in patients pts with tyrosine kinase inhibitor tki resistant succinate dehydrogenase sdh deficient gastrointestinal stromal tumor gist 11513 poster discussion lisaftoclax apg 2575 a phase ib ii study of lisaftoclax apg 2575 a novel bcl 2 inhibitor bcl 2i in patients pts with relapsed refractory chronic lymphocytic leukemia or small lymphocytic lymphoma r r cll sll 7543 poster presentation phase ib ii study of bcl 2 inhibitor lisaftoclax apg 2575 safety and tolerability when administered alone or combined with a cyclin dependent kinase 4 6 cdk4 6 inhibitor in patients with estrogen receptor positive er breast cancer or advanced solid tumors tps1122 poster presentation alrizomadlin apg 115 newly updated activity results of alrizomadlin apg 115 a novel mdm2 p53 inhibitor plus pembrolizumab phase 2 study in adults and children with various solid tumors 9517 poster discussion apg 2449 first in human phase i results of apg 2449 a novel fak and third generation alk ros1 tyrosine kinase inhibitor tki in patients pts with second generation tki resistant alk ros1 non small cell lung cancer nsclc or mesothelioma 9071 poster presentation pelcitoclax apg 1252 updated study results of pelcitoclax apg 1252 in combination with osimertinib in patients pts with egfr mutant non small cell lung cancer nsclc 9116 poster presentation first in human study of pelcitoclax apg 1252 in combination with paclitaxel in patients pts with relapsed refractory small cell lung cancer r r sclc e20612 publication only about ascentage pharma ascentage pharma 6855 hk is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers chronic hepatitis b and age related diseases on october 28 2019 ascentage pharma was listed on the main board of the stock exchange of hong kong limited with the stock code 6855 hk ascentage pharma focuses on developing therapeutics that inhibit protein protein interactions to restore apoptosis or programmed cell death the company has built a pipeline of eight clinical drug candidates including novel highly potent bcl 2 and dual bcl 2 bcl xl inhibitors as well as candidates aimed at iap and mdm2 p53 pathways and next generation tyrosine kinase inhibitors tkis ascentage pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators the company is conducting more than 50 phase i ii clinical trials in the us australia europe and china olverembatinib the company s core drug candidate developed for the treatment of drug resistant chronic myeloid leukemia cml was granted priority review status and a breakthrough therapy designation btd by the center for drug evaluation cde of the china national medical products administration nmpa and is already approved for the indication in addition olverembatinib was also granted an orphan drug designation odd and a fast track designation ftd by the us fda and an orphan designation by the eu to date ascentage pharma has obtained a total of 15 odds 2 ftds and 2 rare pediatric disease rpd designations from the fda and 1 odd from the eu for four of the company s investigational drug candidates ascentage pharma has been designated for multiple major national r d projects including 5 national major new drug discovery and manufacturing projects 1 new drug incubator status 4 innovative drug programs and 1 major project for the prevention and treatment of infectious diseases leveraging its robust r d capabilities ascentage pharma has built a portfolio of global intellectual property rights and entered into global partnerships with numerous renowned biotechnology and pharmaceutical companies and research institutes such as unity biotechnology md anderson cancer center mayo clinic dana farber cancer institute merck astrazeneca and pfizer the company has built a talented team with global experience in discovering developing launching and commercializing innovative drugs and is setting up world class commercial manufacturing and sales marketing teams one pivotal aim of ascentage pharma is to continuously strengthen its r d capabilities and accelerate its clinical development programs in order to fulfil its mission of addressing unmet clinical needs in china and around the world for the benefit of more patients forward looking statements the forward looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article except as required by law ascentage pharma undertakes no obligation to update or revise publicly any forward looking statements whether as a result of new information future events or otherwise after the date on which the statements are made or to reflect the occurrence of unanticipated events you should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect in this article statements of or references to our intentions or those of any of our directors or our company are made as of the date of this article any of these intentions may alter in light of future development view original content to download multimedia source ascentage pharma
the president has called on congress to act now to reduce gun violence and save lives the white house said this legislation would make significant progress toward delivering on that call to action the package would raise the age of purchasing semiautomatic rifles from 18 to 21 create new requirements for storing guns in a home with children prevent gun trafficking require all firearms to be traceable and close the loophole on bump stocks devices that increase the rate of fire of semiautomatic weapons among other things in the house speaker nancy pelosi will bring a more sweeping package of eight related gun control bills for a vote wednesday it s not expected to advance in the evenly divided senate murphy is part of a small bipartisan group of senators working to strike some type of deal to get 10 republican votes for gun legislation meanwhile president joe biden met with sen chris murphy a connecticut democrat on tuesday to discuss gun control negotiations in the senate following the new york mass shooting and a may 24 massacre in uvalde texas in which 19 schoolchildren and two teachers were gunned down extremism is still a sad reality in america we have to do everything to make america safer said dick durbin an illinois democrat and chairman of the judiciary committee buffalo new york was an illustration on why that s necessary witnesses during the hearing also predicted that the spread of white supremacy in the united states will increase acts of domestic terrorism my mom s life mattered he said your actions here will tell us if and how much it mattered to you whitfield talked about his mother and how it s impossible for his family to grasp that she was taken from them by someone full of so much hate it comes under the banner of white supremacy said garnell whitfield jr who lost his mother ruth when the 18 year old white supremacist traveled to a predominantly black neighborhood in buffalo on may 14 and killed 10 black people the gunman in buffalo new york was motivated by the great replacement theory a racist conspiracy theory that claims growing numbers of immigrants and people of color will lead to the extinction of the white race according to the national immigration forum washington the son of a black woman shot and killed by a white supremacist begged members of the u s senate judiciary committee on tuesday to take action against such domestic terrorism no longer a fringe theory at the senate hearing two witnesses michael german of the brennan center for justice and robert pape a political science professor at the university of chicago warned senators that while the great replacement theory is not new it is no longer a fringe idea they said it has become mainstream because of media coverage on outlets such as fox news as well as claims by right wing politicians we need to prepare for potential political violence in the future said pape who is also the director of the chicago project on security and threats the department of homeland security issued a notice tuesday that stated because of the recent violent attacks against communities of color in coming months we expect the threat environment to become more dynamic as several high profile events could be exploited to justify acts of violence against a range of possible targets these targets could include public gatherings faith based institutions schools racial and religious minorities government facilities and personnel u s critical infrastructure the media and perceived ideological opponents the dhs summary said threat actors have recently mobilized to violence due to factors such as personal grievances reactions to current events and adherence to violent extremist ideologies including racially or ethnically motivated or anti government anti authority violent extremism the dhs summary said jan 6 attack pape said his research has shown that a key characteristic of the more than 800 people charged with participating in the jan 6 attack on the u s capitol is they are middle class whites residing in counties with the most loss of white population share exactly who would most likely fear the great replacement as described by prominent political and media leaders he said the white supremacist attack in buffalo was a prime example he added that the last time the u s saw middle class white americans involved in political violence was during the second expansion of the ku klux klan in the 1920s durbin said mass shootings targeting places of worship and communities of color are increasing adding that the first hearing he called on domestic terrorism was 10 years ago after a sikh temple was targeted seven worshipers died durbin asked pape what role social media plays as well as the easy access to firearms used in mass shootings weapons have combined with volatile ideas and beliefs in the mainstream pape said you ve got the combination of these two which is why we re seeing many more of these events in the united states this is a deadly cocktail that promises more violence coming forward pape added that media figures and politicians that either directly or indirectly embrace the great replacement theory are often rewarded from high cable news ratings to campaign donations pape said mass shootings related to the great replacement theory include the 2019 tree of life synagogue shooting in pittsburgh where 11 jewish worshipers were killed and the 2019 el paso shooting in a hispanic neighborhood where 23 latinos were killed while shopping at walmart german a former f b i agent said there needs to be a federal record of domestic terrorism adding that it s not something the department of justice tracks the failure to acknowledge the organized and interstate nature of violent white supremacists and far right militant groups forfeits intelligence that could be used to prepare for and perhaps prevent future attacks he said sen amy klobuchar a minnesota democrat also asked one of the witnesses justin herdman a former u s attorney for the northern district of ohio what role social media played in the spread of misinformation it certainly has not played a positive role in spreading disinformation and radicalizing people who would do harm to others herdman said sen mazie hirono a hawaii democrat said that a large factor in domestic terrorism is the accessibility of assault weapons free speech concerns the top republican on the committee sen chuck grassley of iowa said the threat of domestic terrorism is always shifting and can also include political violence we have to condemn all political violence he said adding that at the same time we have to protect free speech he pointed to the 2017 shooting at the congressional baseball game where republicans were specifically targeted by a left wing political activist as an example of extreme political violence sen marsha blackburn a tennessee republican also raised concerns about political free speech she asked one of the witnesses jonathan turley a professor at george washington university law school how law enforcement can make determinations between extreme speech and free speech the concern is if you tie a particular ideology to the f b i turley said adding that the u s has persecuted people for being communists and marxists senate republicans in late may blocked a bill that would require federal agencies to monitor domestic terrorism incidents including those related to white supremacy republican sen rand paul of kentucky said the bill would brand police and military service members as white supremacists sen cory booker a new jersey democrat said at the hearing that he was worried about the fate of the country on that fateful day in buffalo we realized the danger of allowing hatred in any form in our country to fester he said it tears at the overall fabric of our democracy will we be better at being a multicultural nation
shanghai and hong kong june 7 2022 prnewswire antengene corporation limited antengene sehk 6996 hk a leading innovative commercial stage global biopharmaceutical company dedicated to discovering developing and commercializing first in class and or best in class therapeutics in hematology and oncology today announced that the first patient has been dosed in the phase i stamina 001 trial to evaluate atg 037 as a monotherapy or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors in australia the primary objective of the study is to evaluate the safety tolerability recommended phase ii dose and preliminary antitumor efficacy of atg 037 as a monotherapy and in combination with pembrolizumab secondary objectives include characterization of the pharmacology of atg 037 atg 037 is an orally available small molecule cd73 inhibitor cd73 is an immune checkpoint mediator 1 that interferes with anti tumor immune responses by generating adenosine which leads to immunosuppression in the tumor microenvironment atg 037 can reverse adenosine mediated immunosuppression2 it has demonstrated promising preclinical efficacy as a monotherapy and in combination with icis and chemotherapy agents in preclinical studies this compound overcomes the hook effect that is common in anti cd73 antibodies in addition glp toxicology studies indicate the compound has a potentially wide therapeutic window while icis are widely used in the treatment of various cancers many patients have resistant or refractory disease which has created a large unmet need said dr ganessan kichenadasse principal investigator southern oncology clinical research unit in adelaide australia mounting evidence suggests that adenosine plays a critical role in suppressing anti tumor immunoactivity cd73 can convert adenosine monophosphate amp to adenosine atg 037 an orally available small molecule cd73 inhibitor can block the generation of adenosine we are excited to be a part of the stamina 001 trial this phase i study brings together a group of highly experienced australian investigators to collaborate with antengene we are excited to assess the therapeutic potential of atg 037 for patients with solid tumors as a single agent as well the exploring the opportunity for benefit with the addition of an icis developing agents that can act in the tumor microenvironment to reverse immunosuppression is one of the key focus areas for antengene said dr kevin lynch antengene s chief medical officer preclinical data presented at the 2022 american association of cancer research annual meeting aacr 2022 showed that atg 037 had a stronger ability to restore t cell function in higher amp environments compared with anti cd73 monoclonal antibodies these data highlighted the potential therapeutic advantages of small molecule inhibitors of cd73 over blocking antibodies either as a monotherapy or in combination with other immune oncological treatments we have been very pleased with the drug s performance in preclinical studies and are hopeful that in this phase i study atg 037 can demonstrate the tolerability and signals of activity that will allow us to move forward into a broader development program we are very excited about the start of this first in human clinical trial and look forward to next steps with atg 037 about the stamina 001 trial the stamina 001 trial is a phase i multi center open label dose finding study of atg 037 monotherapy or combination therapy with pembrolizumab in patients with locally advanced and metastatic solid tumors subjects will begin with two monotherapy cycles and then be allowed to receive the addition of pembrolizumab the primary objective of the study is to evaluate the safety and tolerability of atg 037 and to determine the maximum tolerated dose mtd and or recommended phase ii dose rp2d and or optimal biological dose of atg 037 monotherapy and preliminary efficacy secondary objectives include characterization of the pharmacology of atg 037 as a phase i study there will be intensive safety monitoring throughout the trial about atg 037 atg 037 is an orally available highly selective small molecule that completely blocks the activity of cd73 cd73 an ecto 5 nucleotidase catalyzes the conversion of adenosine monophosphate amp to adenosine adenosine production leads to significant immunosuppression in the tumor microenvironment now recognized as one of the most important immunomodulatory pathways in the tumor microenvironment many human tumors overexpress cd73 and this expression is frequently associated with poor prognosis blocking cd73 has been shown to be effective in controlling tumor growth and metastases and cd73 inhibitors may increase the therapeutic activity of icis and chemotherapy agents clinical data so far indicate that cd73 inhibitors add little additional toxicity to standard of care treatments about antengene antengene corporation limited antengene sehk 6996 hk is a leading commercial stage r d driven global biopharmaceutical company focused on the discovery development manufacturing and commercialization of innovative first in class best in class therapeutics for the treatment of hematologic malignancies and solid tumors in realizing its vision of treating patients beyond borders since 2017 antengene has a built broad and expanding pipeline of 15 clinical and preclinical assets of which 10 are global rights assets and 5 came with rights for asia pacific markets including the greater china region to date antengene has obtained 24 investigational new drug ind approvals in the u s and asia and submitted 6 new drug applications ndas in multiple asia pacific markets with the nda for xpovio selinexor already approved in mainland china south korea singapore and australia forward looking statements the forward looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article except as required by law we undertake no obligation to update or revise publicly any forward looking statements whether as a result of new information future events or otherwise after the date on which the statements are made or to reflect the occurrence of unanticipated events you should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect in this article statements of or references to our intentions or those of any of our directors or our company are made as of the date of this article any of these intentions may alter in light of future development for a further discussion of these and other factors that could cause future results to differ materially from any forward looking statement see the section titled risk factors in our periodic reports filed with the hong kong stock exchange and the other risks and uncertainties described in the company s annual report for year end december 31 2021 and subsequent filings with the hong kong stock exchange references 1 allard b longhi ms robson sc stagg j the ectonucleotidases cd39 and cd73 novel checkpoint inhibitor targets immunol rev 2017 276 1 121 144 doi 10 1111 imr 12528 2 antengene r d day 2021 for more information please contact investor contacts donald lunge mail mobile 86 18420672158 pr contacts peter qiane mail mobile 86 13062747000 view original content to download multimedia source antengene corporation limited
article retail giant target is cutting prices in an effort to get rid of excess inventory the company said tuesday the minneapolis based retailer is taking a set of actions to right size its inventory for the balance of the year and create additional flexibility to focus on serving guests in a rapidly changing environment a news release said those actions include canceling orders from suppliers including for home goods and clothing and cutting prices to clear out inventory this move is an example of what retailers are doing in the wake of inflation and changing consumer habits as shoppers return to pre pandemic routines seeking out dressier clothes and services as opposed to the casual clothes and home goods that boosted target s sales during the covid 19 pandemic target s business continues to generate healthy increases in traffic and sales despite sustained volatility in the macro environment including shifting consumer buying patterns and rapidly changing operating conditions target ceo brian cornell said in a statement since we reported our first quarter results we have continued to monitor external conditions and have determined the necessary actions to remain nimble in the current environment the additional steps we are announcing today will ensure that we deliver for our guests while driving further growth while these decisions will result in additional costs in the second quarter we re confident this rapid response will pay off for our business and our shareholders over time resulting in improved profitability in the second half of the year and beyond cornell added target cut its profit margin expectations for the second quarter and shares fell about 1 in early trading on tuesday the associated press contributed to this report
kb home nyse kbh today announced that it has priced an offering of 350 0 million in aggregate principal amount of its 7 25 senior unsecured notes due 2030 the offering is being made under an existing shelf registration statement that kb home previously filed with the securities and exchange commission sec the senior notes due 2030 will bear interest at a rate of 7 25 per annum and will be issued at a public offering price of 100 00 the senior notes will be guaranteed on an unsecured basis by kb home s subsidiaries that have guaranteed kb home s outstanding senior notes kb home estimates the aggregate net proceeds from the offering to be approximately 345 5 million after deducting the underwriting discount and estimated offering expenses payable by kb home kb home intends to use the net proceeds from the offering together with cash on hand as needed toward the retirement of its outstanding 7 5 senior notes due 2022 by redemption pursuant to the optional redemption terms specified for such notes purchase or repayment at maturity kb home intends to use any remaining net proceeds from the senior notes offering for general corporate purposes the closing of the senior notes offering is expected to occur on june 22 2022 subject to the satisfaction of customary closing conditions citigroup global markets inc bofa securities inc bnp paribas securities corp fifth third securities inc j p morgan securities llc and wells fargo securities llc are acting as book running managers for the offering a copy of the prospectus supplement and accompanying prospectus describing the offering when available may be obtained by visiting edgar on the sec s website at www sec gov or by contacting citigroup at the following address c o broadridge financial solutions 1155 long island avenue edgewood ny 11717 email prospectusdept citi com or toll free at 1 800 831 9146 or bofa securities at the following address bofa securities nc1 004 03 43 200 north college street 3rd floor charlotte nc 28255 0001 attn prospectus department email dg prospectus_requests bofa com or bnp paribas at the following address attn syndicate desk 787 seventh avenue new york ny 10019 email dl us syndicate support us bnpparibas com or toll free at 1 800 854 5674 or fifth third securities 38 fountain square plaza cincinnati ohio 45263 toll free at 1 866 531 5353 or j p morgan securities llc at the following address c o broadridge financial solutions 1155 long island avenue edgewood ny 11717 or by calling 866 803 9204 or wells fargo securities at the following address attn wfs customer service 608 2nd avenue south suite 1000 minneapolis mn 55402 email wfscustomerservice wellsfargo com or toll free at 1 800 645 3751 this press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities nor shall there be any sale of such securities in any jurisdiction in which such offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction the senior notes offering is being made only by means of the prospectus supplement and the accompanying prospectus this press release does not constitute a notice of redemption with respect to kb home s 7 5 senior notes due 2022 about kb home kb home is one of the largest and most recognized homebuilders in the united states and has built over 655 000 quality homes in our 65 year history today kb home operates in 47 markets from coast to coast what sets kb home apart is the exceptional personalization we offer our homebuyers from those buying their first home to experienced buyers allowing them to make their home uniquely their own at a price that fits their budget as the leader in energy efficient homebuilding kb home was the first builder to make every home it builds energy star certified a standard of energy performance achieved by fewer than 10 of new homes in america and has built more energy star certified homes than any other builder an energy efficient kb home helps lower the cost of ownership and is designed to be healthier more comfortable and better for the environment than new homes without certification we build strong personal relationships with our customers so they have a real partner in the homebuying process as a result we have the distinction of being the 1 customer ranked national homebuilder in third party buyer satisfaction surveys forward looking and cautionary statements certain matters discussed in this press release including any statements that are predictive in nature or concern future market and economic conditions business and prospects our future financial and operational performance or our future actions and their expected results are forward looking statements within the meaning of the private securities litigation reform act of 1995 forward looking statements are based on current expectations and projections about future events and are not guarantees of future performance we do not have a specific policy or intent of updating or revising forward looking statements actual events and results may differ materially from those expressed or forecasted in forward looking statements due to a number of factors the most important risk factors that could cause our actual performance and future events and actions to differ materially from such forward looking statements include but are not limited to the following general economic employment and business conditions population growth household formations and demographic trends conditions in the capital credit and financial markets our ability to access external financing sources and raise capital through the issuance of common stock debt or other securities and or project financing on favorable terms the execution of any securities repurchases pursuant to our board of directors authorization material and trade costs and availability including building materials especially lumber and appliances consumer and producer price inflation changes in interest rates our debt level including our ratio of debt to capital and our ability to adjust our debt level and maturity schedule our compliance with the terms of our revolving credit facility volatility in the market price of our common stock home selling prices including our homes selling prices increasing at a faster rate than consumer incomes weak or declining consumer confidence either generally or specifically with respect to purchasing homes competition from other sellers of new and resale homes weather events significant natural disasters and other climate and environmental factors any failure of lawmakers to agree on a budget or appropriation legislation to fund the federal government s operations and financial markets and businesses reactions to any such failure government actions policies programs and regulations directed at or affecting the housing market including the tax benefits associated with purchasing and owning a home and the standards fees and size limits applicable to the purchase or insuring of mortgage loans by government sponsored enterprises and government agencies the homebuilding industry or construction activities changes in existing tax laws or enacted corporate income tax rates including those resulting from regulatory guidance and interpretations issued with respect thereto changes in u s trade policies including the imposition of tariffs and duties on homebuilding materials and products and related trade disputes with and retaliatory measures taken by other countries disruptions in world and regional trade flows economic activity and supply chains due to the military conflict in ukraine including those stemming from wide ranging sanctions the u s and other countries have imposed or may further impose on russian business sectors financial organizations individuals and raw materials the impact of which may among other things increase our operational costs exacerbate building materials and appliance shortages and or reduce our revenues and earnings the adoption of new or amended financial accounting standards and the guidance and or interpretations with respect thereto the availability and cost of land in desirable areas and our ability to timely develop acquired land parcels and open new home communities our warranty claims experience with respect to homes previously delivered and actual warranty costs incurred costs and or charges arising from regulatory compliance requirements or from legal arbitral or regulatory proceedings investigations claims or settlements including unfavorable outcomes in any such matters resulting in actual or potential monetary damage awards penalties fines or other direct or indirect payments or injunctions consent decrees or other voluntary or involuntary restrictions or adjustments to our business operations or practices that are beyond our current expectations and or accruals our ability to use realize the net deferred tax assets we have generated our ability to successfully implement our current and planned strategies and initiatives related to our product geographic and market positioning gaining share and scale in our served markets and in entering into new markets our operational and investment concentration in markets in california consumer interest in our new home communities and products particularly from first time homebuyers and higher income consumers our ability to generate orders and convert our backlog of orders to home deliveries and revenues particularly in key markets in california our ability to successfully implement our business strategies and achieve any associated financial and operational targets and objectives including those discussed in this release or in other public filings presentations or disclosures income tax expense volatility associated with stock based compensation the ability of our homebuyers to obtain residential mortgage loans and mortgage banking services the performance of mortgage lenders to our homebuyers the performance of kbhs home loans llc our mortgage banking joint venture information technology failures and data security breaches an epidemic or pandemic such as the outbreak and worldwide spread of covid 19 and the control response measures that international including china federal state and local governments agencies law enforcement and or health authorities implement to address it which may as with covid 19 precipitate or exacerbate one or more of the above mentioned and or other risks and significantly disrupt or prevent us from operating our business in the ordinary course for an extended period and other events outside of our control please see our periodic reports and other filings with the securities and exchange commission for a further discussion of these and other risks and uncertainties applicable to our business view source version on businesswire com
bloomberg hasbro inc investors are expected to reject a board nominee backed by activist investor alta fox capital management llc at a shareholder meeting set for wednesday according to people familiar with the matter preliminary figures show that the dissident investor failed in that effort said the people who asked not to be identified because the matter is private last week alta fox said it was seeking to elect one director to the company s board after first trying to install five and later three the figures are preliminary and could change ahead of the meeting the people added representatives for alta fox and hasbro declined to comment a win would allow newly appointed chief executive officer chris cocks to pursue his growth strategy he said in march he wants hasbro s classic toy digital and entertainment businesses to work together in more profitable ways alta fox which owns 2 6 of hasbro has urged the toymaker to spin off its wizards of the coast playing card and digital gaming business the fort worth texas based investment firm envisioned a three year path to doubling hasbro s stock value with help from an improved strategy and better capital allocation read more hasbro unit s 42 boom minted a new ceo and stoked a proxy fight the wizards gaming unit was one of hasbro s best performers last year with revenue rising 42 to 1 29 billion the division s president cocks was named ceo following the death of longtime chief brian goldner in a letter to investors last week hasbro s board acknowledged that the company s stock had underperformed but said the new ceo is on the right track our promise to each of our shareholders is to continue to listen actively and be responsive to your feedback critiques and ideas the board said in the letter shares of pawtucket rhode island based hasbro were little changed tuesday in new york closing at 88 82 they have declined 13 this year updates with alta fox holding in sixth paragraph adds shares 2022 bloomberg l p
rosemont ill june 07 2022 globe newswire wintrust financial corporation wintrust or the company nasdaq wtfc today announced the pricing of its upsized underwritten public offering of 3 000 000 shares of its common stock at a price to the public of 86 00 per share in connection with the offering wintrust has granted the underwriters a 30 day option to purchase up to 450 000 additional shares of common stock the offering is expected to close on june 10 2022 subject to customary closing conditions assuming the underwriters do not exercise their option to purchase additional shares wintrust expects to receive net proceeds for the offering of approximately 248 4 million after deducting underwriting discounts and commissions and estimated offering expenses wintrust intends to use the net proceeds from this offering for general corporate purposes rbc capital markets llc and raymond james associates inc are acting as joint book running managers for the offering the offering is being made under an effective shelf registration on file with the u s securities and exchange commission the sec the offering may be made only by means of a prospectus supplement and the accompanying prospectus prospective investors should read the prospectus supplement and the accompanying prospectus in the registration statement and other documents wintrust has filed or will file with the sec for more complete information about wintrust and the offering copies of the prospectus supplement and accompanying prospectus describing the offering may be obtained by visiting edgar on the sec s website at www sec gov or by contacting rbc capital markets llc attention equity syndicate 200 vesey street 8th floor new york new york 10281 telephone 877 822 4089 email equityprospectus rbccm com or raymond james associates inc 880 carillon parkway st petersburg fl 33716 or by calling toll free 1 800 248 8863 this press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any securities in any state or jurisdiction in which such an offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction about wintrust wintrust is a financial holding company with assets of approximately 50 billion whose common stock is traded on the nasdaq global select market built on the have it all model wintrust offers sophisticated technology and resources of a large bank while focusing on providing service based community banking to each and every customer wintrust operates fifteen community bank subsidiaries with over 170 banking locations located in the greater chicago and southern wisconsin market areas additionally wintrust operates various non bank business units including business units which provide commercial and life insurance premium financing in the united states a premium finance company operating in canada a company providing short term accounts receivable financing and value added out sourced administrative services to the temporary staffing services industry a business unit engaging primarily in the origination and purchase of residential mortgages for sale into the secondary market throughout the united states and companies providing wealth management services and qualified intermediary services for tax deferred exchanges forward looking statements this press release contains forward looking statements within the meaning of the federal securities laws including without limitation statements related to the completion of the public offering the satisfaction of customary closing conditions related to the public offering and the intended use of proceeds from the public offering these forward looking statements are based on management s current expectations and beliefs and certain assumptions made by our management investors are cautioned that such statements are predictions and actual events or results may differ materially wintrust s expected financial results or other plans are subject to a number of risks and uncertainties for a discussion of such risks and uncertainties which could cause actual results to differ from those contained in the forward looking statements see risk factors and the forward looking statement disclosure contained in wintrust s annual report on form 10 k for the fiscal year ended december 31 2021 and in any of the company s subsequent sec filings forward looking statements speak only as of the date made and except as required by law wintrust undertakes no duty to update its forward looking statements for more information contact edward j wehmer founder chief executive officer david a dykstra vice chairman chief operating officer 847 939 9000
shanghai and hong kong june 7 2022 prnewswire antengene corporation limited antengene sehk 6996 hk a leading innovative commercial stage global biopharmaceutical company dedicated to discovering developing and commercializing first in class and or best in class therapeutics in hematology and oncology today announced that the first patient has been dosed in the phase i stamina 001 trial to evaluate atg 037 as a monotherapy or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors in australia the primary objective of the study is to evaluate the safety tolerability recommended phase ii dose and preliminary antitumor efficacy of atg 037 as a monotherapy and in combination with pembrolizumab secondary objectives include characterization of the pharmacology of atg 037 atg 037 is an orally available small molecule cd73 inhibitor cd73 is an immune checkpoint mediator 1 that interferes with anti tumor immune responses by generating adenosine which leads to immunosuppression in the tumor microenvironment atg 037 can reverse adenosine mediated immunosuppression2 it has demonstrated promising preclinical efficacy as a monotherapy and in combination with icis and chemotherapy agents in preclinical studies this compound overcomes the hook effect that is common in anti cd73 antibodies in addition glp toxicology studies indicate the compound has a potentially wide therapeutic window while icis are widely used in the treatment of various cancers many patients have resistant or refractory disease which has created a large unmet need said dr ganessan kichenadasse principal investigator southern oncology clinical research unit in adelaide australia mounting evidence suggests that adenosine plays a critical role in suppressing anti tumor immunoactivity cd73 can convert adenosine monophosphate amp to adenosine atg 037 an orally available small molecule cd73 inhibitor can block the generation of adenosine we are excited to be a part of the stamina 001 trial this phase i study brings together a group of highly experienced australian investigators to collaborate with antengene we are excited to assess the therapeutic potential of atg 037 for patients with solid tumors as a single agent as well the exploring the opportunity for benefit with the addition of an icis developing agents that can act in the tumor microenvironment to reverse immunosuppression is one of the key focus areas for antengene said dr kevin lynch antengene s chief medical officer preclinical data presented at the 2022 american association of cancer research annual meeting aacr 2022 showed that atg 037 had a stronger ability to restore t cell function in higher amp environments compared with anti cd73 monoclonal antibodies these data highlighted the potential therapeutic advantages of small molecule inhibitors of cd73 over blocking antibodies either as a monotherapy or in combination with other immune oncological treatments we have been very pleased with the drug s performance in preclinical studies and are hopeful that in this phase i study atg 037 can demonstrate the tolerability and signals of activity that will allow us to move forward into a broader development program we are very excited about the start of this first in human clinical trial and look forward to next steps with atg 037 about the stamina 001 trial the stamina 001 trial is a phase i multi center open label dose finding study of atg 037 monotherapy or combination therapy with pembrolizumab in patients with locally advanced and metastatic solid tumors subjects will begin with two monotherapy cycles and then be allowed to receive the addition of pembrolizumab the primary objective of the study is to evaluate the safety and tolerability of atg 037 and to determine the maximum tolerated dose mtd and or recommended phase ii dose rp2d and or optimal biological dose of atg 037 monotherapy and preliminary efficacy secondary objectives include characterization of the pharmacology of atg 037 as a phase i study there will be intensive safety monitoring throughout the trial about atg 037 atg 037 is an orally available highly selective small molecule that completely blocks the activity of cd73 cd73 an ecto 5 nucleotidase catalyzes the conversion of adenosine monophosphate amp to adenosine adenosine production leads to significant immunosuppression in the tumor microenvironment now recognized as one of the most important immunomodulatory pathways in the tumor microenvironment many human tumors overexpress cd73 and this expression is frequently associated with poor prognosis blocking cd73 has been shown to be effective in controlling tumor growth and metastases and cd73 inhibitors may increase the therapeutic activity of icis and chemotherapy agents clinical data so far indicate that cd73 inhibitors add little additional toxicity to standard of care treatments about antengene antengene corporation limited antengene sehk 6996 hk is a leading commercial stage r d driven global biopharmaceutical company focused on the discovery development manufacturing and commercialization of innovative first in class best in class therapeutics for the treatment of hematologic malignancies and solid tumors in realizing its vision of treating patients beyond borders since 2017 antengene has a built broad and expanding pipeline of 15 clinical and preclinical assets of which 10 are global rights assets and 5 came with rights for asia pacific markets including the greater china region to date antengene has obtained 24 investigational new drug ind approvals in the u s and asia and submitted 6 new drug applications ndas in multiple asia pacific markets with the nda for xpovio selinexor already approved in mainland china south korea singapore and australia forward looking statements the forward looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article except as required by law we undertake no obligation to update or revise publicly any forward looking statements whether as a result of new information future events or otherwise after the date on which the statements are made or to reflect the occurrence of unanticipated events you should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect in this article statements of or references to our intentions or those of any of our directors or our company are made as of the date of this article any of these intentions may alter in light of future development for a further discussion of these and other factors that could cause future results to differ materially from any forward looking statement see the section titled risk factors in our periodic reports filed with the hong kong stock exchange and the other risks and uncertainties described in the company s annual report for year end december 31 2021 and subsequent filings with the hong kong stock exchange references 1 allard b longhi ms robson sc stagg j the ectonucleotidases cd39 and cd73 novel checkpoint inhibitor targets immunol rev 2017 276 1 121 144 doi 10 1111 imr 12528 2 antengene r d day 2021 for more information please contact investor contacts donald lung e mail mobile 86 18420672158 pr contacts peter qian e mail mobile 86 13062747000 source antengene corporation limited
immaculate 1979 ford bronco free wheeling features massive fuel injected v8 this stunning 1979 ford bronco free wheeling has a few modern upgrades to enhance its retro appeal while big bodied broncos have plenty of appeal as is many enthusiasts have also fallen in love with the somewhat obscure free wheeling package as of late which is essentially just an appearance upgrade that was available for a handful of blue oval products back in that era this trend has led to some folks adding the free wheeling package s signature colorful stripes to vehicles that didn t come with them in the first place because the retro look just fits these suvs so perfectly regardless this 1979 ford bronco free wheeling recently built by firehouse vintage vehicles in statesville north carolina is one of the nicest examples we ve ever laid eyes on this particular 1979 ford bronco free wheeling isn t stock by any measure but it has been modified in an extremely tasteful period correct manner with some modern drivetrain bits thrown in for good measure on the outside the big suv features flawless body and paintwork shiny enough to use as a mirror and perfectly complemented by those signature stripes the second gen bronco rolls on a set of equally vintage looking chrome wheels wrapped with beefy 35 inch bfgoodrich tires enhanced by a four inch lift for the perfect stance too thankfully firehouse also left the interior mostly alone because there s too much retro goodness here to change anything in our humble opinion thus the cabin is still full of lots of faux wood trim captain s chairs and seats with plaid inserts though this particular bronco also has some modern amenities like air conditioning and a sport steering wheel mechanically speaking this 1979 bronco has more than enough juice to get it going thanks to a massive ford 460 cubic inch v8 under the hood that big mill has been treated to a holley sniper fuel injection setup to make it extra reliable and efficient or at least as efficient as one of these monster motors can possible be firehouse notes that this big beautiful bronco build is for sale but hasn t listed any sort of price of course that means that the ages old rule of if you have to ask you can t afford it probably applies here but that won t stop us from admiring it from afar photos firehouse vintage vehicles
a recent poll of likely voters in el paso county and colorado springs found nearly all who rent think local housing costs are a significant problem and nearly half of all homeowners surveyed agreed the colorado springs chamber of commerce edc told county commissioners tuesday in december the chamber commissioned a poll of likely voters in the county and city to find out what local issues deeply concerned them its president and ceo johnna reeder kleymeyer said housing was a top answer she said it was unclear how many people were surveyed poll results presented tuesday show residents with household incomes of 100 000 a year or less were more likely to find it difficult to find affordable housing in colorado springs eighty nine percent of those surveyed with an income of 50 000 or less a year said housing costs created a big problem in finding affordable housing while 71 of residents earning between 50 000 and 100 000 annually agreed only slightly less than half 49 of those surveyed with a household income of 100 000 or more a year said they thought it was a problem i don t know about you but that blows my mind reeder kleymeyer said that s our new employee that s our recent college graduates that s our nurses that s our teachers that s our military families they are what she and other affordable housing advocates called missing middle earners they re people who make between 60 and 150 of the area s median income in this case residents with household incomes of between 50 000 and 100 000 a year missing middle earners increasingly struggle to afford satisfactory housing within the region s existing housing inventory said andrea barlow a member of the colorado springs housing building association s executive committee and the housing market in the colorado springs area has reached record breaking numbers a report from the pikes peak association of realtors released last week showed the median price of single family homes that sold in may climbed to a record high 487 000 the gazette previously reported that s more than the 484 450 mark set in april the report said and it s over 160 000 more than what would be considered an affordable purchase price for buyers earning 100 of the area median income or those earning around 64 712 a year according to the data presented by housing advocates an affordable home purchase price for those households is about 325 000 and affordable rent is about 1 618 per month barlow said for those earning 80 of the area median income or 51 769 an affordable home purchase price is about 256 000 and rent around 1 294 a month for those in the 60 range earning 38 377 a year an affordable home is around 191 000 and rent about 970 a month limited housing stock rising costs of business more remote workers an influx of new residents and people opposed to building more multi family housing in their neighborhoods are some contributing factors to the crunch housing advocates said ann kidd broker and owner of true north realty and chairwoman of the pikes peak association of realtors highlighted the housing stock shortage she told commissioners a client of hers searching for a 250 000 home in el paso county this week found only two on the market that fit their criteria after raising the purchase price to 350 000 only 11 homes in all el paso county were available we are in crisis mode here i have nothing to show buyers that are coming to the door kidd said sign up for free news alerts stay in the know on the stories that affect you the most sign up for free view all of our newsletters success thank you for subscribing to our newsletter view all of our newsletters laura nelson executive director of the apartment association of southern colorado said rental units are a very important part of this missing middle yet rents are high and supply is low in the second quarter of 2022 there is only a 5 vacancy rate in rental units or roughly 2 000 units in all of colorado springs she said the average rent is 1 500 a month that was with adding 228 units in the first quarter of 2022 she said we added 2 000 units last year the demand just keeps coming millennials between 26 and 41 years old and older members of generation z are driving demand nelson said because they re less likely to want to buy a home since they change jobs more frequently than older earners baby boomers who are retiring and choosing to live in rental properties and remote workers who moved to colorado springs from more expensive cities like denver are also driving up demand fewer multihousing options are on the market as well because people are generally disapproving of building new multifamily housing units near their neighborhoods nelson said a rental housing unit doesn t necessarily drive down the rate of their homes she said we haven t seen home prices drop with any addition of apartments in any area some developers like darsey nicklasson and her company dhn development are working to increase the availability of affordable market rate multifamily housing in the area when she found her own employees were having trouble paying their rents or finding affordable places to live nicklasson wanted to build more multifamily housing units and charge the lowest amount possible for them she said her company bought two pieces of land in southeast colorado springs where they plan to build two multifamily housing units with 373 total for rent apartments she said the apartments will offer one to four bedrooms to better accommodate middle earner families who are being priced out of the market the company will own the units for 10 years to control rents she said the units will cost 339 000 each to build expected rents are 1 600 a month between the 100 to 120 of area median income range the cost is higher than what might be expected because of a 30 increase in construction labor and materials and set development and general contractor fees constant regulatory increases constant price increases there s nothing i can do about that she said what i can do is set those rents and do our best to maintain those rents by minimizing operating costs and yet still provide a good place to live but the county can build itself out of this crisis said kevin walker a volunteer with the housing and building association there is no other solution but to build our way out of this he said if we want to make an impact on housing affordability we ve got to be able to build more houses and moderate that price issue other ideas for solutions include lobbying for a 40 year mortgage and working on lumber and other tariffs at the federal level among others at the state level making the best use of available federal american rescue plan act funds dedicated to housing and increasing tax credits among others and at the local level revising the county s master development plan to allow for more density and flexibility support annexations of especially enclaves and near enclaves and encouraging and empowering more infill and high density projects mostly in colorado springs among others walker said
it s that time again mad money host jim cramer rings the lightning round bell which means he s giving his answers to callers stock questions at rapid speed blackline inc they re losing money we can just not go with it enbridge inc that is exactly what you should be buying axogen inc it s a medical device and i think you have to stick with tried and true johnson johnson get southern california news weather forecasts and entertainment stories to your inbox sign up for nbc la newsletters metlife inc i m going to have to say yes to that even as i m not a great fan of the insurers that is too cheap a stock bridge investment group holdings we don t really know what they do pass because there s too much room for error farfetch ltd i say buy target down here disclosure cramer s charitable trust owns shares of johnson johnson sign up now for the cnbc investing club to follow jim cramer s every move in the market disclaimer questions for cramer call cramer 1 800 743 cnbc want to take a deep dive into cramer s world hit him up mad money twitter jim cramer twitter facebook instagram questions comments suggestions for the mad money website madcap cnbc com
shares in asia pacific were higher on wednesday with hong kong leading gains regionally the reserve bank of india will raise the policy repo rate by 50 basis points to 4 9 with immediate effect governor shaktikanta das announced wednesday the repo rate refers to the rate at which the central bank lends to commercial banks japan s economy shrank an annualized 0 5 in the first quarter revised government data showed wednesday an improvement over the initial estimate of a 1 contraction singapore shares in asia pacific were higher on wednesday with hong kong leading gains regionally the hang seng index in hong kong jumped 2 24 to close at 22 014 59 as chinese tech stocks listed in the city soared alibaba surged 10 12 while tencent climbed 6 47 and netease gained 5 66 the shanghai composite in mainland china closed 0 68 higher at 3 263 79 while the shenzhen component climbed 0 818 to 12 033 26 get southern california news weather forecasts and entertainment stories to your inbox sign up for nbc la newsletters rbi announces rate hike the reserve bank of india on wednesday raised a key interest rate the rbi will raise the policy repo rate by 50 basis points to 4 9 with immediate effect governor shaktikanta das said the repo rate refers to the rate at which the central bank lends to commercial banks economists in a reuters poll had predicted a rate hike of between 25 to 75 basis points it may be noted in this context that the repo rate still remains below its pre pandemic level the indian central bank chief said following the announcement both the nifty 50 and bse sensex in india rose close to 0 4 each as of 1 44 p m local time the indian rupee traded at 77 763 per dollar weaker as compared with levels below 77 4 seen against the greenback last week the rbi s decision comes after the reserve bank of australia s surprise 50 basis point rate hike on tuesday in other markets the nikkei 225 in japan advanced 1 04 to close at 28 234 29 while the topix index climbed 1 18 to 1 969 98 japan s economy shrank an annualized 0 5 in the first quarter revised government data showed wednesday an improvement over the initial estimate of a 1 contraction south korea s kospi closed little changed at 2 626 15 the s p asx 200 in australia rose 0 36 to finish the trading day at 7 121 10 msci s broadest index of asia pacific shares outside japan gained 1 13 the world bank on tuesday cut its global growth forecast to 2 9 for 2022 and warned of the world economy slipping into a period of stagflation reminiscent of the 1970s these sort of headlines around risk of stagflation slower growth these are things the market has been you know trading on for most of the year already kieran calder head of equity research for asia at ubp told cnbc s street signs asia on wednesday calder described the world bank s expectation for 4 3 growth in 2022 for china as pretty aggressive given that multiple banks have cut their outlook for the country ubp is looking for below 4 gdp growth in china this year he said currencies and oil the u s dollar index which tracks the greenback against a basket of its peers was at 102 619 after seeing an earlier low of 102 387 the japanese yen traded at 133 62 per dollar weaker than levels below 132 seen against the dollar yesterday the australian dollar was at 0 7189 off an earlier high of 0 7235 oil prices were higher in the afternoon of asia trading hours with international benchmark brent crude futures up 0 39 to 121 04 per barrel u s crude futures gained 0 55 to 120 07 per barrel
washington a former member of donald trump s cabinet will attempt a return to the u s congress in montana and california democrats concerned about crime may oust one of their own as voters head to the polls in midterm primary elections in seven states on tuesday voters in south dakota new jersey iowa mississippi and new mexico will also cast ballots in nominating contests that will set the competitive field for nov 8 s elections which will determine control of congress for the next two years with president joe biden slumping in the polls and soaring inflation souring voters moods republicans are expected to win control of the house of representatives and possibly the senate which would bring biden s legislative agenda to a halt and give republicans the power to launch distracting and possibly politically damaging investigations in montana ryan zinke who served as interior secretary under republican former president trump is running for a newly created house seat that the state gained thanks to population growth and the once a decade redistricting process zinke who served in congress previously faces four republican challengers some of whom claim that he is too liberal or lacks commitment to the state because his wife s residence is in california advertisement zinke was accused in an inspector general report this year of using is position as head of the interior department to advance a development project in his hometown and lying to an ethics investigator he has denied wrongdoing south dakota s conservative republican governor kristi noem faces a challenge by steven haugaard a member of the south dakota house of representatives noem has been mentioned as a possible vice presidential running mate if former president donald trump seeks election again in 2024 or as a white house candidate in her own right if he does not the winners of each of those republican primaries are favored to win in november california shakeout a pair of races in california will also illustrate liberal leaning voters frustrations with spikes in homicides and gun violence polls show that san francisco s progressive district attorney chesa boudin is likely to be pushed out of office in a recall vote a replacement would be chosen by the city s mayor london breed a democrat who has criticized boudin but has not taken a stance on the recall in los angeles rick caruso a billionaire developer and former republican is battling u s representative karen bass and a host of other liberal candidates in the mayoral election caruso who has spent more than 30 million of his own money in the campaign made crime the centerpiece of his candidacy in a city that saw homicides reach a 15 year high in 2021 that forced bass a longtime progressive champion in congress to move to the center and pledge to put more police on the streets caruso and bass could be headed to a runoff polls show advertisement new jersey iowa challenges republicans in new jersey and iowa will also be picking challengers to embattled incumbent house democrats representatives tom malinowski in new jersey and cindy axne in iowa former state senate republican leader tom kean jr the son of popular two time governor thomas kean leads a crowded republican field to challenge malinowski malinowski a two term incumbent who entered congress by flipping a republican seat in 2018 won reelection by defeating kean by 1 2 percentage points in 2020 since then his prospects have been weakened by redistricting and by a house ethics investigation after reports that he failed to disclose hundreds of thousands of dollars in stock trades it was a nail biter in 2020 and his district has become a little more favorable for republicans so it s going to be a significant challenge said benjamin dworkin director of the rowan university institute of public policy citizenship in iowa three republicans are vying for the chance to challenge axne businesswoman nicole hasso construction consultant gary leffler and former state senator zach nunn nunn the only republican contender who has held elective office boasts a string of endorsements from high profile party luminaries including trump s former secretary of state mike pompeo and several sitting house republicans
the u s supreme court found in 2008 that the second amendment protects individual gun possession for traditional uses such as self protection in the home a 2010 opinion expanded those protections to the states jim leach said he does not disagree with legalizing guns for hunting and protection in the home but the supreme court opinions laid a foundation for opposition to any restrictions on guns we re talking about semiautomatic weapons automatic weapons bump stocks guns that you know you can shoot dozens of bullets then reload in a second and kill the kinds of people we see killed on almost a weekly basis recently he said the supreme court s 2008 heller opinion was written by antonin scalia who noted that lawmakers could still impose regulations such as restricting sales and types of weapons and denying gun possession to felons and the mentally ill but leach said legislators in congress and certain states won t do that for fear of retribution south dakota s legislature considered a proposal in 2013 to deny gun rights to people deemed to be a danger to themselves or others the bill didn t make it past the first committee hearing our legislatures seem to be united in being terrified of the gun lobby and it s a sad state of affairs when even the most common sense restrictions are not even on the table cannot even be reasonably discussed he said the u s supreme court heard arguments in november on a century old gun law in new york that opinion has not yet been released and several challenges to other state laws are waiting to be heard
jpmorgan s marko kolanovic predicts oil is surging higher but so are stocks kolanovic who serves as the firm s chief global markets strategist and co head of global research believes the u s economy is strong enough to handle oil prices as high as 150 a barrel there could be some potential further spikes in oil especially given the situation in europe and the war so we wouldn t be surprised he told cnbc s fast money on tuesday but it could be a short lived spike and eventually sort of normalize get southern california news weather forecasts and entertainment stories to your inbox sign up for nbc la newsletters wti crude is trading around three month highs settling up 0 77 to 119 41 a barrel on tuesday brent crude closed at the 120 57 mark the bullish move came as shanghai reopened from a two month covid 19 lockdown opening the door for higher demand and more upside we think the consumer can handle oil at 130 135 because we had that back in 2010 to 2014 inflation adjusted that was basically the level so we think the consumer can handle that said kolanovic who has earned top honors from institutional investor for accurate forecasts multiple years in a row his base case is the u s and global economy will avoid a recession but at a financial conference last week jpmorgan chase chairman and ceo jamie dimon told investors he s preparing for an economic hurricane which could be a minor one or superstorm sandy kolanovic contends it s vital to be ready for all possibilities we do forecast some slow down he said nobody is saying that there are no problems his firm s official s p 500 year end target is 4 900 but in a recent note kolanovic speculated the index would end the year around 4 800 still on par with all time highs hit on jan 4 right now the s p is 16 below its record high we don t think investors will stick in cash we don t think investors will stick in cash for the next 12 months you know waiting for this recession kolanovic said if we continue to see consumer especially on the services side holding up which we do expect then we think investors will gradually come back into equity markets kolanovic s top call remains energy a group he has been bullish on since 2019 actually valuations went lower despite the stock price appreciation kolanovic said earnings grow faster so multiples are actually lower now in energy than they were a year ago he s also bullish on small caps and high beta technology stocks that have gotten crushed this year disclaimer
boston business wire jun 7 2022 cabot corporation nyse cbt today announced that it priced a public offering of 400 million of 5 000 senior unsecured notes due 2032 the notes are being sold to the public at a price of 99 330 of the face amount thereof cabot will pay interest on the notes semiannually on june 30 and december 30 of each year beginning december 30 2022 the sale of the notes is expected to close on june 22 2022 subject to customary closing conditions cabot intends to use the net proceeds from the offering to redeem its senior unsecured notes due july 2022 the 2022 notes in full and the remainder if any for working capital and other general corporate purposes j p morgan mizuho securities us bancorp citigroup wells fargo securities td securities and pnc capital markets llc are the joint bookrunning managers for the offering bofa securities loop capital markets and hsbc are the co managers for the offering the offering of these securities is being made only by means of a prospectus and related prospectus supplement electronic copies of the preliminary prospectus supplement and the accompanying base prospectus which was filed as part of cabot s automatically effective shelf registration statement on form s 3asr filed on february 11 2020 file no 333 236374 may be obtained for free by searching the securities and exchange commission sec online data base edgar on the sec web site at alternatively copies of the preliminary prospectus supplement and the accompanying base prospectus relating to the offering may be obtained by contacting j p morgan securities llc c o broadridge financial solutions 1155 long island avenue edgewood new york 11717 or by calling 866 803 9204 or at 383 madison avenue new york new york 10179 attention investment grade syndicate desk 3rd floor or by calling collect at 212 834 4533 mizuho securities usa llc 1271 avenue of the americas new york new york 10020 attention debt capital markets or by calling 1 866 271 7403 or u s bancorp investments inc 214 n tryon street 26th floor charlotte north carolina 28202 attention credit fixed income or by calling toll free at 877 558 2607 this press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor shall there be any sale of these securities in any state or jurisdiction in which such an offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction this press release shall not constitute a notice of or a solicitation of an offer to redeem the 2022 notes about cabot corporation cabot corporation nyse cbt is a global specialty chemicals and performance materials company headquartered in boston massachusetts the company is a leading provider of carbon black specialty carbons engineered elastomer composites inkjet colorants masterbatches and conductive compounds fumed silica and aerogel forward looking statements this press release contains forward looking statements including statements about timing of the closing of the notes offering and the expected use of proceeds these statements are not guarantees that these events will occur and involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements the offering may be adversely affected by market conditions adverse changes to cabot s business or prospects and the other risks and uncertainties that are described in cabot s filings with the sec including under the heading risk factors in cabot s annual report on form 10 k for the fiscal year ended september 30 2021 and in cabot s quarterly report on form 10 q for the fiscal quarter ended march 31 2022 these statements are based on current beliefs and expectations and speak only as of the date of this press release cabot does not undertake any obligation to publicly update any forward looking statements except as required by law view source version on businesswire com contact cabot corporation steve delahunt 617 342 6255 vice president investor relations and treasurer keyword massachusetts united states north america industry keyword chemicals plastics professional services manufacturing finance source cabot corporation copyright business wire 2022 pub 06 07 2022 07 50 pm disc 06 07 2022 07 51 pm
bloomberg a former analyst at citadel llc was ordered to spend more than four years in federal prison for scamming 4 6 million in covid relief loans for his startup hedge fund most of which he lost in the market gregory blotnick 35 was sentenced on tuesday to 51 months behind bars by a federal judge in newark new jersey and ordered to pay 4 6 million in restitution he pleaded guilty in october to submitting 21 fraudulent loan applications to 13 lenders under the paycheck protection program of the march 2020 covid stimulus bill blotnick worked as an analyst at citadel for less than a year and was let go in 2018 according to firm spokeswoman zia ahmed he founded brattle street capital llc in 2019 according to an sec filing defense lawyer adam kaufmann said blotnick accepted full responsibility for his actions and had taken steps to make things right mr blotnick will serve his time with dignity and looks forward to becoming a contributing member of society when his sentence is completed kaufmann said fake payroll prosecutors said blotnick falsified information about brattle street in his ppp loan applications telling one bank the fund employed 45 people with a monthly payroll of more than 325 000 in reality according to the government brattle street paid no wages at all in 2019 or 2020 blotnick a resident of new york and palm beach florida sought 6 8 million in loans and received about 4 6 million prosecutors said he went on to deposit much of the money in brokerage funds and lost more than 3 million in unsuccessful stock trades the federal sentence may not be the only jail time blotnick gets according to court records he also pleaded guilty in october to similar charges brought by the manhattan district attorney s office he faces a possible state court sentencing on thursday the case is u s v blotnick 21 cr 796 u s district court district of new jersey newark 2022 bloomberg l p
fort worth texas joining a growing list of airlines expecting summer demand to be greater than previous predictions as the travel industry recovers from the covid 19 pandemic american airlines aa has announced its forecast for second quarter revenues the fort worth texas based airline predicts that its revenues would rise 11 to 13 percent above the second quarter of 2019 easily beating its earlier forecast of a 6 to 8 percent increase in 2019 as the number of people flying in the u s moves closer to pre pandemic levels delta southwest jetblue and others airlines have also raised revenue forecasts while offering fewer flights than in 2019 helping them increase average fares according to american revenue per seat will jump by up to 22 percent compared with 2019 considerably greater than earlier forecasts of an increase of 14 to 16 percent that revenue is offsetting some real cost pressures out there ceo robert isom said figures from banking firm cowen also confirmed that airfares are up nearly 50 percent from this time last year while jet fuel is expected to rise by up to 11 percent per seat a slower increase than delta reported adding that american expects to pay nearly 4 per gallon for fuel nearly twice the price it paid three years ago
new york new york u s stocks advanced on tuesday despite concerns from the u s treasury about unacceptable inflation we currently face macroeconomic challenges including unacceptable levels of inflation as well as the headwinds associated with the disruptions caused by the pandemic s effect on supply chains and the effects of supply side disturbances to oil and food markets resulting from russia s war in ukraine treasury secretary janet yellen told a senate finance committee hearing tuesday the dow jones industrials rallied 264 36 points or 0 80 percent to 33 180 14 the nasdaq composite finished with a 113 86 points or 0 94 percent gain to 12 175 23 the standard and poor s advanced 39 24 points or 0 95 percent to 4 160 67 the u s dollar was sold off the euro cruised higher to 1 0709 around the new york close tuesday the british pound strengthened to 1 2598 the canadian dollar jumped to 1 2525 the australian dollar on the back of an rba 50 basis points rate hike accelerated to 0 7237 the new zealand dollar was slightly higher at 0 6497 the japanese yen went against the trend crumbling to a more than a two decade low of 132 62 the swiss franc too weakened last trading at 0 9728 equity markets overseas mostly finished in the red in london the ftse 100 fell 0 12 percent the german dax declined 0 66 percent the cac 40 in paris france was off 0 74 percent the australian all ordinaries tumbled 114 50 points or 1 54 percent to 7 318 60 in new zealand the s p nzx 50 sank 151 64 points or 1 33 percent to 11 265 70 south korea s kospi composite dived 44 31 points or 1 66 percent to 2 626 30 hong kong s hang seng declined 122 23 points or 0 56 percent to 21 531 67 in tokyo the nikkei 225 going against the trend added 28 06 points or 0 10 percent to close at 27 943 95 china s shanghai composite finished a little better than flat up 5 39 points or 0 17 percent at 3 241 76
rttnews the singapore stock market has alternated between positive and negative finishes through the last six trading days since the end of the three day winning streak in which it had gained almost 60 points or 1 9 percent the straits times index now rests just above the 3 230 point plateau and it s tipped to open in the green again on wednesday the global forecast for the asian markets is mixed to higher with support expected from the oil and technology sectors the european markets were down and the u s bourses were up and the asian markets figure to follow the latter lead the sti finished slightly higher on tuesday following mixed performances from the financial shares property stocks and industrial issues for the day the index rose 4 91 points or 0 15 percent to finish at the daily high of 3 231 54 after moving as low as 3 214 34 volume was 1 9 billion shares worth 1 1 billion singapore dollars there were 253 decliners and 242 gainers among the actives ascendas reit dropped 0 35 percent while capitaland investment shed 0 26 percent city developments fell 0 12 percent comfort delgro declined 0 69 percent dbs group added 0 33 percent hongkong land spiked 1 36 percent keppel corp rose 0 29 percent mapletree commercial trust jumped 0 56 percent mapletree industrial trust slumped 0 40 percent mapletree logistics trust retreated 0 60 percent oversea chinese banking corporation collected 0 34 percent sats plunged 1 22 percent singapore exchange gained 0 31 percent singapore technologies engineering soared 1 71 percent singtel climbed 0 39 percent united overseas bank sank 0 38 percent wilmar international tumbled 0 71 percent yangzijiang financial plummeted 2 78 percent yangzijiang shipbuilding surged 2 00 percent and genting singapore capitaland integrated commercial trust sembcorp industries and thai beverage were unchanged the lead from wall street is upbeat as the major averages shook off a lower open on tuesday picking up steam as the session progressed to end firmly in the green the dow jumped 264 36 points or 0 80 percent to finish at 33 180 14 while the nasdaq spiked 113 86 points or 0 94 percent to end at 12 175 23 and the s p 500 gained 39 25 points or 0 95 percent to close at 4 160 68 worries about slowing growth a weak margin guidance from target and a sell off in the technology space contributed to wall street s weakness in early trades however top technology stocks soon recovered and the broad market too started climbing higher as well in u s economic news the commerce department said the u s trade deficit narrowed significantly in the month of april to 87 1 billion in april from 107 7 billion in march crude oil prices climbed higher on tuesday as prospects of increased demand from china and supply concerns outweighed concerns about growth west texas intermediate crude oil futures for july ended higher by 0 91 or 0 8 percent at 119 41 a barrel
tokyo japan japanese prime minister fumio kishida is making plans to attend a north atlantic treaty organization nato summit to discuss russia s invasion of ukraine to be held in late june while kishida has repeatedly condemned russia in what he described as a war crime against ukraine attending the nato summit would be an unusually aggressive stance for a japanese prime minister as japan and russia have wrangled over decades old territorial disputes japanese leaders have previously maintained a careful line in their relations with russia as the nato summit will take place on 29th and 30th june in the spanish capital madrid it would likely overlap with the campaign for japanese upper house elections to be held on 10th july kishida is expected to make a final decision later accounting for japan s political situation nato has invited japan to the summit along with its partners in the asia pacific region which include australia new zealand and south korea kishida s attendance at the summit would deliver a strong message of international solidarity with ukraine according to observers
article 3 months old daily market reports jun 08 2022 this story features zip co limited for more info share analysis zip world overnight spi overnight 7146 00 45 00 0 63 s p asx 200 7095 70 110 60 1 53 s p500 4160 68 39 25 0 95 nasdaq comp 12175 23 113 86 0 94 djia 33180 14 264 36 0 80 s p500 vix 24 02 1 05 4 19 us 10 year yield 2 97 0 07 2 17 usd index 102 34 0 05 0 05 ftse100 7598 93 9 29 0 12 dax30 14556 62 97 19 0 66 by greg peel shock and awe given the current inflation pressures in the economy and the still very low level of interest rates the board decided to move by 50 basis points today the board expects to take further steps in the process of normalising monetary conditions in australia over the months ahead the size and timing of future interest rate increases will be guided by the incoming data and the board s assessment of the outlook for inflation and the labour market the board is committed to doing what is necessary to ensure that inflation in australia returns to target over time after wall street had closed slightly higher yesterday morning and the futures were showing down a mere 5 points it was clear the asx was in for a quiet period in the lead up to the rba decision at 2 30pm except that the asx200 was down 50 points in the first half hour us futures had turned lower but it appears as if an uneasy feeling of dread had crept across the market around half of economists were forecasting the rba would go a full 40 points rate hike when only a bit more than a third said 25 a couple of fools even suggested 50 points by 2 30pm the index was already down 65 points the driving force were the banks never mind the benefit of increased net interest margins a rate hike and particularly a 40 points rate hike would bring australian households are already suffering from soaring food and fuel prices wages not keeping pace with inflation and household debt to income levels at historical highs so all australians need right now is a big jump in their variable mortgage payments when the rba statement was released the index immediately plunged to be down 124 points there was not much reprieve thereafter the financials sector closed down 2 3 not the biggest percentage move on the day but by far the most powerful technology fell 3 0 mostly because apple announced it was jumping on the bnpl bandwagon sending zip co zip down 14 4 to be the worst index performer on the day along with its peers real estate fell 2 9 as higher bond rates undermine reit dividends the aussie ten year yield rose 7 points to 3 55 the two year jumped 17 points to 2 76 consumer discretionary fell 2 3 with consumers forced to lock down their wallets even staples fell 1 6 the resource sectors tried manfully to hold on but in the end materials closed down 0 2 and energy 0 3 all sectors closed in the red the question now is will the rba do it again next month the board expects to take further steps in the process of normalising monetary conditions in australia over the months ahead another 50 pointer the size and timing of future interest rate increases will be guided by the incoming data anz bank economists for one who were in the 40 points camp suggest a 50 pointer in august is more likely than july given the june quarter cpi result will be known by then otherwise there s only monthly jobs numbers this implies only 25 in july but we know the rba is now on a tear to fight inflation nothing should really be that surprising a lot of potential buyers would have just stood aside and let it happen yesterday this morning the futures are up 45 points grim determination only three weeks after an earnings report that sent wall street into a tailspin us target downgraded its margin guidance last night the prior shock of weak june quarter earnings guidance was all about lockdown suitable inventory the chain couldn t shift it was stuck with trackie daks up to the eyeballs and garden lounges were clogging the aisles the only way to move it is to discount the dow fell 270 points from the open target s not a dow stock there is a wider implication yet after falling sharply early target clawed its way back to close down only 2 3 indeed wall street spent all session recovering and then pushing higher there will be no surprise when the fed hikes by 50 points next week nor any surprise when it follows up in july september remains up in the air no august meeting but wall street is coming to the conclusion that will probably be 50 as well this is very bad news for growth stocks but the nasdaq rallied 0 9 last night as did the s p500 the bottom line is most of those growth stocks had fallen as far as 60 70 or even 80 year to date how much further can they fall investors are looking for bargains and it didn t hurt that the us ten year yield slipped back below 3 last night by contrast the energy sector is up almost 70 year to date yet last night the sector again outperformed the index in rising a further 3 many on wall street remain convinced the market can continue to rally at least in the near term thereafter it likely depends on the trajectory of inflation plenty still believe the 2022 low is not yet in commodities spot metals minerals energy futures gold oz 1852 10 10 70 0 58 silver oz 22 22 0 19 0 86 copper lb 4 32 0 05 1 11 aluminium lb 1 36 0 01 0 50 lead lb 0 99 0 01 0 98 nickel lb 13 05 0 20 1 53 zinc lb 1 72 0 04 2 42 west texas crude 119 41 0 91 0 77 brent crude 120 81 0 71 0 59 iron ore t 145 81 0 57 0 39 the us has begun shipping in oil from venezuela opec has increased its production quota but shanghai continues to reopen and the us summer driving season has begun oil prices press higher following a 0 5 rate hike from the rba the aussie is up 0 5 at us 0 7234 today the spi overnight closed up 45 points or 0 6 there s nothing of particular note on the calendar today the australian share market over the past thirty days broker recommendation changes past three trading days ann ansell downgrade to underperform from neutral credit suisse apx appen downgrade to neutral from buy citi coe cooper energy upgrade to neutral from underperform macquarie upgrade to accumulate from hold ord minnett cpu computershare upgrade to hold from lighten ord minnett dmp domino s pizza enterprises upgrade to buy from accumulate ord minnett hls healius upgrade to buy from neutral citi ipl incitec pivot downgrade to hold from accumulate ord minnett tah tabcorp downgrade to hold from add morgans tcl transurban group downgrade to neutral from outperform credit suisse for more detail go to fnarena s australian broker call report which is updated each morning mon fri all overnight and intraday prices average prices currency conversions and charts for stock indices currencies commodities bonds vix and more available on the fnarena website click here subscribers can access prices on the website readers should note that all commentary observations names and calculations are provided for informative and educational purposes only investors should always consult with their licensed investment advisor first before making any decisions all views expressed are the author s and not by association fnarena s see disclaimer on the website all paying members at fnarena are being reminded they can set an email alert specifically for the overnight report go to portfolio and alerts on the website and tick the box in front of the overnight report you will receive an email alert every time a new overnight report has been published on the website find out why fnarena subscribers like the service so much your feedback thank you warning this story contains unashamedly positive feedback on the service provided www fnarena com fnarena is proud about its track record and past achievements ten years on click to view our glossary of financial terms charts
1 aspira women s health inc 12117 bee caves road building iii suite 100 austin texas 78738 512 519 0400 supplementary information about the 2022 annual meeting of stockholders to be held in a virtual meeting format only via live webcast at 8 00 a m eastern daylight time on thursday june 23 2022 this statement this supplement supplements and amends the definitive proxy statement dated april 29 2022 the proxy statement of aspira women s health inc the company we us or our furnished to holders of company common stock par value 0 001 per share common stock in connection with the solicitation of proxies on behalf of the company s board of directors our board for the 2022 annual meeting of stockholders the annual meeting scheduled to be held on june 23 2022 and any adjournment or postponement thereof the annual meeting will be held in a virtual meeting format only via live webcast at 8 00 a m eastern daylight time on thursday june 23 2022 the record date for the determination of the stockholders who are entitled to vote at the annual meeting is the close of business on april 27 2022 which is the same record date specified in the proxy statement except as described in this supplement the information provided in the proxy statement continues to apply this supplement is being filed with the securities and exchange commission and is being made available to our stockholders on june 7 2022 the proxy statement contains important additional information and this supplement should be read in conjunction with it removal of proposal three regarding approval of an amendment to the vermillion inc 2019 stock incentive plan from stockholder consideration on june 6 2022 our board determined not to seek stockholder approval at the annual meeting of proposal three regarding an amendment to the vermillion inc 2019 stock incentive plan the 2019 plan which would i change the name of the 2019 plan to the aspira women s health inc 2019 stock incentive plan and ii effectuate an increase in the number of shares of common stock authorized to be granted under the 2019 plan by 8 000 000 shares from 10 492 283 to 18 492 283 accordingly we are no longer proposing to modify the 2019 plan as set forth in proposal three and proposal three has been removed from the agenda for the annual meeting and will not be considered or voted on at the annual meeting all other proposals presented in the proxy statement remain on the agenda for the annual meeting and will be considered and voted on at the annual meeting as set forth in the proxy statement although our board believes that proposal three was appropriately proposed by us upon further review and careful consideration of various marketplace factors and the views of company management and the company s advisors our board has determined that it is in the best interest of the company and our stockholders to remove proposal three from stockholder consideration at the annual meeting in light of the removal of proposal three from consideration at the annual meeting we note to our stockholders the following important matters regarding voting we will not make available or distribute and you do not need to sign new proxy cards or submit new voting instructions solely as a result of the removal of proposal three any proxy card or voting instructions received to date or received in the future for proposal one the election of the seven director nominees named in the proxy statement proposal two the approval on an advisory basis of the compensation of the company s named executive officers as disclosed in the proxy statement and proposal four the ratification of the selection of bdo usa llp as the company s independent registered public accounting firm for the year ending december 31 2022 are and will be valid any voting directions on proposal three received via proxy cards or voting instructions will be disregarded and no shares will be voted with respect to proposal three proxy cards or voting instructions received and providing direction on the remaining proposals proposals one two and four will remain valid and will be voted on those proposals as directed in such proxy card or voting instructions and if you have already submitted a proxy card or voting instructions you do not need to resubmit them with different directions unless you wish to change any votes previously cast on the remaining proposals or revoke your proxy as discussed in greater detail in the proxy statement you may change your vote at any time prior to the annual meeting as discussed in greater detail in the proxy statement your votes regarding the remaining proposals are important please vote on these proposals as described in the proxy statement additional information and where to find it in connection with the annual meeting we filed the proxy statement with the securities and exchange commission on april 29 2022 and on or about may 13 2022 we commenced mailing our notice of internet availability of proxy materials which serves to notify our stockholders that the proxy statement its related proxy card a notice of meeting and our annual report on form 10 k for the year ended december 31 2021 are available to them over the internet unless otherwise instructed by the stockholder before making any voting decision stockholders are urged to read the proxy statement and all of the related proxy materials carefully copies of the proxy materials including the proxy statement and our annual report on form 10 k for the year ended december 31 2021 are available at www aspirawh com and www proxyvote com
woodcliff lake n j june 07 2022 globe newswire hudson technologies inc nasdaq hdsn a leading provider of innovative and sustainable refrigerant products and services to the heating ventilation air conditioning and refrigeration industry and one of the nation s largest refrigerant reclaimers today announced that it is set to join the russell 2000 index at the conclusion of the 2022 russell indexes annual reconstitution effective after the us market opens on monday june 27 2022 according to a preliminary list of additions posted friday june 3 2022 annual russell indexes reconstitution captures the 4 000 largest us stocks as of may 6 2022 ranking them by total market capitalization membership in the us all cap russell 3000 index which remains in place for one year means automatic inclusion in the large cap russell 1000 index or small cap russell 2000 index as well as the appropriate growth and value style indexes ftse russell determines membership for its russell indexes primarily by objective market capitalization rankings and style attributes brian f coleman president and chief executive officer of hudson technologies commented we re pleased that we are being added to the russell 2000 index and believe our selection demonstrates the strength of our business model as a provider of products and services designed to promote the sustainable and environmentally sound operation of cooling and refrigeration systems we welcome the enhanced visibility provided by our inclusion in the russell 2000 index as we execute on our strategy to drive continued growth and shareholder value russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies approximately 12 trillion in assets are benchmarked against russell s us indexes russell indexes are part of ftse russell a leading global index provider for more information on the russell 3000 index and the russell indexes reconstitution go to the russell reconstitution section on the ftse russell website about hudson technologies hudson technologies inc is a leading provider of innovative and sustainable refrigerant products and services to the heating ventilation air conditioning and refrigeration industry for nearly three decades we have demonstrated our commitment to our customers and the environment by becoming one of the first in the united states and largest refrigerant reclaimers through multimillion dollar investments in the plants and advanced separation technology required to recover a wide variety of refrigerants and restoring them to air conditioning heating and refrigeration institute standard for reuse as certified emerald refrigerants the company s products and services are primarily used in commercial air conditioning industrial processing and refrigeration systems and include refrigerant and industrial gas sales refrigerant management services consisting primarily of reclamation of refrigerants and refrigerantside services performed at a customer s site consisting of system decontamination to remove moisture oils and other contaminants the company s smartenergy ops service is a web based real time continuous monitoring service applicable to a facility s refrigeration systems and other energy systems the company s chiller chemistry and chill smart services are also predictive and diagnostic service offerings as a component of the company s products and services the company also generates carbon offset projects about ftse russell ftse russell is a global index leader that provides innovative benchmarking analytics and data solutions for investors worldwide ftse russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries covering 98 of the investable market globally ftse russell index expertise and products are used extensively by institutional and retail investors globally approximately 20 trillion is currently benchmarked to ftse russell indexes for over 30 years leading asset owners asset managers etf providers and investment banks have chosen ftse russell indexes to benchmark their investment performance and create etfs structured products and index based derivatives a core set of universal principles guides ftse russell index design and management a transparent rules based methodology is informed by independent committees of leading market participants ftse russell is focused on applying the highest industry standards in index design and governance and embraces the iosco principles ftse russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth depth and reach of its offering ftse russell is wholly owned by london stock exchange group for more information visit www ftserussell com safe harbor statement under the private securities litigation reform act of 1995 statements contained herein which are not historical facts constitute forward looking statements such forward looking statements involve a number of known and unknown risks uncertainties and other factors which may cause the actual results performance or achievements of the company to be materially different from any future results performance or achievements expressed or implied by such forward looking statements such factors include but are not limited to changes in the laws and regulations affecting the industry changes in the demand and price for refrigerants including unfavorable market conditions adversely affecting the demand for and the price of refrigerants the company s ability to source refrigerants regulatory and economic factors seasonality competition litigation the nature of supplier or customer arrangements that become available to the company in the future adverse weather conditions possible technological obsolescence of existing products and services possible reduction in the carrying value of long lived assets estimates of the useful life of its assets potential environmental liability customer concentration the ability to obtain financing the ability to meet financial covenants under existing credit facilities any delays or interruptions in bringing products and services to market the timely availability of any requisite permits and authorizations from governmental entities and third parties as well as factors relating to doing business outside the united states including changes in the laws regulations policies and political financial and economic conditions including inflation interest and currency exchange rates of countries in which the company may seek to conduct business the company s ability to successfully integrate any assets it acquires from third parties into its operations the impact of the current covid 19 pandemic and other risks detailed in the company s 10 k for the year ended december 31 2021 and other subsequent filings with the securities and exchange commission the words believe expect anticipate may plan should and similar expressions identify forward looking statements readers are cautioned not to place undue reliance on these forward looking statements which speak only as of the date the statement was made investor relations contact john nesbett jennifer belodeauims investor relations 203 972 9200 company contact brian f coleman president ceohudson technologies inc 845 735 6000 source hudson technologies
chicago business wire coeur mining inc s coeur or the company nyse cde senior vice president and chief financial officer thomas s whelan will participate in the rbc capital markets global mining and materials conference on thursday june 9 2022 the rbc capital markets global mining and materials conference is an invitation only investment conference presentation materials will be made available on the company s website at www coeur com about coeur coeur mining inc is a u s based well diversified growing precious metals producer with four wholly owned operations the palmarejo gold silver complex in mexico the rochester silver gold mine in nevada the kensington gold mine in alaska and the wharf gold mine in south dakota in addition the company wholly owns the silvertip silver zinc lead development project in british columbia and has interests in several precious metals exploration projects throughout north america contacts coeur mining inc jeff wilhoit director investor relations phone 312 489 5800 www coeur com
bragar eagel squire p c a nationally recognized stockholder rights law firm announces that a class action lawsuit has been filed against verrica pharmaceuticals inc verrica or the company nasdaq vrca in the united states district court for the eastern district of pennsylvania on behalf of all persons and entities who purchased or otherwise acquired verrica securities between may 28 2021 and may 24 2022 both dates inclusive the class period investors have until august 5 2022 to apply to the court to be appointed as lead plaintiff in the lawsuit click here to participate in the action in december 2020 verrica submitted its new drug application nda to the u s food and drug administration fda seeking regulatory approval of vp 102 for the treatment of molluscum on september 20 2021 after the market closed verrica announced receipt of a complete response letter crl due to deficiencies at a facility of verrica s contract manufacturer in connection with the company s nda on this news the company s stock price fell 1 00 or 8 3 to close at 11 03 per share on september 21 2021 on unusually heavy trading volume in november 2021 verrica resubmitted the nda for vp 102 claiming he resubmission addresses the successful resolution of inspection deficiencies at the manufacturing facility then on may 24 2022 after the market closed verrica announced receipt of another complete response letter regarding the vp 102 nda citing deficiencies identified during a general reinspection of sterling pharmaceuticals services llc sterling the contract manufacturing organization cmo that manufactures verrica s bulk solution drug product on this news the company s shares fell 3 55 or 63 8 to close at 2 01 per share on may 25 2022 on unusually heavy trading volume the complaint filed in this class action alleges that throughout the class period defendants made materially false and or misleading statements as well as failed to disclose material adverse facts about the company s business operations and prospects specifically defendants failed to disclose to investors 1 that there were manufacturing deficiencies at the facility where verrica s contract manufacturer produced bulk solution for vp 102 2 that these deficiencies were not remediated when verrica resubmitted its nda for vp 102 for molluscum 3 that the foregoing presented significant risks to verrica obtaining regulatory approval of vp 102 for molluscum and 4 that as a result of the foregoing defendants positive statements about the company s business operations and prospects were materially misleading and or lacked a reasonable basis if you purchased or otherwise acquired verrica shares and suffered a loss are a long term stockholder have information would like to learn more about these claims or have any questions concerning this announcement or your rights or interests with respect to these matters please contact brandon walker or melissa fortunato by email at investigations bespc com telephone at 212 355 4648 or by filling out this contact form there is no cost or obligation to you about bragar eagel squire p c bragar eagel squire p c is a nationally recognized law firm with offices in new york california and south carolina the firm represents individual and institutional investors in commercial securities derivative and other complex litigation in state and federal courts across the country for more information about the firm please visit www bespc com attorney advertising prior results do not guarantee similar outcomes view source version on businesswire com
amid the most competitive job market in recent history numerous banks last year granted special compensation to their ceos and other high ranking executives in an effort to persuade them not to leave nearly one quarter of 59 large and midsize banks reported such awards in their latest proxy statements according to an analysis this spring by the consulting firm compensation advisory partners the special awards ranged in value from 100 000 to 52 6 million of the 14 banks that granted them 10 companies cited retention as at least one of the reasons it did so doling out such prizes delivers a strong message to chief executives and other corporate leaders who may or may not be currently engaged in employment discussions elsewhere said kelly malafis a founding partner at compensation advisory partners sometimes the individuals who get these awards are not even necessarily looking for a new job said malafis whose firm reviewed executive compensation packages at banks with at least 10 billion of assets but the management team and the compensation committee want to signal that they are important to the organization and hopefully shut down those discussions before they happen she said the battle for talent in banking which was facing a skills deficit even before the covid 19 pandemic disrupted the workforce continues to rage across much of the industry to combat hiring and retention difficulties banks are raising wages and salaries reskilling existing employees and accommodating employees growing demand for hybrid or remote jobs it s what we saw last summer times 10 said cameron boyd director of the financial services practice at the executive search firm smith wilkinson which works primarily with community and regional banks the market simply could not be any tighter at the c suite level retention awards are one way to encourage key executives to stick around when they might be tempted to retire or leave for another job said adam eckels the founder and ceo of aj consultants an executive search firm in kingston pennsylvania that works with banks credit unions and fintechs to fill open positions we re seeing a lot of premeditated stuff before a person says they are unhappy eckels said there s a plan as to how to keep them happy engaged and knowing what the next step is in most instances the awards should work in terms of hanging onto key talent eckels said it s very hard for somebody to walk away from a large guaranteed chunk of cash or stock compensation he said they call it golden handcuffs and they call it that for a good reason the 14 banks that made retention awards in 2021 range in size from banking giants jpmorgan chase and bank of america to regional banks such as citizens financial group in providence rhode island and community banks such as renasant corp in tupelo mississippi different banks took different approaches some awards were handed out as cash payments while others were structured as time vested restricted stock units or performance based stock units or as some combination of those award types the largest retention award went to jpmorgan ceo jamie dimon who last summer received stock options worth 52 6 million according to the company s most recent proxy statement the options have a 10 year term and cannot be exercised until at least mid 2026 the decision reflects the board s desire for dimon 66 to lead the company for several more years and reflects the unique inflection point in tenure and the importance of his continued leadership and support of the firm s succession plans according to the proxy statement dimon s award and a 27 9 million award to jpmorgan chief operating officer daniel pinto are outliers in comparison with the smaller awards given by other banks bank of america awarded 7 2 million in restricted stock units to vice chair and former chief financial officer paul donofrio and 2 4 million in rsus to current cfo alastair borthwick industry news bank ceos who got the heftiest raises last year the chief executives of keycorp comerica cullen frost first republic and bank of america all received pay bumps of between 31 and 64 in 2021 here s a look at the industry s top 10 finishers june 6 the charlotte north carolina company said in its proxy statement that the awards are based on record 2021 performance and the ongoing criticality of both men to the company in future years to receive full payment of the awards which were granted in february of this year both donofrio and borthwick must remain employed at bank of america through a four year back loaded vesting period that grants 50 of the awards in february 2025 and the remaining 50 in february 2026 the proxy statement said at old national bancorp in evansville indiana the executive leadership team including ceo jim ryan received retention awards for 2021 in part to motivate them to achieve performance and cost savings goals related to old national s recent merger with first midwest bancorp in chicago but also to support retention of certain leaders the proxy statement said the value of the old national awards which were distributed in cash and performance based stock units ranged from 628 000 to 5 3 million according to compensation advisory partners analysis atlantic union bankshares in richmond virginia recognized chief operating officer maria tedesco with a 250 000 retention award in the form of restricted stock the company cited tedesco s leadership and performance but also wanted to incentivize her to stay with the bank meanwhile bank of hawaii in honolulu gave awards to four members of its executive team citing an uptick in competition for banking executive expertise in the local marketplace its proxy statement said the awards to chief banking officer james polk chief risk officer mary sellers chief financial officer dean shigamura and sharon crofts who leads the client solutions group ranged from 1 million to 4 million and were a mix of cash and stock options the bank of hawaii awards only vest if the individuals keep working at the bank for a certain number of years and if they perform at least at a level that meets expectations the final award amounts depend on the company s performance relative to its regional bank peers industry news bank ceo compensation soared last year alongside surging stock prices total direct compensation for the chief executives at large and midsize banks rose by 21 5 up from a 5 increase in 2020 according to a new analysis strong earnings growth and a hot stock market were key factors june 2 across the banking industry retention awards were a fairly balanced mix of smaller time based awards and larger performance based awards said shaun bisman principal at compensation advisory partners linking the larger awards to future performance can be key to pleasing shareholders who pay attention to pay packages he said that s generally more palatable to shareholders and investor advisory firms when it s tied to performance or vesting over four years or more bisman said jpmorgan s retention awards to dimon and pinto were not related to the bank s 2021 performance the awards drew attention last month when just 33 of shareholders voted in favor of the company s executive compensation packages for 2021 the non binding advisory vote during jpmorgan s annual meeting came after the investor advisory firms glass lewis and institutional shareholder services recommended that shareholders reject the company s pay packages saying the one time grants to dimon and pinto were excessive the likelihood that retention awards will be handed out at the same pace during 2022 as last year is slim according to executive compensation experts so far this year the stock performance of banks is down from 2021 and it would be hard to justify such awards when banks aren t as profitable experts said all these banks can t keep pouring retention awards upon retention awards and still be where they need to be from a bottom line standpoint eckels said eventually it will peter out
new york new york u s stocks advanced on tuesday despite concerns from the u s treasury about unacceptable inflation we currently face macroeconomic challenges including unacceptable levels of inflation as well as the headwinds associated with the disruptions caused by the pandemic s effect on supply chains and the effects of supply side disturbances to oil and food markets resulting from russia s war in ukraine treasury secretary janet yellen told a senate finance committee hearing tuesday the dow jones industrials rallied 264 36 points or 0 80 percent to 33 180 14 the nasdaq composite finished with a 113 86 points or 0 94 percent gain to 12 175 23 the standard and poor s advanced 39 24 points or 0 95 percent to 4 160 67 the u s dollar was sold off the euro cruised higher to 1 0709 around the new york close tuesday the british pound strengthened to 1 2598 the canadian dollar jumped to 1 2525 the australian dollar on the back of an rba 50 basis points rate hike accelerated to 0 7237 the new zealand dollar was slightly higher at 0 6497 the japanese yen went against the trend crumbling to a more than a two decade low of 132 62 the swiss franc too weakened last trading at 0 9728 equity markets overseas mostly finished in the red in london the ftse 100 fell 0 12 percent the german dax declined 0 66 percent the cac 40 in paris france was off 0 74 percent the australian all ordinaries tumbled 114 50 points or 1 54 percent to 7 318 60 in new zealand the s p nzx 50 sank 151 64 points or 1 33 percent to 11 265 70 south korea s kospi composite dived 44 31 points or 1 66 percent to 2 626 30 hong kong s hang seng declined 122 23 points or 0 56 percent to 21 531 67 in tokyo the nikkei 225 going against the trend added 28 06 points or 0 10 percent to close at 27 943 95 china s shanghai composite finished a little better than flat up 5 39 points or 0 17 percent at 3 241 76
bragar eagel squire p c a nationally recognized stockholder rights law firm announces that a class action lawsuit has been filed against digital turbine inc digital turbine or the company nasdaq apps in the united states district court for the western district of texas on behalf of all persons and entities who purchased or otherwise acquired digital turbine securities between august 9 2021 and may 17 2022 both dates inclusive the class period investors have until august 5 2022 to apply to the court to be appointed as lead plaintiff in the lawsuit click here to participate in the action digital turbine is a software company that delivers products to assist third parties in monetizing through the utilization of mobile advertising the company completed the acquisitions of adcolony holdings as adcolony and fyber n v fyber on april 29 and may 25 2021 respectively on may 17 2022 digital turbine issued a press release revealing that it will restate its financial statements for the interim periods ended june 30 2021 september 30 2021 and december 31 2021 following a review of the presentation of revenue net of license fees and revenue share for the company s recently acquired businesses on this news the company s shares fell 1 93 or 7 1 to close at 25 28 per share on may 18 2022 on unusually heavy trading volume the complaint filed in this class action alleges that throughout the class period defendants made materially false and or misleading statements as well as failed to disclose material adverse facts about the company s business operations and prospects specifically defendants failed to disclose to investors 1 that the company s recent acquisitions adcolony and fyber act as agents in certain of their respective product lines 2 that as a result revenues for those product lines must be reported net of license fees and revenue share rather than on a gross basis 3 that the company s internal control over financial reporting as to revenue recognition was deficient and 4 that as a result of the foregoing the company s net revenues was overstated throughout fiscal 2022 and 5 that as a result of the foregoing defendants positive statements about the company s business operations and prospects were materially misleading and or lacked a reasonable basis if you purchased or otherwise acquired digital turbine shares and suffered a loss are a long term stockholder have information would like to learn more about these claims or have any questions concerning this announcement or your rights or interests with respect to these matters please contact brandon walker or melissa fortunato by email at investigations bespc com telephone at 212 355 4648 or by filling out this contact form there is no cost or obligation to you about bragar eagel squire p c bragar eagel squire p c is a nationally recognized law firm with offices in new york california and south carolina the firm represents individual and institutional investors in commercial securities derivative and other complex litigation in state and federal courts across the country for more information about the firm please visit www bespc com attorney advertising prior results do not guarantee similar outcomes view source version on businesswire com
the american dream s ownership overslept its alarm last week missing an interest payment on a nine figure debt don ghermezian s triple five group failed to make its semiannual payment on a 800 million municipal bond the wall street journal reported bondholder trustee u s bank na informed bondholders two days after wednesday s missed payment bondholders instead received payment from an 11 35 million debt service reserve account according to the publication but if triple five does not fork over what was due by the end of the grace period on june 16 it could be declared in default the money troubles are nothing new for the beleaguered 6 billion mall in east rutherford last month a securities filing revealed the property lost roughly 60 million last year generating 173 million in revenue against 232 million in expenses the extravagant retail complex recorded 305 million in sales last year well below the 2 billion once forecasted for its first year of operation earlier this year triple five began hunting for a four year extension to pay off 1 7 billion in construction financing the loans came from a group including jpmorganchase including a 1 2 billion senior loan and 475 million mezzanine loan due to be repaid last year sign up for the undefined newsletter sign up in february the mall needed to take 9 3 million from a reserve account to make a debt payment a securities filing revealed there was only 820 left in the account after the payment was made after years of delays the star crossed mall opened in 2019 around the same time the novel coronavirus began replicating in hubei province its first stores didn t open until october 2020 half a year into the pandemic s onset in america cash flow problems quickly arose leading senior construction loan holders to take minority stakes in other triple five properties including the mall of america and the west edmonton mall the new jersey property s near term future has not come into focus but east rutherford mayor jeffrey lahullier said monday that the mall s definitely in trouble according to northjersey com curiously the mayor floated that the mall could be too big to fail noting taxpayer contributions to the complex lahullier said the mall is at least 5 5 million behind in payments in lieu of taxes but the mall is clearly not systemically important to new jersey s economy and the vast majority of it was privately financed making the possibility of a government bailout remote holden walter warner
bragar eagel squire p c a nationally recognized stockholder rights law firm is investigating potential claims against cognyte software ltd cognyte or the company nasdaq cgnt on behalf of cognyte stockholders our investigation concerns whether cognyte has violated the federal securities laws and or engaged in other unlawful business practices click here to participate in the action on april 5 2022 cognyte reported its fourth quarter 2021 financial results including revenue of 125 million which was about 3 5 million below the midpoint of the company s own guidance cognyte cited lower conversions within its product pipeline along with supply chain issues during the related conference call cognyte s chief executive officer stated that a longer sales cycle in the lower than expected bookings in q4 and acknowledged that management didn t execute well on this news cognyte s stock fell 3 63 or 31 1 to close at 8 03 per share on april 5 2022 thereby injuring investors if you purchased or otherwise acquired cognyte shares and suffered a loss are a long term stockholder have information would like to learn more about these claims or have any questions concerning this announcement or your rights or interests with respect to these matters please contact brandon walker or melissa fortunato by email at investigations bespc com by telephone at 212 355 4648 or by filling out this contact form there is no cost or obligation to you about bragar eagel squire p c bragar eagel squire p c is a nationally recognized law firm with offices in new york and california the firm represents individual and institutional investors in commercial securities derivative and other complex litigation in state and federal courts across the country for more information about the firm please visit www bespc com attorney advertising prior results do not guarantee similar outcomes view source version on businesswire com
washington a former member of donald trump s cabinet will attempt a return to the u s congress in montana and california democrats concerned about crime may oust one of their own as voters head to the polls in midterm primary elections in seven states on tuesday voters in south dakota new jersey iowa mississippi and new mexico will also cast ballots in nominating contests that will set the competitive field for nov 8 s elections which will determine control of congress for the next two years with president joe biden slumping in the polls and soaring inflation souring voters moods republicans are expected to win control of the house of representatives and possibly the senate which would bring biden s legislative agenda to a halt and give republicans the power to launch distracting and possibly politically damaging investigations in montana ryan zinke who served as interior secretary under republican former president trump is running for a newly created house seat that the state gained thanks to population growth and the once a decade redistricting process zinke who served in congress previously faces four republican challengers some of whom claim that he is too liberal or lacks commitment to the state because his wife s residence is in california advertisement zinke was accused in an inspector general report this year of using is position as head of the interior department to advance a development project in his hometown and lying to an ethics investigator he has denied wrongdoing south dakota s conservative republican governor kristi noem faces a challenge by steven haugaard a member of the south dakota house of representatives noem has been mentioned as a possible vice presidential running mate if former president donald trump seeks election again in 2024 or as a white house candidate in her own right if he does not the winners of each of those republican primaries are favored to win in november california shakeout a pair of races in california will also illustrate liberal leaning voters frustrations with spikes in homicides and gun violence polls show that san francisco s progressive district attorney chesa boudin is likely to be pushed out of office in a recall vote a replacement would be chosen by the city s mayor london breed a democrat who has criticized boudin but has not taken a stance on the recall in los angeles rick caruso a billionaire developer and former republican is battling u s representative karen bass and a host of other liberal candidates in the mayoral election caruso who has spent more than 30 million of his own money in the campaign made crime the centerpiece of his candidacy in a city that saw homicides reach a 15 year high in 2021 that forced bass a longtime progressive champion in congress to move to the center and pledge to put more police on the streets caruso and bass could be headed to a runoff polls show advertisement new jersey iowa challenges republicans in new jersey and iowa will also be picking challengers to embattled incumbent house democrats representatives tom malinowski in new jersey and cindy axne in iowa former state senate republican leader tom kean jr the son of popular two time governor thomas kean leads a crowded republican field to challenge malinowski malinowski a two term incumbent who entered congress by flipping a republican seat in 2018 won reelection by defeating kean by 1 2 percentage points in 2020 since then his prospects have been weakened by redistricting and by a house ethics investigation after reports that he failed to disclose hundreds of thousands of dollars in stock trades it was a nail biter in 2020 and his district has become a little more favorable for republicans so it s going to be a significant challenge said benjamin dworkin director of the rowan university institute of public policy citizenship in iowa three republicans are vying for the chance to challenge axne businesswoman nicole hasso construction consultant gary leffler and former state senator zach nunn nunn the only republican contender who has held elective office boasts a string of endorsements from high profile party luminaries including trump s former secretary of state mike pompeo and several sitting house republicans
franchise group inc and kohl s are in negotiations for franchise group to purchase kohl s for 60 a share in cash here s what we know about franchise group franchise group is based in ohio franchise group inc is based in delaware ohio a suburb about 30 miles north of columbus franchise group is a relatively young company formed in june 2019 and has grown quickly through a series of acquisitions primarily in the retail sector for the fiscal year ended dec 25 2021 franchise group earned 363 8 million on revenue of 3 26 billion franchise group s best known brands are already in wisconsin among franchise group s brands are pet supplies plus the vitamin shoppe and sylvan learning pet supplies plus there are a number of pet supplies plus stores in wisconsin including in germantown mequon west bend sheboygan appleton neenah green bay marshfield and fitchburg pet supplies plus has more than 600 stores in 39 states most pet supplies plus stores are franchises which means they are independently owned and operated the vitamin shoppe franchise group s other well known brand is the vitamin shoppe there are vitamin shoppe locations in wauwatosa greenfield and madison there are about 700 vitamin shoppe locations in the u s all of them are company operated but represent a significant refranchising opportunity the company said in a recent investor presentation sylvan learning another brand is sylvan learning an omnichannel tutoring franchise for pre k through high school students the brand has more than 700 locations in 49 states and seven countries nearly all the locations are franchises other brands include badcock home furniture more home furnishings retailer with 383 stores across eight states in the rural southeastern u s american freight retailer of value furniture and appliances with more than 369 locations across 30 states sells as is appliances including scratch and dent one of a kind and overstocks and serves as a liquidation channel for major appliance vendors corporate culture as of dec 25 franchise group employed 9 119 full time and 5 551 part time employees this is how the company describes itself in its annual report filed with the u s securities and exchange commission we operate in a performance based environment where results matter and financial discipline is enforced we strive to create a highly collaborative culture in which employees feel that their input is sought after and valued at the same time we believe in holding individuals accountable and endeavor to create a culture in which employees do what they say they are going to do we believe that our culture is a long term competitive advantage for us fuels our ability to execute our business strategy and is a critical component of our employee talent strategy an equity firm owns more than 10 of franchise group as of dec 25 vintage capital management llc a private and public equity firm owned 12 3 of franchise group stock the two are closely related brian kahn president chief executive officer and a director of franchise group is also the founder and serves as investment manager of vintage capital management shares of franchise group trade under stock ticker frg on the nasdaq exchange
tokyo japan japanese prime minister fumio kishida is making plans to attend a north atlantic treaty organization nato summit to discuss russia s invasion of ukraine to be held in late june while kishida has repeatedly condemned russia in what he described as a war crime against ukraine attending the nato summit would be an unusually aggressive stance for a japanese prime minister as japan and russia have wrangled over decades old territorial disputes japanese leaders have previously maintained a careful line in their relations with russia as the nato summit will take place on 29th and 30th june in the spanish capital madrid it would likely overlap with the campaign for japanese upper house elections to be held on 10th july kishida is expected to make a final decision later accounting for japan s political situation nato has invited japan to the summit along with its partners in the asia pacific region which include australia new zealand and south korea kishida s attendance at the summit would deliver a strong message of international solidarity with ukraine according to observers
crypto in crisis event is scheduled to take place on tuesday june 14 at 7 p m et when charlie shrem and luke lango will reveal the world s first quant crypto system this system can reliably tell you which cryptos will soar and what cryptos you should avoid crypto in crisis event claim your free spot here crypto in crisis event what is all about unless you ve been living under a rock you know the crypto markets have been getting hammered the past 6 months we ve seen trillions of dollars in wealth erased sometimes in just a handful of days but get this according to crypto pioneer charlie shrem and investing prodigy luke lango things are about to get much worse more specifically they have new research that shows 98 of the cryptos in the world today could soon go to zero but for the remaining 2 they could soon see massive amounts of money flow into them as crypto enters a new era which is why next tuesday june 14 at 7 p m et charlie and luke are holding the most important crypto event of the year it s called crypto in crisis and you can sign up for free and learn more about what they ll be discussing by going here they re going to reveal a phenomenon that explains why cryptos have been hit hard this year and why 98 of the cryptos in the world could soon go to zero they claim cryptos are entering a new era and a handful of small under the radar cryptos will lead the charge and mint the next wave of crypto millionaires they have the research to back it up and are going to give you the name and ticker symbol to one of these cryptos for free during their crypto in crisis event what will charlie shrem and luke lango share through crypto in crisis event during the crypto in crisis event charlie and luke are going to reveal something that could give you an enormous edge in the crypto markets moving forward it s already being called the biggest breakthrough in crypto investing since the creation of the first crypto exchange you can be among the first to see this breakthrough with your own eyes how to sign up for the crypto in crisis event you can sign up for free here upon entering those residing in the u s or have a u s based phone number will also be presented with the chance of becoming vips this service is free to use and is the best way to make sure you don t miss any of the valuable content charlie and luke are sharing leading up to tuesday night as a vip member the following extra bonus will be sent out immediately charlie and luke have decided to give you their brand new special report 10 widely held cryptos knocking on death s door based on data from a new investing breakthrough charlie and luke will reveal during the crypto in crisis event these cryptos will likely never recover from the recent sell offs these cryptos are widely held and some of the most popular in the world today and if you re holding them right now you should consider selling them immediately before things get much worse who is charlie shrem charlie shrem is one of the first people to read the infamous white paper from bitcoin creator satoshi nakamoto charlie bought his first bitcoin around 5 up as much as 1 200 000 000 since then which turns every 1 000 into 12 million he s considered one of the most influential people in cryptocurrencies and was a founding member of the bitcoin foundation he s been called one of bitcoin s first tycoons bitcoin royalty and a crypto visionary charlie launched bitinstant one of the first and ultimately largest bitcoin exchanges at the dawn of the crypto era in 2011 the company was processing about 30 of all bitcoin transactions at one point charlie has advised and invested in more than two dozen digital currency companies launched and managed numerous partnerships between crypto and non crypto companies and is the go to guy for some of the world s wealthiest entrepreneurs he s been featured in fortune forbes cnn 60 minutes ted talks bloomberg and the wall street journal to name a few his story has been featured in numerous netflix documentaries and bestselling books including the seminal blockbuster bitcoin billionaires few words about luke lango luke graduated from the california institute of technology caltech with a degree in economics in 2020 he was ranked 1 stock picker in america by tipranks beating over 15 000 other investors including wall street traders and hedge fund managers he s recommended over 15 investments that have soared past the 1 000 mark like 12 000 from gme and over 8 000 from amd his readers have had nearly 200 chances to double their money or more based on luke s research over the past few years bottom line should you join crypto in crisis event next tuesday june 14 at 7 p m et charlie shrem will be sitting down with one of america s top investors luke lango at the crypto in crisis event they re going to share a shocking development unfolding in the crypto markets that charlie believes could soon send 98 of cryptos crashing to zero and a select few cryptos soaring to new highs they re also going to reveal a new breakthrough that can be a massive advantage at finding the next millionaire maker crypto you don t want to miss any of it especially the free urgent buy crypto recommendation they re going to reveal during the event you can sign up for free and learn more about the event right here disclaimer there is no offer to sell no solicitation of an offer to buy and no recommendation of any security or any other product or service in this article moreover nothing contained in this pr should be construed as a recommendation to buy sell or hold any investment or security or to engage in any investment strategy or transaction it is your responsibility to determine whether any investment investment strategy security or related transaction is appropriate for you based on your investment objectives financial circumstances and risk tolerance consult your business advisor attorney or tax advisor regarding your specific business legal or tax situation the news is not intended to be used in countries where bitcoin crypto is banned or not authorized media details contact us phone number 347 669 1180 website facebook twitter via kisspr com press release distribution service media contact this content is published on behalf of the above source please contact them directly for any concern related to the above
chris horn director of liquids for the heavy restaurant group has been in the industry since the 90s he brings the perspective of having seen the industry thrown for a loop by the dot com bubble and the great recession to discussing the challenges of pandemic dining and the silver linings that have emerged how has this past year been for you challenging would be an understatement we thought 2021 was a mess 2022 has its own set of challenges we have had a really hard time attracting talent you know i went from having a team of 12 people that could take my job any day down to i have two sommeliers between the two restaurants now and that s it s bonkers i think that when the pandemic hit i really was super concerned about all my staff but they all found other things to do some moved to florida some moved to michigan some got jobs waiting tables somewhere else some left the industry altogether some went back to school on new opportunities and revising the wine list there is a silver lining you know i look at all our locations and and everybody s new i think i have four employees downtown who were on the staff before the pandemic and stayed it s an opportunity to readdress how we do things because you don t have that legacy culture you don t have that legacy knowledge you also don t maybe have the legacy of certain habits that you get into so you know it is an opportunity to bring up a brand new generation of hospitality professionals it s an opportunity to rethink how you teach things before the pandemic we were teaching at a very high level we had a wine class every week in all our locations and now these classes have taken a step back and are a little more about the basics i think that s not a bad thing to remember the nuts and bolts of wine and food and wine pairing and hospitality so there are some positive things that are giving us hope the fact that we ve gone from a wine list that was 140 pages to a qr code that people swipe their phone and look at it with gone from 600 bottles to 120 that has been a great opportunity as well because playing in a smaller sandbox makes you edit really thoughtfully yeah it feels bad to not be more inclusive especially when you are in a wine producing state i used to have hundreds of local wines now i can t do that and that doesn t feel as good certainly but from a guest perspective and actually from an education perspective for the staff it s a lot easier to sit down and taste all the spanish wines that you re serving by the glass and by the bottle so that the next time a guest has a waiter who attended that wine class about spanish wines they will have experienced them all and that s something you could not do before when you had dozens of iberian peninsula selections on pandemic changes i remember at the beginning we were all like yeah we need to support local restaurants we re all buying gift cards and doing to go food and there was this real feeling of like we re going to help people out we were selling wine at retail just to keep things going and people were super supportive now it s like people yelping about my to go food wasn t hot when it got to me you re like of course it wasn t because you live 20 minutes away and your uber driver stopped at five other places after they picked up the stuff from our place all that goodwill seems to be gone i don t know how that happened but i guess it s just that we re all tired of this thing and we all want to lash out and have something to blame on unexpected shortages for our bartenders our bar managers i ve basically had to say stop using cool ingredients because they re gonna be out of stock next week just last week st elizabeth allspice dram is gone and it s in a cocktail we couldn t get campari for a while we couldn t get aperol for a while i still can t get oban scotch there are so many scotches i can t get so yeah there s tons of stuff i couldn t get our well bourbon for a while so i was buying plastic bottles of it at the walkup store everything has had a supply chain issue especially in the bar especially spirits especially anything that has to come across the pond so what we ve ended up doing is relying on local vodka local gin trying to make sure that we re no longer putting money in the pockets of those people that are making our lives difficult on the future of the industry i ve always said that people love restaurants first and their discipline second that if you love wine more than you love restaurants you shouldn t be in a restaurant as a wine professional if you love spirits more than restaurants you shouldn t be a bartender i think that my hope is that this next generation of restaurant people fall in love with restaurants first and whatever subset of restaurants be it spirits or beer or wine that gives them juice is something they take seriously but that they take restaurants more seriously than they take their chosen shield of expertise i wouldn t mind there being less emphasis on testing and achievement through third parties i think that some of the best wine professionals i ve worked with are the best not because they took some tests and achieved some level of expertise that was verified by a third party i think the best people in restaurants are the people who love restaurants so i would hope that in the future people will stop asking me what level of somm i am because it doesn t matter you re not here to ask me about my work history you re here to have a good time and just trust that if a sommelier approaches your table and wants to talk to you about your selection tonight that you should not quiz them about what level they are i don t go to the mechanic and ask about what level of expertise he or she has to change my oil i don t go to the grocery store and before i check out ask the checker what level checker they are i think that we ve done a disservice to hospitality by building a pedestal underneath the job of sommelier i think that has created some confusion and misunderstanding of what the job is that not only attracts sometimes the wrong people to the job but it also diminishes the understanding of how much work actually goes into being a sommelier it s not just sitting around tasting wine and guessing what it is it is moving boxes it is doing spreadsheets it s getting the best deal you can get for the best wine for your guests it s tasting your food and pairing it with wine before your guests arrive so when they want something to drink with the thing they order you have that the job is so much more than what the media has painted that people don t have a clue about how backbreaking this job can be this is a w s web exclusive get access to all of our feature stories by signing up today
shares in asia pacific were higher on wednesday with hong kong leading gains regionally the reserve bank of india will raise the policy repo rate by 50 basis points to 4 9 with immediate effect governor shaktikanta das announced wednesday the repo rate refers to the rate at which the central bank lends to commercial banks japan s economy shrank an annualized 0 5 in the first quarter revised government data showed wednesday an improvement over the initial estimate of a 1 contraction singapore shares in asia pacific were higher on wednesday with hong kong leading gains regionally the hang seng index in hong kong jumped 2 24 to close at 22 014 59 as chinese tech stocks listed in the city soared alibaba surged 10 12 while tencent climbed 6 47 and netease gained 5 66 the shanghai composite in mainland china closed 0 68 higher at 3 263 79 while the shenzhen component climbed 0 818 to 12 033 26 feeling out of the loop we ll catch you up on the chicago news you need to know sign up for the weekly chicago catch up newsletter here rbi announces rate hike the reserve bank of india on wednesday raised a key interest rate the rbi will raise the policy repo rate by 50 basis points to 4 9 with immediate effect governor shaktikanta das said the repo rate refers to the rate at which the central bank lends to commercial banks economists in a reuters poll had predicted a rate hike of between 25 to 75 basis points it may be noted in this context that the repo rate still remains below its pre pandemic level the indian central bank chief said following the announcement both the nifty 50 and bse sensex in india rose close to 0 4 each as of 1 44 p m local time the indian rupee traded at 77 763 per dollar weaker as compared with levels below 77 4 seen against the greenback last week the rbi s decision comes after the reserve bank of australia s surprise 50 basis point rate hike on tuesday in other markets the nikkei 225 in japan advanced 1 04 to close at 28 234 29 while the topix index climbed 1 18 to 1 969 98 japan s economy shrank an annualized 0 5 in the first quarter revised government data showed wednesday an improvement over the initial estimate of a 1 contraction south korea s kospi closed little changed at 2 626 15 the s p asx 200 in australia rose 0 36 to finish the trading day at 7 121 10 msci s broadest index of asia pacific shares outside japan gained 1 13 the world bank on tuesday cut its global growth forecast to 2 9 for 2022 and warned of the world economy slipping into a period of stagflation reminiscent of the 1970s these sort of headlines around risk of stagflation slower growth these are things the market has been you know trading on for most of the year already kieran calder head of equity research for asia at ubp told cnbc s street signs asia on wednesday calder described the world bank s expectation for 4 3 growth in 2022 for china as pretty aggressive given that multiple banks have cut their outlook for the country ubp is looking for below 4 gdp growth in china this year he said currencies and oil the u s dollar index which tracks the greenback against a basket of its peers was at 102 619 after seeing an earlier low of 102 387 the japanese yen traded at 133 62 per dollar weaker than levels below 132 seen against the dollar yesterday the australian dollar was at 0 7189 off an earlier high of 0 7235 oil prices were higher in the afternoon of asia trading hours with international benchmark brent crude futures up 0 39 to 121 04 per barrel u s crude futures gained 0 55 to 120 07 per barrel
for the first time in history the economy is collapsing faster than the stock market t co akngzattha the percentage of americans who feel dissatisfied with their finances is at the highest level since the poll began in 1972 bulls specialize in ignoring risk pic twitter com o994gjhcvq mac10 suburbandrone june 7 2022 forget cpi the week s most important data point is today s monthly consumer credit update last month we saw a blowout record surge in credit card usage as consumers tapped out pic twitter com foz5xe4jwi zerohedge zerohedge june 7 2022 fed gdp tracker is hitting stall speed 9 for q2 following 1 5 in q1 avg econodunce expect 3 growth t co h5bxffwjco two negative quarters recession cme double rate hike odds 100 pic twitter com owhyb08esf mac10 suburbandrone june 7 2022 consumer discretionary stock guidance revisions for 2q22 are almost all downward revisions pic twitter com 1xvtcqpjtw weimar silver baron bankerweimar june 7 2022 the amount of tightening next week 2x hikes 1x qt will be more than what broke global markets in 2016 and 2018 this time breadth is pre collapsed should be interesting pic twitter com ylkn84dr6x mac10 suburbandrone june 7 2022 pre pandemic the last time the u s flirted with recession was the summer of 2019 back then the fed cut rates three times this year they are going to raise rates ten more times and double tighten the balance sheet this isn t about the stock market anymore pic twitter com pljmb9k3zx mac10 suburbandrone june 7 2022 much talk about economy soft landing orange we are skeptical but global investors are not yet positioned even for this they seem outright risk on again blue line whoa pic twitter com l1wpl9pe93t co wb4efas36q for regular data crossborder capital crossbordercap june 7 2022 are they preparing us for a 10 cpi report t co wc02mswala wall street silver wallstreetsilv june 7 2022 world bank slashes global growth forecast to 2 9 warns of stagflation risk t co wxcyuv9zve pic twitter com y4pnay4yws reuters reuters june 7 2022 usa housing would you say it s a good time to buy real price index vs buying conditions pic twitter com 2ww671hntw wall street silver wallstreetsilv june 7 2022 one chart sums it all up what happens to consumer sentiment when asset prices go down we ve never seen this before pic twitter com hkoiq5c4cy mac10 suburbandrone june 7 2022 diesel rose to a record 5 70 up by 74 from a year ago most consumers don t pay for diesel directly but nearly all goods that consumers buy sooner or later end up on a truck and shipping costs sooner or later pic twitter com 0kfry28isf wall street silver wallstreetsilv june 7 2022 the consumer is on a borrowing spree as inflation erodes budgets forcing difficult choices nobody wants to buy essential goods on high interest credit but they will if they have to do so this can only last for so long before people max out and defaults ramp higher though t co gu1zvv0w05 markets mayhem mayhem4markets june 7 2022 airflation russia s invasion of ukraine has exacerbated a steady rise in crude oil prices over the past 18 months jet fuel now represents as much as 38 of an average airline s costs up from 27 in the years leading to 2019 for some budget airlines it can be as high as 50 pic twitter com e9vgahuwvp markets mayhem mayhem4markets june 7 2022 u s trade deficit sharply reversed in april to 87 1 billion this is the quickest reversal in the trade deficit since the global financial crisis of 2008 when the us was in a recession pic twitter com dzksvzgqt1 golden coast cassandra gregcrennan june 7 2022 the american consumer is dying on the vine target stock is down over 40 since november the destruction of the us economy is on purpose recession inflation underbiden brian glenn brianglenntv june 7 2022 driven by rising interest rates and the accumulation of federal debt interest will nearly triple in the next 10 years and reach a historic high relative to the size of the economy by 2032 shinzo abe s camp says deficit is misunderstood but top finance officials seek balanced budget likening the nation to a ship heading for an iceberg we are primarily funded by readers please subscribe and donate to support us the charts above show that the federal reserve was able to get through world war i the great depression world war ii the vietnam war and the stagflation of the 1970s without an explosion in its balance sheet but since ben bernanke janet yellen and jerome powell have in turn sat at the helm of the federal reserve there has been unprecedented growth in the fed s balance sheet
washington a former member of donald trump s cabinet will attempt a return to the u s congress in montana and california democrats concerned about crime may oust one of their own as voters head to the polls in midterm primary elections in seven states on tuesday voters in south dakota new jersey iowa mississippi and new mexico will also cast ballots in nominating contests that will set the competitive field for nov 8 s elections which will determine control of congress for the next two years with president joe biden slumping in the polls and soaring inflation souring voters moods republicans are expected to win control of the house of representatives and possibly the senate which would bring biden s legislative agenda to a halt and give republicans the power to launch distracting and possibly politically damaging investigations in montana ryan zinke who served as interior secretary under republican former president trump is running for a newly created house seat that the state gained thanks to population growth and the once a decade redistricting process zinke who served in congress previously faces four republican challengers some of whom claim that he is too liberal or lacks commitment to the state because his wife s residence is in california advertisement zinke was accused in an inspector general report this year of using is position as head of the interior department to advance a development project in his hometown and lying to an ethics investigator he has denied wrongdoing south dakota s conservative republican governor kristi noem faces a challenge by steven haugaard a member of the south dakota house of representatives noem has been mentioned as a possible vice presidential running mate if former president donald trump seeks election again in 2024 or as a white house candidate in her own right if he does not the winners of each of those republican primaries are favored to win in november california shakeout a pair of races in california will also illustrate liberal leaning voters frustrations with spikes in homicides and gun violence polls show that san francisco s progressive district attorney chesa boudin is likely to be pushed out of office in a recall vote a replacement would be chosen by the city s mayor london breed a democrat who has criticized boudin but has not taken a stance on the recall in los angeles rick caruso a billionaire developer and former republican is battling u s representative karen bass and a host of other liberal candidates in the mayoral election caruso who has spent more than 30 million of his own money in the campaign made crime the centerpiece of his candidacy in a city that saw homicides reach a 15 year high in 2021 that forced bass a longtime progressive champion in congress to move to the center and pledge to put more police on the streets caruso and bass could be headed to a runoff polls show advertisement new jersey iowa challenges republicans in new jersey and iowa will also be picking challengers to embattled incumbent house democrats representatives tom malinowski in new jersey and cindy axne in iowa former state senate republican leader tom kean jr the son of popular two time governor thomas kean leads a crowded republican field to challenge malinowski malinowski a two term incumbent who entered congress by flipping a republican seat in 2018 won reelection by defeating kean by 1 2 percentage points in 2020 since then his prospects have been weakened by redistricting and by a house ethics investigation after reports that he failed to disclose hundreds of thousands of dollars in stock trades it was a nail biter in 2020 and his district has become a little more favorable for republicans so it s going to be a significant challenge said benjamin dworkin director of the rowan university institute of public policy citizenship in iowa three republicans are vying for the chance to challenge axne businesswoman nicole hasso construction consultant gary leffler and former state senator zach nunn nunn the only republican contender who has held elective office boasts a string of endorsements from high profile party luminaries including trump s former secretary of state mike pompeo and several sitting house republicans
jpmorgan s marko kolanovic predicts oil is surging higher but so are stocks kolanovic who serves as the firm s chief global markets strategist and co head of global research believes the u s economy is strong enough to handle oil prices as high as 150 a barrel there could be some potential further spikes in oil especially given the situation in europe and the war so we wouldn t be surprised he told cnbc s fast money on tuesday but it could be a short lived spike and eventually sort of normalize feeling out of the loop we ll catch you up on the chicago news you need to know sign up for the weekly chicago catch up newsletter here wti crude is trading around three month highs settling up 0 77 to 119 41 a barrel on tuesday brent crude closed at the 120 57 mark the bullish move came as shanghai reopened from a two month covid 19 lockdown opening the door for higher demand and more upside we think the consumer can handle oil at 130 135 because we had that back in 2010 to 2014 inflation adjusted that was basically the level so we think the consumer can handle that said kolanovic who has earned top honors from institutional investor for accurate forecasts multiple years in a row his base case is the u s and global economy will avoid a recession but at a financial conference last week jpmorgan chase chairman and ceo jamie dimon told investors he s preparing for an economic hurricane which could be a minor one or superstorm sandy kolanovic contends it s vital to be ready for all possibilities we do forecast some slow down he said nobody is saying that there are no problems his firm s official s p 500 year end target is 4 900 but in a recent note kolanovic speculated the index would end the year around 4 800 still on par with all time highs hit on jan 4 right now the s p is 16 below its record high we don t think investors will stick in cash we don t think investors will stick in cash for the next 12 months you know waiting for this recession kolanovic said if we continue to see consumer especially on the services side holding up which we do expect then we think investors will gradually come back into equity markets kolanovic s top call remains energy a group he has been bullish on since 2019 actually valuations went lower despite the stock price appreciation kolanovic said earnings grow faster so multiples are actually lower now in energy than they were a year ago he s also bullish on small caps and high beta technology stocks that have gotten crushed this year disclaimer
by lance roberts on real investment advice for example the net percentage of bullish responses from the american association of individual investors aaii and the institutional investors index invi are near previous bear market lows such is despite the sharp rally over the last two weeks despite hopes for a rally the national association of investment managers naaim shows the same bearishness with sentiment so negative one would assume that a bear market was in full swing along with an economic recession however while it seems investors are terrified of the market and its outlook the sell off since january has remained quite orderly as shown the s p 500 index took almost 6 months to decline nearly 20 from its previous peak however what is interesting is that if investors are terrified why are they not selling investors are terrified but no sign of fear despite nearly 6 months of continuous selling rampant headlines of impending doom and cnbc s constant market s in turmoil specials little fear remains below the surface a couple of different gauges provide a view of market stress the first is the volatility index or vix more commonly referred to as a fear gauge the vix is a financial benchmark operating in real time it gives investors an indication of volatility expectations in the market for the coming 30 days historically spikes in the vix correlate to market bottoms as investors dump equities despite the recent selling pressure in the market over the last couple of months volatility remains subdued suggesting little panic in the markets another measure of market stress comes from the bond market by calculating the difference in yields or spreads between various bonds one standard measure is the yield difference between junk and a rated bonds while that spread has risen as of late which one would expect with recent market stresses it remains very low by historical standards when markets were in the grips of a bear if the market were indeed in the grips of a capitulatory selling event i would suggest both measures of market stress would be substantially higher that suggests that even though the media and investors are highly concerned about the markets they aren t doing much about it investors aren t selling over the last decade repeated rounds of monetary interventions created a sense of moral hazard in the financial markets what exactly is the definition of moral hazard noun economicsthe lack of incentive to guard against risk where one is protected from its consequences e g by insurance the massive federal reserve interventions bailouts and zero rates provided a perverse incentive to take on extreme forms of risk from speculative ipos to spacs to cryptocurrencies investors believed the fed was protecting them from the consequences of risk in other words the fed effectively insured them against potential losses the lesson taught to investors was that the fed would bail out any market decline therefore the fear of missing out overrides the need to get out we are primarily funded by readers please subscribe and donate to support us as shown below the aaii investor allocation to stocks bonds and cash tells the story despite aaii investor sentiment at very bearish levels the allocation to equities remains very high while bonds and cash remain low interestingly seemingly terrified investors are still unwilling to sell for the fear of missing out i should qualify that statement while investors aren t selling just yet it doesn t mean they won t there is a point at which every investor will sell for some it may be a 10 decline for others it may be a 40 decline however at some point everyone sells since 2009 every time the market dipped weaved or bobbed the federal reserve ran to the rescue by increasing monetary interventions not surprisingly many investors hope they will do so again sooner rather than later the problem for the market comes when investors begin to realize that with inflation running over 8 annually the fed may not be coming to the rescue anytime soon eventually everyone sells as noted there is a price where everyone sells the emotional strain eventually erodes investor confidence in their previous decisions this is crucial because there is generally no investment strategy or discipline the herding effect and loss aversion are the most significant behaviors that compound the issues of investor mistakes over time as markets rise individuals believe the current price trend will continue indefinitely the longer the rising trend lasts the more ingrained the belief becomes eventually the last holdouts finally buy in as the market evolves into a euphoric state as markets decline there is a slow realization that this decline is not a buy the dip opportunity as losses mount the need to avert loss increases until individuals seek to avert further loss by selling this behavioral trend runs counter intuitive to the buy low sell high investment rule such is the point investors now face as losses mount on financial statements and every decision made seems to be wrong given the lack of panic capitulation and discouragement it is highly likely this particular market cycle is not yet complete we continue to suggest using rallies to reduce risk rebalance allocations and increase cash levels opportunistically such generally provides better outcomes than forced selling when markets fall apart as noted the biggest challenge for most investors is the lack of an investment strategy or discipline from the outset such provides the basis for investment decisions based on fundamental technical or statistical analysis rather than emotion of course if you don t know what an investment strategy or discipline comprises that may be the best place to start
jasper in accesswire june 7 2022 svb t corporation otcqx svbt has been named to american banker magazine s top 200 publicly traded community banks in the nation in its may 2022 issue american banker ranked svb t corporation 132nd on its prestigious nationwide list in 2021 the corporation ranked 182nd in 2020 the corporation ranked 153rd and in 2019 the corporation ranked 102nd out of 601 publicly traded community banks and thrifts with 2 billion or less in assets springs valley is honored and humbled by our selection as one of the top 200 banks as defined by the american banker in their may issue said jamie shinabarger president ceo we are especially proud about climbing 50 spots in the rankings moving from 182nd in 2020 up to 132nd in 2021 he added essentially we have been able to provide our shareholders the benefit of both safety and return given the combination of our 11 55 year end capital ratio with our 11 05 roae up 100 basis points from last year this makes achieving the top 200 list even more impressive shinabarger concluded the study examined 438 well capitalized publicly traded banks with 2 billion or less in assets rankings are determined by each institution s return on average equity roae a measure of profitability widely used by investors to analyze business performance springs valley bank trust company is a subsidiary of svb t corporation headquartered at 8482 west state road 56 french lick indiana 47432 with administrative offices at 1500 main street jasper indiana 47546 springs valley has locations in dubois daviess gibson and orange counties offering full service bank and financial services springs valley has products and services for all types of families and businesses including checking and savings accounts certificates of deposit electronic services online consumer and mortgage applications and a variety of other loan options springs valley bank is a member of fdic and is an equal housing lender in addition the company has a full service financial advisory group managed by experienced talented professionals specializing in estate planning tax planning and wealth management investment services are also offered by a licensed professional springs valley representative trust and investment products are not deposits not insured by the fdic not a deposit or other obligation of or guaranteed by the depository institution not insured by any federal government agency may lose value subject to investment risks including possible loss of the principal amount invested more information can be found online at www svbt bank the company s stock is traded on the otcqx trading platform under ticker symbol svbt www otcmarkets com for more information contact dianna b land sevp hr marketing manager at 812 634 4963 or email at source svb t corporation view source version on accesswire com
kuala lumpur june 7 here is a brief look at some corporate announcements and news flow on tuesday june 7 involving ihh healthcare bhd dialog group bhd impiana hotels bhd cimb group holdings bhd capitaland malaysia trust dynaciate group bhd boustead plantations bhd bpb sarawak consolidated industries bhd scib hibiscus petroleum bhd uem sunrise bhd bintai kinden corp bhd dayang enterprise holdings bhd reservoir link energy bhd and advance information marketing bhd aim ihh healthcare bhd is embarking on disposal exercises worth rm1 35 billion including a divestment of its entire stake in imu health sdn bhd imuh to inbound education holdings sdn bhd for rm1 24 billion in conjunction with the imuh disposal ihh is also selling a hospital that is still under construction in kuala lumpur together with its assets and liabilities to columbia asia sdn bhd for rm139 million less an outstanding bank loan amount of rm38 million as of dec 31 2021 ihh said the move is in line with the group s strategy to divest its non core assets and recycle its capital by deploying the proceeds to grow its core healthcare delivery services business dialog group bhd s wholly owned singapore subsidiary dialog systems asia pte ltd dsapl via dsapl s 100 owned canada based company 2432707 alberta ltd is buying the entire stake in canada listed oil and gas firm pan orient energy corp poec for us 38 7 million rm170 million in dialog s first upstream o g venture outside malaysia for mature oil producing fields impiana hotels bhd has proposed to undertake a five to one share consolidation and issuances of redeemable convertible notes to raise up to rm150 million mainly for repayment of borrowings and working capital the group said the proposed share consolidation is undertaken due to amongst others the potential dilutive effect arising from the increase in the number of shares resulting from the conversion of the notes it added that the exercise should potentially help in reducing volatility in its trading price cimb group holdings bhd s subsidiaries cimb bank bhd and cimb islamic bank bhd have committed rm100 million in financing through bank negara malaysia s bnm low carbon transition facility lctf to encourage and empower businesses including small and medium enterprises sme to adopt low carbon and sustainable practices for business resilience cimb group said the rm100 million facility is being offered as part of the lctf financing scheme established by bnm in january 2022 capitaland malaysia trust has proposed to buy industrial properties in penang from dynaciate group bhd for rm80 million to venture into the logistics sector the group said the acquisition includes 5 11 hectares of freehold land with a single storey warehouse annexed to a double storey office building two single storey detached warehouses and other ancillary buildings the reit said the acquisition will enable it to gain a foothold in malaysia s logistics sector with sizeable property that comes with a total net lettable area of 335 000 sq ft boustead plantations bhd bpb has sealed a rm45 million green financing agreement with china construction bank m bhd ccbm to facilitate its sustainable replanting exercise as part of its commitment towards environmental social and governance efforts bpb one of malaysia s major palm oil companies seeks to leverage financing to maximise its ongoing accelerated sustainable replanting programme particularly for its plantation assets in sabah from this year until 2024 sarawak consolidated industries bhd scib has bagged an engineering procurement construction and commissioning contract worth rm30 75 million the firm said its unit scib properties sdn bhd had received a contract from ennova sdn bhd to provide project engineering services for kuala lumpur city hall s dbkl integrated smart lamp pole replacement within the klang valley involving 200 units of poles monopoles hibiscus petroleum bhd said its subsidiary repsol oil gas m ltd rml has discontinued the payment of state sales tax sst imposed by sabah after its appeal against the tax enforcement was met with silence from the sabah finance minister rml which has a production sharing contract psc in the kinabalu oil field had been making sst payment since 2020 under protest said hibiscus another subsidiary sea hibiscus sdn bhd which is the holder and operator of the 2011 north sabah enhanced oil recovery psc has not been paying sst to the state at all uem sunrise bhd has teamed up with nine companies in specialised fields to explore ways to address the rising cost of building materials and leverage on existing platforms the property developer signed a memorandum of understanding with the nine companies to develop and strengthen mutually beneficial cooperation under the group s vendors partnership programme bintai kinden corp bhd has been appointed as the authorised distributor of uk based wolff pipelines ltd s piping products the company said its unit bintai energy sdn bhd had received an exclusive appointment letter from wolff for stock and supply of stainless and carbon steel pipes flanges and fittings in accordance with the american and european standards for the oil and gas market in malaysia dayang enterprise holdings bhd has won a contract to provide maintenance construction and modification for the pm8e seligi oil fields located some 240 kilometres offshore peninsular malaysia the sarawak based oil and gas group said the contract was awarded to its wholly owned unit dayang enterprise sdn bhd by enquest petroleum production malaysia ltd the value of the contract is based on work orders issued by enquest and will include any other work and services which is generally related to the scope of works in the contract reservoir link energy bhd has secured letters of award to develop two solar rooftops the company said it had received an loa from osram opto semiconductors malaysia sdn bhd to develop solar rooftops in kulim the company said its subsidiary rl sunseap energy sdn bhd with collaboration between reservoir link and sunseap energy malaysia sdn bhd had secured the loa that includes building integrated photovoltaic power generation facilities
via birchgold group from peter reagan at birch gold group this week your news to know rounds up the latest top stories involving gold and the overall economy stories include the parallel collapse of stock and bond markets reminds us of real safe havens jeremy grantham and ray dalio dive deep into economic woes and gold remains the primary inflation resistant asset for an interesting reason bond investors might be surprised that their safe haven is failing but our readers are not the editor in chief of moneyweek merryn somerset webb recently wrote a financial times editorial to gently break some news to newer or forgetful investors if you have only been knocking around in markets for say 15 years you are seeing the collapse of everything that you have been told is true and have also observed to be true about markets the timespan she provides is an interesting one 15 years in the investment sphere might be a cycle for someone like ray dalio but for many it might very well be the entirety of their exposure to the markets the truth is that one doesn t need dalio s tenure in the markets to in so many words know better our readers don t need five years just one is plenty enough to alert those who are paying attention to market reality she continues outlining some of the false narratives that fueled the everything bubble for so long it turns out that quality growth stocks do not always outperform that the federal reserve will not always step in to protect your wealth and that the prices of the growth stocks in your portfolio have long been more a function of loose monetary policy than the priceless nature of innovative thinking in other words prices matter overpaying for overvalued assets doesn t make them worth more it just makes them cost more especially when the so called fed put is dead with our nation s central bankers demonstrating their willingness to stand back and watch while stocks and bonds tank together in response to their too little too late attempts to deal with inflation speaking of stocks and bonds finally it turns out that the idea of sticking with a long term portfolio consisting of 60 per cent equities and 40 per cent bonds does not mean everything will always be fine in 2019 we placed special emphasis on bonds going into negative territory when many ignored the issue the bond market was already in a historic crisis the treasury was being squeezed as the only sovereign bond offering a yield and a historically low one too the deutsche bundesbank offered bonds at a negative interest rate even before inflation that means owners of german bonds were literally paying the government for the privilege of loaning the government money in subsequent years we reported the growing movement away from the 60 40 portfolio model toward one that treats gold as a necessary diversification large cap money managers were coming around to this perspective possibly too late so far this year the s p 500 is down about 17 shockingly the 40 of the traditional 60 40 portfolio is down sharply as well if we consider the ishares 10 20 year treasury bond etf tlh as a proxy for the bond component 60 40 investors lost 16 so far this year on the safe part of their savings many americans are surprised i m confident regular readers of my columns are a lot less surprised the point of bonds in a 60 40 portfolio is to diversify away from risky equities unfortunately in this case diversifying away from equity risk has brought with it a slew of totally different risks including interest rate risk duration risk default risk inflation risk how can a safe haven perform its role when its market is in a historic crisis we discussed this last week here in the segment bonds fail to protect we also discussed verdad s research on gold s performance in such an environment our readers will also know that the consensus is that the stock market s losses so far are not the end of the bear cycle that we d expect to come after the longest bull market in history that cycle we expect will make 18 losses look minor like verdad s analysts last week webb also turns to history to discover what works during such market crises the only good news is that while all this feels new and is new to most market participants it is not actually new much of it mirrors the conditions of the 1970s another time in which everything seemed to change at once everything is not completely the same but there is enough that is to be worth checking on the few things that then made people richer not poorer so what are those things that then made people richer not poorer webb s answer hold gold if you agree that history provides examples of similar episodes and what worked then should work again today this is very likely sound advice bridgewater s dalio and gmo s grantham on the end of the everything bubble when it comes to long term money management experience what more can we ask for than bridgewater s ray dalio and gmo s jeremy grantham their in depth conversation covered virtually all topics relevant to the economic situation and the financial implications the theme of an everything bubble is once again overarching and it s being mixed with several other anchors to drag individual wealth down these include factors like russia and china s soft exit from the global commodity market and its effects of worsening inflation and straining supplies of goods the world has become dependent on but it also covers some not exactly new albeit intensifying issues where ideology is clashing with growth grantham highlighted how the world has grown extremely vulnerable to supply disruptions not just of goods but of labor as well we are primarily funded by readers please subscribe and donate to support us and that is the world we d better get used to living in we re going to have a world of increasing number of bottlenecks and shortages and the same applies to food the un food index is higher today than any time in its history over the last 50 years since it started so you have price pressure on raw materials metals food you have price pressure long term on labor this surely feels like a new era in which inflation will be part of the background music just like it was in the 20th century and perhaps more so in other words grantham sees this not as a typical market cycle but as a totally new paradigm a new normal to use the oft abused phrase a world in which food and raw materials permanently cost more and inflationary pressures don t go away regardless of the fed s interest rate decisions both money managers are very much concerned with the debt bubble breaking and the stock market collapsing with dalio pointing out that stocks are now running on a 14 year long bull market until recently this was propped up by historically loose monetary policies of an almost unimaginable magnitude this is old ground and not an idea we ll explore further today grantham on the other hand believes the coming market meltdown will fall into line historically we have a market today which feels superficially like 2000 and i think it s going to play out initially like 2000 then the deflationary effects on the economy and the stock market will result in a world rather like the 1970s where all assets are simply much lower priced than they are today dalio thinks that wealth itself may need to be redefined that may sound radical but in dalio s defense all of the world s major sovereign nations are suffering from the same systemic problems specifically systemic problems are the easy money policies that fueled the everything bubble that happens by creating money and credit which creates debt and that dynamic means that you must have a decline in real wealth measured by that because the financial wealth has become enormous relative to the real wealth everybody who s holding bonds or assets and particularly the debt assets believes or financial assets in general which are just journal entries they re claims but they believe that they can take that buying power and sell it and buy goods and services one extremely important point here financial assets in general are just journal entries or claims in other words an iou from someone these in dalio s view are completely different from real wealth which is not a claim or an iou gold is pretty much the only investment that meets dalio s real wealth criteria dalio calls gold both an asset and a currency and believes allocating 15 of your savings to gold has a negligible impact on returns while serving as a massive insurance policy why gold dalio says gold is the third largest reserve currency held by central banks and in periods of time of war or such periods of time of credibility it is the medium like they say it s the only asset that you could have that s not somebody else s liability that means you have to be dependent on them giving you money or giving you something and it is international it can be moved and it s tried and true this is probably the best description of gold s safe haven status i ve ever seen gold s price doesn t really change in forbes contributor john tamny recently made a bold assertion gold s price doesn t move what we see as fluctuations in gold s price well those are simply tracking the value of the dollar it s not a matter of supply or demand but rather how the currency itself is faring he says a major contribution to this misunderstanding of moves in gold price comes down to a fundamental misapprehension of what inflation is to begin it s useful to stress up front what s not stressed in just about every media discussion of inflation it s not rising prices there s a major major difference between rising prices and inflation inflation is a decline in the value of a currency period rising prices are a consequence of inflation or better yet can be a consequence but they re not inflation itself to presume that rising prices cause inflation is the equivalent of asserting that wet sidewalks cause rain causation is reversed stop and think about this tamny s perspective stems from bitcoin s inability to outperform gold during the latest bout of rising inflation despite having a more limited supply indeed the two assets have been compared often over the last year or two with bitcoin taking some heat from a lot of analysts and called digital gold by others we d like to offer a more tempered view that falls somewhere in the middle i think of bitcoin as both a hedge and an anti inflation tool the main consideration here is that it is a hedge and an anti inflation tool gold on the other hand is both the hedge and the anti inflation tool in tamny s words to be clear gold doesn t rise as a result of inflation rather gold s rise is the signal of inflation when the dollar weakens gold reflects this weakness gold s rise is the inflation to understand why it s crucial to understand that the price of gold itself doesn t move repeat the previous truth over and over again gold is the constant and it s the constant due to highly unique stock flow characteristics such that increases in supply or demand for the yellow metal don t move its price whether one invests in bitcoin for speculative returns oriented reasons or even inflation protective reasons they are making a bet it a bet similar to the ones made on stocks and for that matter bonds but it s also fundamentally different stocks and bonds have a track record well over a century old as we discussed above how stocks and bonds behave in economic situations like these are a matter of historical record we can look it up bitcoin s historical track record is much shorter and no one knows with certainty how such a novel asset will react when economic situations change take one example 30 day volatility figures for bitcoin 65 and gold 8 45 this tells us that over the last 30 days bitcoin s price has moved about 8x more than gold s price what does it tell us about tomorrow next month nothing now if we were to take a much longer term view comparing rolling volatility periods over years over different economic environments we might begin to unearth useful information alas in this particular case we can t regardless of the amount of history an asset has we can t know how any asset will perform as circumstances change we can merely guess for assets with a long history our guesses are more likely to be correct or at least closer to reality on the other hand those who own gold can have confidence their investment will pay off so long as they invested for the right reasons savings protection and risk management gold s returns can disappoint growth minded investors however it s important to keep gold s primary purpose in mind if you buy gold as an inflation resistant safe haven a reliable long term store of wealth you re unlikely to be disappointed
scheduled for completion in 2023 the marshall expansion project will increase capacity and create 75 new jobs marshall tx accesswire june 7 2022 prysmian group the world leader in the energy and telecom cable systems industry today broke ground on a 50 million expansion project at its marshall texas plant to support growth in the power distribution and transmission markets scheduled for completion in early summer of 2023 prysmian s 50 million investment will create 75 new jobs expand the plant to over a million square feet and include capability upgrades as part of prysmian s original 100 million commitment made last october to upgrade plants across its north american footprint this investment is helping to meet the need for infrastructure upgrades in the region and the growing demand for clean energy sources the marshall expansion is crucial in our commitment to develop the next generation power distribution and transmission grids that will support the energy transition in the u s and canada said andrea pirondini ceo of prysmian group north america this investment is another step towards transforming how our region distributes and transmits power throughout north america prysmian values its role as a longtime employer in marshall fueling the economic growth of the region for more than 50 years the 75 jobs will add stability to the local economy and create new employment opportunities for the community the marshall facility is the group s largest plant in north america where the bulk of the region s renewable energy products are manufactured and this investment also is crucial to enabling the energy transition and digital transformation across the region as we grow our footprint in north america we recognize the importance of our marshall plant and the products that are manufactured in this facility for our customers for energy sustainability and for the local community said paul furtado coo of prysmian group north america this investment will not only expand our capacity and enhance our capabilities but it will add new team members to our talented workforce and contribute to the economic growth of marshall and the surrounding community the investment comes on the heels of major project announcements for prysmian including receiving the largest submarine cable contact in the u s from dominion energy along with the vineyard offshore wind farm project and the soo green link project to deliver high voltage direct current underground transmission cables along existing railroad corridors the marshall expansion project significantly supports prysmian s growing cable system portfolio in north america and its goal of becoming the strategic partner of choice for building the u s clean energy grid prysmian group acquired general cable in 2018 and expanded its north american footprint the marshall facility currently has more than 400 employees and will add 75 new positions including machine operators logistics and skilled trades this is a great opportunity for those who want to work for a longtime employer in the region said david cooper marshall plant director we have a strong team here in marshall and i m looking forward to seeing it expand this investment is the beginning of big things for our community marshall has started hiring for the open positions and plans to complete the process in the fall to learn more about the job opportunities text marshall to 866 745 6271 or visit prysmian s careers page about prysmian group north america prysmian group is the world leader in the design manufacture and sales of wire and cable products based in highland heights ky prysmian group north america operations include 28 manufacturing facilities 8 distribution centers 6 r d centers and more than 5 800 employees with net sales of over 4 billion from wire and cable products and solutions for the transmission and distribution of low medium high and extra high voltage systems to a cutting edge offering of optical fiber and copper cables and connectivity systems for voice video and data transmission the group serves the most comprehensive range of markets including power transmission and distribution telecommunications construction and infrastructure energy projects and specialty industries for countless applications in the united states and canada prysmian group is a public company listed on the italian stock exchange in the ftse mib index additional information is available at na prysmiangroup com media relations lauren kane external communications manager justine david mower on behalf of prysmian group source prysmian group view source version on accesswire com
philadelphia pa accesswire june 7 2022 the board of trustees of aberdeen income credit strategies fund the fund has declared a cash distribution of 0 328125 per share of the fund s 5 250 series a perpetual preferred shares nyse acp pra series a preferred shares the distribution is payable on june 30 2022 to holders of series a preferred shares of record on june 17 2022 ex dividend date june 16 2022 the series a preferred shares trade on the nyse under the symbol acp pra are rated a2 by moody s investors service and have an annual dividend rate of 1 3125 per share the series a preferred shares were issued on may 10 2021 at 25 00 per share and pay distributions quarterly distributions may be paid from sources of income other than ordinary income such as net realized short term capital gains net realized long term capital gains and return of capital the actual amounts and sources of the amounts for tax reporting purposes will depend upon the fund s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations in january 2023 a form 1099 div will be sent to shareholders which will state the amount and composition of distributions and provide information with respect to their appropriate tax treatment for the 2022 calendar year you should not draw any conclusions about the fund s investment performance from the amount of this distribution in the united states abrdn is the marketing name for the following affiliated registered investment advisers abrdn inc aberdeen asset managers ltd abrdn australia limited abrdn asia limited aberdeen capital management llc abrdn etfs advisors llc and aberdeen standard alternative funds limited closed end funds are traded on the secondary market through one of the stock exchanges the fund s investment return and principal value will fluctuate so that an investor s shares may be worth more or less than the original cost shares of closed end funds may trade above a premium or below a discount the net asset value nav of the fund s portfolio there is no assurance that the fund will achieve its investment objective if you wish to receive this information electronically please contact for more information contact abrdn inc investor relations 1 800 522 5465 source abrdn asia pacific income fund vcc view source version on accesswire com
beijing dpa afx the china stock market has climbed higher in three straight sessions gathering almost 60 points or 1 9 percent along the way the shanghai composite index now sits just above the 3 240 point plateau and it s tipped to open in the green again on wednesday the global forecast for the asian markets is mixed to higher with support expected from the oil and technology sectors the european markets were down and the u s bourses were up and the asian markets figure to follow the latter lead the sci finished slightly higher on tuesday as gains from the financial shares and property stocks were capped by weakness from the resource companies for the day the index rose 5 39 points or 0 17 percent to finish at 3 241 76 after trading between 3 222 64 and 3 253 09 the shenzhen composite index eased 0 97 points or 0 05 percent to end at 2 072 58 among the actives industrial and commercial bank of china rose 0 22 percent while bank of china collected 0 31 percent china construction bank perked 0 17 percent china merchants bank advanced 0 98 percent bank of communications was up 0 20 percent china minsheng bank improved 0 26 percent china life insurance increased 0 28 percent jiangxi copper shed 0 48 percent aluminum corp of china chalco retreated 1 37 percent yankuang energy skidded 1 17 percent china petroleum and chemical sinopec rallied 0 90 percent huaneng power climbed 1 12 percent china shenhua energy dropped 0 97 percent gemdale jumped 1 84 percent poly developments soared 2 34 percent china vanke gained 0 81 percent china fortune land gathered 1 23 percent and petrochina was unchanged the lead from wall street is upbeat as the major averages shook off a lower open on tuesday picking up steam as the session progressed to end firmly in the green the dow jumped 264 36 points or 0 80 percent to finish at 33 180 14 while the nasdaq spiked 113 86 points or 0 94 percent to end at 12 175 23 and the s p 500 gained 39 25 points or 0 95 percent to close at 4 160 68 worries about slowing growth a weak margin guidance from target and a sell off in the technology space contributed to wall street s weakness in early trades however top technology stocks soon recovered and the broad market too started climbing higher as well in u s economic news the commerce department said the u s trade deficit narrowed significantly in the month of april to 87 1 billion in april from 107 7 billion in march crude oil prices climbed higher on tuesday as prospects of increased demand from china and supply concerns outweighed concerns about growth west texas intermediate crude oil futures for july ended higher by 0 91 or 0 8 percent at 119 41 a barrel copyright c 2022 rttnews com all rights reserved copyright rtt news dpa afx groer insider report 2024 von dr dennis riedl wenn insider handeln sollten sie aufmerksam werden in diesem kostenlosen report erfahren sie welche aktien sie im moment im blick behalten und von welchen sie lieber die finger lassen sollten hier klicken
gov gavin newsom visited and praised astra space inc in alameda last week highlighting the state s interest in supporting the aerospace industry astra nasdaq astr a rocket technology company that puts satellites in low earth orbit has been based in the island city since 2017 astra has been working with go biz the state s point of contact for economic development and job creation efforts companies like astra demonstrate the best of california driving towards ambitious innovative goals and leaning into the rich talent that is so abundant in our state said newsom in a press release california has always been and will continue to be the home of companies on the cutting edge and we are excited to support and partner with the next stars of the space industry danielle gomes astra s director of real estate development said newsom was extremely engaged with astra employees interacting with co founder adam london technicians machinists and other individuals doing hands on work on rockets gomes added that astra s success in california will be assisted through ongoing collaborations and partnerships with the state specifically the go biz office to help the state s initiative of supporting the commercial space industry while also bolstering astra s competitiveness we were very excited about the opportunity for newsom to come out and i think that is really just the beginning of the state s support for us to be competitive to stay and continue to grow in the state of california gomes said of course it s really expensive to do business in california so with the collaboration of the go biz office and their informing us and supporting astra by way of ensuring that we are capitalizing on grants and incentive programs that the state offers that s really the support we re going to be seeing and feeling directly from the state astra has grown its alameda footprint over the last year from 100 000 to 225 000 square feet as we reported last month and told investors that it plans to take it to 350 000 square feet the company employs over 324 full time california employees contributing 50 million to alameda s gross domestic product annually according to a press release from newsom s office the company is recruiting both within and outside the state for specialized talent with a headcount increase of 258 over the past 12 months gomes added astra is also working toward increasing manufacturing production to a rocket a week gomes highlighted major benefits of having their base of operations in california including access to amazing talent from silicon valley nasa spacex rocket lab and other aerospace companies california has helped us achieve fantastic milestones in a very short period of time and we ve been able to source and hire amazing talent and get where we are today gomes said
in some cultures life and sentience are believed to exist for only certain beings such as humans animals and plants in other belief systems however places and objects are also believed to have some level of sentience this is the case with animism the belief that all things including plants animals objects locations and even concepts are spiritually alive animism is fascinating as it is not necessarily a religion in and of itself but a belief that is a part of many different religions it focuses on the soul of all beings and emphasizes a spiritual connection between all things both scientifically living and non living animism is an incredibly common aspect of many indigenous cultures worldwide and provides a common link between some of these cultures in many indigenous cultures animism is so interwoven with their way of life that they don t even have a term for animism it is the basis of their entire worldview any event that occurs in the world is attributed to these supposed spirits if a natural disaster such as a tornado earthquake or drought occurs it indicates displeasure or dissatisfaction amongst their respective spirits in some religions individuals believe that humans can impact the mood or responses of these spirits in others the behavior of the spirits is out of their control and they must rely on them for survival but where did animism come from and how has it evolved over time the anthropologist edward tylor wrote the book primitive culture where the concept of animism was first coined public domain from old to new a brief history of animism even though animism as a concept has existed for years identifying the concept and giving it a name took quite a while in 1871 english anthropologist sir edward tylor wrote the book primitive culture in which he describes and compares groups that he considered primitive or civilized though the book is often considered unsubstantiated by modern anthropologists it was a key piece of anthropological literature in the late 1800s in this book tylor coined the term animism which he described as the general doctrine of souls and other spiritual beings in general an idea pervading life and will in nature tylor at the time had believed that animism was a primitive form of religion and possibly the oldest religious concept though this has been widely debated it is clear that animism is a significant part of ancient religions such as hinduism and buddhism even if the idea of one ancient global religion has been dismissed by other archaeologists tylor s book and his definition of animism is considered one of the earliest defining moments in the subject of anthropology the study of humanity and human behavior other budding anthropologists at the time considered animism to be the primary religion of primitive groups around the world it was believed when comparing primitive groups with civilized groups that there was an inverse correlation between civilization and animism in essence they believed that as civilization in these primitive groups increased belief in animism decreased other theories about animism began to arise throughout the 1900s in the early 1900s swiss psychologist jean piaget proposed that individuals are born with an innate belief in animism that they grow out of as they develop and learn about the world around them in the later 20th century american anthropologist margaret mead proposed the opposite that individuals are not born with an innate belief of animism but instead developed this belief as their culture guided them to the same way as other religious and cultural beliefs in the early 2000s an updated definition to tylor s was proposed stewart guthrie an anthropologist from yale university defined animism as the attribution of spirits to natural phenomena such as stones and trees he also claimed that the development of animism originally may have been in response to evolutionary instincts in humans since early humans needed to be on high alert to survive in the face of predators and natural disasters they may have begun anthropomorphizing or spiritualizing natural objects as a way to protect themselves against them however this theory has ultimately not been proven many modern anthropologists use guthrie s definition and have gone a step further by studying how animists see themselves in relation to nature and the world itself according to modern anthropologists most animists don t see themselves as a superior being above the objects around them instead they consider themselves an equal part of the earth living in it while also being their own separate species like a piece of one big puzzle meditation in nature to attain harmony is a common practice amongst buddhists a belief which is rooted in animism song_about_summer adobe stock tying cultures together though animism is a concept in and of itself it can look slightly different between cultures as a result some anthropologists have debated whether animism is a single religion in and of itself similar to christianity with its different denominations or if each culture has its own individual religion with belief in animism as a singular part debate is still ongoing though many consider it an aspect of various religions since religion can differ greatly between cultures even if animism is a common theme between them in africa many sub saharan african religions emphasize some element of animism in addition to other beliefs such as polytheism and ancestor worship in the northern saharan region of africa the berbers make up the predominant religion the berbers are northwestern africa s largest indigenous ethnic group and they practice several different religions one of which is the traditional berber religion this traditional ancient religion has aspects of polytheism shamanism and of course animism asian cultures on the other hand have an even stronger basis in animism in many indian originating religions for example animism is a dominating theme buddhism for one has a significant emphasis on coexisting with nature meditation amongst nature is a common practice amongst buddhists who believe that meditating amongst nature will result in harmony this spiritual understanding of nature is rooted in animism sikhism is similar sikhism is an ancient religion with origins in india which focuses on living a practical life of truthfulness fidelity self control and purity like buddhism it also has a significant relationship with nature and shares the belief that humans are spiritually sensitive to nature and the natural world respect for and harmony with nature is an essential aspect of sikhism as the sikh holy scripture even says air is the guru water is the father and earth is the great mother this is a clear example of animism as one of sikhism s many core beliefs other indian religions also focus on worshipping specific trees such as the bodhi and bonsai they may also revere sacred rivers mountains and other landscapes as part of their beliefs in the spirituality of nature during vat purnima women tie thread around banyan trees to disply their love for their husbands georgeburba adobe stock some tree species are more sacred than others and may be used in specific religious rituals or grown at places of worship for example vat purnima is a hindu celebration held by married women during this celebration women use a banyan tree to publicly display their love for their husbands these women will come together to tie a thread around the tree to represent their love they may also offer copper coins to the tree as a combination of coins and regular celebration with the thread is thought to please the tree and give their husbands health and longevity in addition to this ceremony the leaves of the tree are seen as highly sacred krishna a major hindu deity is believed to live on the leaves of banyan trees because of this they are planted in important areas and treated with the utmost care by those who practice hinduism in the philippines indigenous religions that worship anito ancestral spirits and bathala a major deity in the region also believe in animism in anito worship especially it is believed that there is an alternative spiritual world that exists alongside the physical world where the deceased remain those that believe in this believe that the spiritual world often interacts with the spiritual world which results in natural objects such as grass trees and rocks having their own spirits outside of india and the phillipines japan pakistan and korea all hold similar beliefs in their own native religions no matter which country you look in most will have some sort of indigenous history which includes animism after analysis it becomes clearer that animism is a common string tying many different religions together even if they aren t correlated with one another whether it s the beauty power or wonder of nature it s clear many people of many different cultures have attributed unique spirituality to it indian woman worshiping a tree ashish_wassup6730 adobe stock isn t dying anytime soon animism is still mostly practiced by indigenous groups worldwide though some modern religions have continued to incorporate animism into their beliefs for example modern day pagans have outwardly claimed to be animists and demonstrate this by showing immense respect and reverence for nature and other living things they also believe that humans share the world with spirits and that these spirits should be respected though animism may not be considered a mainstream belief it is still incredibly common in different regions throughout the world understanding the beliefs of others gives us a greater insight to the cultures and priorities of other people and can show us how human thought has evolved over time even those that don t worship using animism may find that they hold something in common with animistic beliefs such as respect for nature even if you don t believe it has a spirit the next time you re exploring nature consider its beauty and its power perhaps you ll come to understand just why some people consider it a spiritual force of its own top image the concept of meditating in nature is based in beliefs in animism source ittipol adobe stock by lex leigh
shanghai jun 8 this is a roundup of global macroeconomic news last night and what is expected today the u s dollar index retreated from earlier highs and fell on tuesday as u s equities shook off an early risk off mood and turned positive but the greenback managed to hit its highest level in 20 years against the japanese yen stocks on wall street advanced in the early portion of trading reversing course after each of the major indexes on wall street opened with sharp losses and the nasdaq lost more than 1 dampening the appetite for the safe haven dollar the dollar index fell 0 12 to 102 32 with the euro up 0 09 to 1 0704 the yen weakened to touch 132 99 per dollar its lowest since april 3 2002 the greenback has been strengthening against the yen as the policy paths of their countries respective central banks diverge stock futures fell marginally in overnight trading tuesday after two consecutive days of gains on wall street futures on the dow jones industrial average dipped 55 points s p 500 futures and nasdaq 100 futures both declined just 0 2 investors shrugged off some signs of an economic slowdown ahead of a key inflation reading the s p 500 gained nearly 1 rising for a second straight day the 30 stock dow advanced more than 260 points tuesday while the tech heavy nasdaq composite rose 0 9 oil prices settled higher on tuesday as the market balanced risk sentiment with supply concerns and the prospect of higher demand as china relaxes its covid curbs brent crude futures added 0 89 to settle at 120 57 a barrel u s west texas intermediate wti crude futures gained 0 77 to settle at 119 41 its highest settle since march 8 oil futures were down earlier in the session risk sentiment is responsible for the drop with european equity markets negative said ubs analyst giovanni staunovo u s state department authorisation for eni and repsol to start shipping venezuelan crude to europe from july to replace lost russian barrels has also weighed on prices in recent days gold prices rose on tuesday after mounting inflation concerns boosted safe haven bids for the precious metal and as a decline in u s treasury yields added support spot gold rose 0 69 to 1 853 72 per ounce earlier in the session bullion touched 1 836 10 its lowest since june 1 u s gold futures climbed 0 68 to 1 856 3 the pan european stoxx 600 provisionally ended 0 3 lower with technology stocks shedding 1 2 to lead losses as most sectors and major bourses slid into negative territory conversely mining stocks and oil and gas stocks closed over 1 2 higher
kalamazoo mi wkzo am fm united way of south central michigan is joining with the michigan association of united ways the kellogg company and local united ways statewide in a two week virtual effort to feed families by helping stock the shelves of michigan s food banks and pantries the second annual summer stock up aims to raise funds to help address the need for more food resources between june and august when demand at food banks grows by 20 donors can make a financial gift online at www summerstockup org the fund drive runs monday june 13 through friday june 24 having enough food is a basic challenge for hard working low income and poverty level households said chris sargent uwscmi president and ceo that challenge becomes more difficult during summer when the days get longer and children aren t eating meals at school add to that the rapid rise in food costs and families face impossible decisions like choosing between food and medicine or food and rent sargent said the success of the inaugural summer stock up in 2021 bodes well for the power of the program last year s effort raised over 63 000 and collected more than 46 000 pounds of food helping 220 food pantries across the state summer stock up is one of many partnerships and initiatives we participate in to help ensure everyone has access to fresh healthy food through summer and beyond sargent said to support the summer stock up in your community or learn more visit www summerstockup org
washington united states a panel of experts convened by the us drug regulator on tuesday recommended the novavax covid 19 shot a late runner in the fight against the virus that could nonetheless play a role in overcoming vaccine hesitancy files this file photo illustration picture shows vials with covid 19 vaccine stickers attached and syringes with the logo of us biotech company novavax on november 17 2020 justin tallis afp three vaccines are currently approved in the united states pfizer and moderna which are based on messenger rna and johnson and johnson which recently received a recommendation against broad use becase of links to a serious form of clotting experts voted 21 in favor of the novavax vaccine with none against and one abstention despite some concerns it may be linked to rare cases of heart inflammation the food and drug administration which called the meeting is expected to issue an emergency use authorization soon then another agency the centers for disease control and prevention will weigh in with guidance on how it should best be used maryland based novavax was an early frontrunner in the global vaccine race but fell behind after being hit by manufacturing and regulatory delays the us was one of the few major markets where it hasn t yet received authorization while the eu uk canada australia are among many that have already given it the green light officials hope that the shot which is based on lab grown viral proteins could provide an alternative for people still hesitant of the mrna technology it also doesn t have the same cold storage requirements as pfizer and moderna s shots there really is a population of patients who are willing to take this and not going to take existing vaccines i think it s pretty compelling said eric rubin an infectious disease specialist who participated in the meeting explaining his vote in favor of the various vaccine technologies mrna has been subject to the most misinformation efforts novavax s vaccine was found to be more than 90 percent effective against symptomatic cases of the disease but its trial was conducted long before the currently circulating sub variants of omicron were dominant and the company may yet have to add a booster or update its shot what s more six cases of myocarditis an inflammation of the heart muscle were detected in the group that received the vaccine against one case in the placebo group in a trial of around 40 000 people novavax says there is insufficient evidence to establish a causal relationship between the cases of myocarditis and the vaccine such a link has been established with mrna vaccines but it only became apparent when they were used on millions of people in the real world rather than tens of thousands in a trial the fda voiced concern over the myocarditis link on friday and a warning is likely to be included on the eventual label earlier trading in novavax shares on nasdaq was halted pending the meeting known as a protein subunit vaccine novavax is administered in two doses it is based on a lab created version of the spikes that dot the surface of the coronavirus to evoke an immune response the company uses a modified spike gene inserted into another kind of virus called a baculovirus which is used to infect moth cells which then produce the spikes on their surface these spikes are harvested and assembled into nanoparticles which are injected into patients a compound of soapbark tree is added to the vaccine to heighten the response
rosemont ill june 07 2022 globe newswire wintrust financial corporation wintrust or the company nasdaq wtfc today announced the pricing of its upsized underwritten public offering of 3 000 000 shares of its common stock at a price to the public of 86 00 per share in connection with the offering wintrust has granted the underwriters a 30 day option to purchase up to 450 000 additional shares of common stock the offering is expected to close on june 10 2022 subject to customary closing conditions assuming the underwriters do not exercise their option to purchase additional shares wintrust expects to receive net proceeds for the offering of approximately 248 4 million after deducting underwriting discounts and commissions and estimated offering expenses wintrust intends to use the net proceeds from this offering for general corporate purposes rbc capital markets llc and raymond james associates inc are acting as joint book running managers for the offering the offering is being made under an effective shelf registration on file with the u s securities and exchange commission the sec the offering may be made only by means of a prospectus supplement and the accompanying prospectus prospective investors should read the prospectus supplement and the accompanying prospectus in the registration statement and other documents wintrust has filed or will file with the sec for more complete information about wintrust and the offering copies of the prospectus supplement and accompanying prospectus describing the offering may be obtained by visiting edgar on the sec s website at www sec gov or by contacting rbc capital markets llc attention equity syndicate 200 vesey street 8th floor new york new york 10281 telephone 877 822 4089 email or raymond james associates inc 880 carillon parkway st petersburg fl 33716 or by calling toll free 1 800 248 8863 this press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any securities in any state or jurisdiction in which such an offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction about wintrust wintrust is a financial holding company with assets of approximately 50 billion whose common stock is traded on the nasdaq global select market built on the have it all model wintrust offers sophisticated technology and resources of a large bank while focusing on providing service based community banking to each and every customer wintrust operates fifteen community bank subsidiaries with over 170 banking locations located in the greater chicago and southern wisconsin market areas additionally wintrust operates various non bank business units including business units which provide commercial and life insurance premium financing in the united states a premium finance company operating in canada a company providing short term accounts receivable financing and value added out sourced administrative services to the temporary staffing services industry a business unit engaging primarily in the origination and purchase of residential mortgages for sale into the secondary market throughout the united states and companies providing wealth management services and qualified intermediary services for tax deferred exchanges forward looking statements this press release contains forward looking statements within the meaning of the federal securities laws including without limitation statements related to the completion of the public offering the satisfaction of customary closing conditions related to the public offering and the intended use of proceeds from the public offering these forward looking statements are based on management s current expectations and beliefs and certain assumptions made by our management investors are cautioned that such statements are predictions and actual events or results may differ materially wintrust s expected financial results or other plans are subject to a number of risks and uncertainties for a discussion of such risks and uncertainties which could cause actual results to differ from those contained in the forward looking statements see risk factors and the forward looking statement disclosure contained in wintrust s annual report on form 10 k for the fiscal year ended december 31 2021 and in any of the company s subsequent sec filings forward looking statements speak only as of the date made and except as required by law wintrust undertakes no duty to update its forward looking statements for more information contact edward j wehmer founder chief executive officerdavid a dykstra vice chairman chief operating officer 847 939 9000 source wintrust financial corporation
washington a former member of donald trump s cabinet will attempt a return to the u s congress in montana and california democrats concerned about crime may oust one of their own as voters head to the polls in midterm primary elections in seven states on tuesday voters in south dakota new jersey iowa mississippi and new mexico will also cast ballots in nominating contests that will set the competitive field for nov 8 s elections which will determine control of congress for the next two years with president joe biden slumping in the polls and soaring inflation souring voters moods republicans are expected to win control of the house of representatives and possibly the senate which would bring biden s legislative agenda to a halt and give republicans the power to launch distracting and possibly politically damaging investigations in montana ryan zinke who served as interior secretary under republican former president trump is running for a newly created house seat that the state gained thanks to population growth and the once a decade redistricting process zinke who served in congress previously faces four republican challengers some of whom claim that he is too liberal or lacks commitment to the state because his wife s residence is in california advertisement zinke was accused in an inspector general report this year of using is position as head of the interior department to advance a development project in his hometown and lying to an ethics investigator he has denied wrongdoing south dakota s conservative republican governor kristi noem faces a challenge by steven haugaard a member of the south dakota house of representatives noem has been mentioned as a possible vice presidential running mate if former president donald trump seeks election again in 2024 or as a white house candidate in her own right if he does not the winners of each of those republican primaries are favored to win in november california shakeout a pair of races in california will also illustrate liberal leaning voters frustrations with spikes in homicides and gun violence polls show that san francisco s progressive district attorney chesa boudin is likely to be pushed out of office in a recall vote a replacement would be chosen by the city s mayor london breed a democrat who has criticized boudin but has not taken a stance on the recall in los angeles rick caruso a billionaire developer and former republican is battling u s representative karen bass and a host of other liberal candidates in the mayoral election caruso who has spent more than 30 million of his own money in the campaign made crime the centerpiece of his candidacy in a city that saw homicides reach a 15 year high in 2021 that forced bass a longtime progressive champion in congress to move to the center and pledge to put more police on the streets caruso and bass could be headed to a runoff polls show advertisement new jersey iowa challenges republicans in new jersey and iowa will also be picking challengers to embattled incumbent house democrats representatives tom malinowski in new jersey and cindy axne in iowa former state senate republican leader tom kean jr the son of popular two time governor thomas kean leads a crowded republican field to challenge malinowski malinowski a two term incumbent who entered congress by flipping a republican seat in 2018 won reelection by defeating kean by 1 2 percentage points in 2020 since then his prospects have been weakened by redistricting and by a house ethics investigation after reports that he failed to disclose hundreds of thousands of dollars in stock trades it was a nail biter in 2020 and his district has become a little more favorable for republicans so it s going to be a significant challenge said benjamin dworkin director of the rowan university institute of public policy citizenship in iowa three republicans are vying for the chance to challenge axne businesswoman nicole hasso construction consultant gary leffler and former state senator zach nunn nunn the only republican contender who has held elective office boasts a string of endorsements from high profile party luminaries including trump s former secretary of state mike pompeo and several sitting house republicans
san francisco district attorney chesa boudin is facing a recall as voters head to the polls justin sullivan getty images tuesday s primary elections in seven states will once again test whether republican voters are willing to punish incumbents with track records of winning competitive races for failing to be sufficiently supportive of former president donald trump in california frustrations over crime and homelessness have shaped an effort to recall san francisco s district attorney and the los angeles mayor s race pits a billionaire republican turned democrat against a veteran congresswoman who was on president biden s vice presidential short list here are key things to watch in today s elections in the golden state billionaire former republican vs progressive democrat in liberal los angeles republican shopping mall magnate turned democratic mayoral candidate rick caruso is giving rep karen bass a stout challenge in their bids to be mayor of los angeles caruso has poured millions of his own fortune into the race pledging to tackle the city s pervasive homelessness combat corruption and address the city s crime rate by increasing the size of the police force bass a longtime congresswoman and former member of the california state assembly is highlighting many of the same issues including crime and homelessness but with a more progressive message and is touting her connection to the city if she were to become los angeles mayor she would be the first woman to hold the office there is a good chance this could be just the first time caruso and bass face off if no candidate in the 12 person field gets 50 of the vote the top two finishers in the race move on to a runoff in november san francisco district attorney at risk of recall san francisco district attorney chesa boudin was swept into office in 2019 on concerns over police misconduct criminal justice reform and mass incarceration a high point for the movement to elect more progressive prosecutors three years and one pandemic later the winds have so dramatically shifted against the progressive district attorney and his lax approach to certain kinds of crime that he is facing a recall the effort and boudin s time in office cannot be separated from the coronavirus pandemic which coincided with a rise in property crime rates in san francisco the recall is as much about the feeling among san francisco residents as it is about crime rates homelessness remains a persistent issue in the city as residents report feeling uncomfortable in large swaths of commercial areas because of drug use and crime while republican money is helping the effort the push to recall boudin was initially supported by democrats house republicans face challenges from the right rep david valadao one of 10 republicans to support trump s 2021 impeachment is facing a challenge in california s 22nd district from republican chris mathys who has campaigned as an ardent trump supporter and made valadao s vote his core argument against the incumbent california s orange curtain trends back toward republicans in 2018 democrats seized on anti republican sentiments in orange county and turned the historically republican area known politically as california s orange curtain into a democratic stronghold winning all six congressional seats in the county that year but in 2020 republicans won back two seats in orange county michelle steel and young kim defeated democratic incumbents to flip two seats and the party is hopeful it could win at least two other orange county congressional seats this year which could be a historically bad year for democrats in just four years democrats went from newly dominant in orange county to notably threatened california central valley seat to be filled the next occupant of former gop rep devin nunes onetime congressional district will be selected on tuesday the seat was vacated when nunes the controversial congressman who attempted to help trump avoid scrutiny around russia s involvement in the 2016 election decided to leave congress to become ceo of trump s media company trump media technology group the seat which includes much of california s san joaquin valley leans toward republicans and all indications are that republican connie conway the former minority leader in the california state assembly will win the race she finished well ahead of democrat lourin hubbard in the april primary here are key things to watch in the other states holding primaries tuesday
china s foreign exchange market registered a stable operation in may with the forex reserves expanding official data showed on tuesday china s forex holdings amounted to 3 1278 trillion u s dollars at the end of may up 8 1 billion u s dollars or 0 26 percent from the end of april ending a four month declining streak according to the state administration of foreign exchange the supply and demand of the domestic foreign exchange market remained balanced said wang chunying the administration s deputy head commenting on the data wang attributed the increase in forex reserves to the combined impacts of the slight decline in the dollar index due to monetary policy and expectations in major economies global economic growth prospects and geopolitical situations deeming the external situations as complex and grim wang said that the global financial market still faces uncertainties amid increasing risks and challenges in the global economy but china s economic fundamentals for long term growth remained unchanged thanks to its efforts in coordinating covid 19 prevention and control with economic and social development which will help stabilize the country s forex reserves said wang echoing wang s views wen bin chief analyst at china minsheng bank said he expects the country s forex reserves to maintain stability in the next stage as the country has rolled out policies to stabilize the economy an executive meeting last month decided to implement 33 measures in six areas to keep the economy running within an appropriate range and the country then ordered government departments to introduce practical implementation measures by the end of may the economic recovery will consolidate with the covid 19 impacts wearing thin and the policy incentives taking effect providing a more solid foundation for the smooth operation of the foreign exchange market said wen inflation in the united states has slowed down and the dollar index eased which is conducive to maintaining the yuan s exchange rate within a reasonable and balanced range he said wen also noted that china would likely report a reasonable surplus in international goods trade and remain a strong magnet for foreign investment tuesday s data also showed china s gold reserves remained flat at 62 64 million ounces valuing 115 18 billion u s dollars the country should accelerate the implementation of the pro growth measures to bolster the market confidence and fend off domestic and external risks to keep the forex reserves generally stable said wen
washington business wire aids healthcare foundation ahf welcomes the u s federal trade commission ftc announcement today that it will launch an inquiry into the practices of prescription drug middlemen and their questionable conduct thank you ftc for hearing the voices of tens of thousands of pharmacies and patients across the country and launching an inquiry into the impact of vertically integrated pharmacy benefit managers pbms on access and affordability of medicine for a decade pbms have been silently growing in the regulatory shadows like a fungus on the healthcare industry they have amassed enormous power through unchecked vertical integrations and are using that power to hurt patient access to healthcare and drive up healthcare costs while lining their own pockets on behalf of our hiv patients whose care has been fragmented by pbm practices and on behalf of our and other pharmacies which regularly suffer pbm abuses as they try to care for our patients we welcome the light that ftc will shine on this dark area of healthcare said laura boudreau chief of operations risk management and quality improvement for aids healthcare foundation aids healthcare foundation is the largest provider of hiv primary care in the world serving in 16 u s states the district of columbia puerto rico and 45 countries aids healthcare foundation ahf the largest global aids organization currently provides medical care and or services to over 1 6 million people in 45 countries worldwide in the us africa latin america caribbean the asia pacific region and eastern europe to learn more about ahf please visit our website www aidshealth org find us on facebook www facebook com aidshealth and follow us on twitter aidshealthcare and instagram aidshealthcare view source version on businesswire com washington john hassell national director of advocacy ahf 1 202 774 4854 los angeles ged kenslea senior director communications ahf 1 323 791 5526 atlanta imara canady regional director communications community engagement for ahf 770 940 6555 mobile source aids healthcare foundation
as the number of monkeypox cases rises around the world the biden administration is ramping up its ability to dispatch thousands or potentially millions of vaccine doses to fight what has quickly become the largest outbreak of the virus in history but troubling early indicators of groups that may be at high risk for contracting could mean that the guidelines dictating who is eligible for those vaccines may need to shift on monday the department of health and human services instructed the manufacturer of the latest vaccine for the virus to deliver 36 000 doses from an american stockpile in europe once delivered the centers for disease control and prevention will be able to distribute them to a dozen states where cases of the rare illness have been confirmed since mid may the swift request of tens of thousands of vaccine doses comes as the number of known domestic cases reached 31 on monday according to the cdc part of a pair of outbreaks that have seen more than a thousand cases across nearly three dozen countries the request as well as the swift creation of guidelines for who will receive doses of the vaccines public health experts said showcases that some of the lessons learned from early missteps in the covid 19 pandemic response have been put into practice advertisement advertisement but with several superspreader events related to lgbt venues and events in europe some public health experts are hoping for a more aggressive posture on who will be able to receive a vaccine even though no public health experts are calling for a covid esque mass vaccination strategy i applaud the biden administration in securing additional doses of the vaccine but it needs a more coherent strategy for identification of cases and close contacts and for determining which individuals or populations should be offered the vaccine said lawrence gostin director of the o neill institute for national and global health law at georgetown law center i worry greatly that we will see an escalation of cases especially in high risk groups such as men who have sex with men i also worry that we are repeating the errors of the aids epidemic by stigmatizing these communities and driving them underground sex at european raves could explain monkeypox outbreak who adviser the monkeypox virus which despite its name primarily affects rodents has previously been restricted largely to central and west african communities although an american outbreak in 2003 infected more than 40 people after the virus found a reservoir in prairie dogs in the american southwest but this most recent outbreak is the widest in the known history of the virus with more than a thousand confirmed cases as of tuesday largely in western europe and the united states advertisement advertisement monkeypox is not dissimilar from chickenpox and smallpox with symptoms including fever headaches and soreness as well as swollen lymph nodes eventually leading to fluid filled lesions that can leave permanent scars all of the people who have contracted the illness in the latest outbreak have recovered but the long term side effects of the illness are not well understood we are prepared but i ve always learned it s wise to face infectious disease threats not with overconfidence but with humility dr raj panjabi the white house s senior director for global health security and biodefense told reporters in a call on friday a monkeypox outbreak of this scale and scope across the world it has not been seen before although president joe biden called the outbreak something that everybody should be concerned about on may 22 he later sought to dampen concern about the virus particularly for pandemic weary americans concerned about another virus i just don t think it rises to the level of the kind of concern that existed with covid 19 biden told reporters last month but i think people should be careful advertisement advertisement an hhs spokesperson declined to comment on the record but noted that the request for increased vaccination doses from the american stockpile is intended to give public health agencies the ability to respond to any future needs rather than in response to any anticipated increase in case numbers we will continue to work with jurisdictions to support their response dawn o co nnell hhs s assistant secretary for preparedness and response wrote in a blog post announcing the vaccine instruction on monday however at this time we do not anticipate the need for widespread mass deployment of vaccines and treatments if there were such a need the u s is sitting on an enormous stockpile of the vaccines currently held in storage in europe there are actually about 1 5 million doses that have been produced freedman said they re in single vials fda approved ready to go advertisement advertisement the 36 000 doses requested by hhs on monday will come from that repository and will be distributed to state health authorities by the cdc previous outbreaks outside of central and west africa have primarily been limited to zoonotic transmission that is direct transmission from an animal to a human but the current outbreaks appear to have been spread by human to human transmission making the swift implementation of a vaccination strategy of critical importance to prevent the illness from becoming endemic in new human populations it s unlikely based on what we ve seen so far that a mass vaccination strategy of the general population is going to be required the thoughts now are to continue with a so called ring vaccination strategy said dr david freedman a professor emeritus of infectious diseases at the university of alabama and an expert in tropical diseases you identify a case and then identify anybody they came into contact with for seven days or 14 days before they actually got sick and then vaccinate those people effectively freedman said you re vaccinating a ring around those people to prevent the virus from spreading advertisement advertisement the ring however can be quite wide including not just close physical contacts like family members roommates and sex partners but also the medical staff tasked with treating confirmed cases monkeypox is spreading during sex and that is actually a relief but while infectious disease experts note that monkeypox is far less contagious than smallpox the related virus that was once a global scourge but was effectively brought to extinction in the late 1970s by a worldwide vaccination campaign several apparent superspreader events in europe most of them popular with transgender people and men who have sex with men have raised concerns that this outbreak is more effective at human to human transmission the biden administration told the daily beast that the increase in doses requested from the national stockpile roughly 1 200 of which have already been administered has nothing to do with an expected strengthening of the outbreak or the possibility that the guidance on who is eligible for these vaccines will change to include members of high risk groups advertisement advertisement but as pride month kicks into gear in the united states freedman said the cdc s current guidance on who is eligible for vaccine doses could be expanded particularly after apparent amplifying events in europe a sauna in madrid a rave in antwerp a pride festival in the canary island were linked to a high number of monkeypox cases many of them apparently transmitted through sexual contact if more events like that come to light it would make sense to say that if you attended this event you d be eligible freedman said the cdc has not gone so far as some other national health organizations in emphasizing the risk that monkeypox presents to men who have sex with men but a newly published guidance on social gatherings safer sex and monkeypox includes recommendations on safer behavior at raves parties clubs and festivals as well as clipart of people waving rainbow flags at a parade sample guidance a rave party or club where there is minimal clothing and where there is direct personal often skin to skin contact has some risk the world health organization is still finalizing full guidance for national authorities on the best approach to vaccination in the management of monkeypox said tarik jaarevi a spokesperson for the who advertisement advertisement u s guidelines however are already in effect currently the cdc s guidance for monkeypox vaccination calls for doses to be distributed to confirmed cases as well as the ring of people who have had unprotected contact with a known case s skin mucous membranes or bodily fluids as well as close enough physical proximity to risk infection by aerosolized saliva that strategy is known as post exposure prophylaxis or pep perhaps best known as a treatment course following potential exposure to the human immunodeficiency virus that so far is the extent of those eligible for a monkeypox vaccination said dave daigle an associate communications director with the cdc s office on public health preparedness and response we are not currently recommending a second ring which is the recommendation of vaccination of contacts of contacts daigle said until we know more we will be using available vaccine stocks for people who ve had close contact with known cases and people at highest risk for exposure through their jobs like healthcare workers treating monkeypox patients dr timothy brewer a professor of epidemiology at ucla s fielding school of public health and of medicine noted that the ring vaccination strategy was a successful tool in the fight against smallpox strengthening the administration s argument that targeted vaccinations are an effective tactic in combating the outbreak so far advertisement advertisement identifying cases and vaccinating contacts was the approach the who used to eradicate smallpox a more transmissible virus for humans than monkeypox brewer said given the success with smallpox limiting vaccination to direct contacts of cases and individuals likely to be exposed to monkeypox because of their jobs is a reasonable initial strategy read more at the daily beast got a tip send it to the daily beast here get the daily beast s biggest scoops and scandals delivered right to your inbox sign up now stay informed and gain unlimited access to the daily beast s unmatched reporting subscribe now
new york rallied late on tuesday to end higher for a second straight day as technology and energy shares gained while corp s warning about excess inventory weighed on retail stocks for much of the session apple inc shares climbed 1 8 despite news earlier in the day that the company must change the connector on iphones sold in europe by 2024 after eu countries and lawmakers agreed to a single charging port for mobile phones tablets and cameras the s p 500 technology index rose 1 and gave the benchmark index its biggest boost microsoft corp shares added 1 4 the s p 500 energy sector index jumped 3 1 to end at its highest level since 2014 with oil prices sharply higher at the same time shares of target corp fell 2 3 after the retailer said it would have to offer deeper discounts and cut back on stocking discretionary items equity trading was choppy with indexes down early in the day but the market has been recovering from recent steep losses recently we ve had a nice bounce and in general investors are feeling better right now but we are very much in a seesaw market as we ve seen all year said tim ghriskey senior portfolio strategist at ingalls snyder in new york at some point we will put in a bottom and the market will move higher we have a hard time believing that s any time soon given a number of fundamental issues overhanging the market he said certainly what we ve seen today from target isn t good news in terms of the consumer long dated us treasury yields tumbled after the target news however as it fueled some speculation that the worst of inflation may be in the past the industrial average rose 264 36 points or 0 8 to 33 180 14 the s p 500 gained 39 25 points or 0 95 to 4 160 68 and the composite added 113 86 points or 0 94 to 12 175 23 shares of walmart fell 1 2 and the s p retail index was down 1 consumer price data on friday is expected to show that inflation remained elevated in may though core consumer prices which exclude the volatile food and energy sectors likely ticked down on an annual basis not all retailers were in the red kohl s corp shares jumped 9 5 after news the department store chain entered exclusive talks with retail store operator franchise group inc over a potential sale that would value it at nearly 8 billion advancing issues outnumbered declining ones on the nyse by a 2 36 to 1 ratio on nasdaq a 1 69 to 1 ratio favored advancers the s p 500 posted 3 new 52 week highs and 30 new lows the nasdaq composite recorded 35 new highs and 121 new lows volume on us exchanges was 10 38 billion shares compared with the 12 50 billion average for the full session over the last 20 trading days
zvamaida murwira senior reporter farmers who deliver maize and traditional grains to the grain marketing board before the end of next month will now get an extra us 90 a tonne over and above the 75 000 a tonne producer prices set recently for all four summer grains with the same us 90 a tonne incentive given for deliveries of the pricier sunflower and soya beans the cabinet agreed to the extra incentive bonus yesterday which will be backdated to the beginning of april when the marketing season opened so farmers who have already delivered will the getting the extra the bonus is an incentive for farmers to push their harvesting drying and delivery timelines government yesterday described the package and pricing as the most competitive in the region the announcement was made after yesterday s cabinet meeting by information communication and technology postal and courier services minister dr jenfan muswere who was standing in for information publicity and broadcasting services minister monica mutsvangwa the measures to reward the most efficient farmers were tabled before cabinet by lands agriculture fisheries water and rural development minister anxious masuka zimbabwe started the new marketing season with large carryover stocks from last season on april 1 when the gmb was ready to take deliveries from the new harvest there were stocks of 453 717 tonnes carried over from the previous season as a strategic grain reserve cabinet also approved a review of the price of maize to ensure farmers viability dr muswere said cabinet resolved that cotton will now be treated as an export crop just like tobacco with prices being determined by fair pricing based on international lint prices this should motivate growers to produce more in the coming seasons he said he also gave a status report on wheat and tobacco and tobacco sales so far commenting on the producer price structure dr masuka said the 75 000 a tonne paid for maize sorghum millet and rapoko coupled with the us 90 incentive adds up to the equivalent of us 350 a figure he said was competitive if you look at the import parity price for maize and if you look at this price framework this is a very lucrative arrangement for farmers it is giving them the equivalent of us 350 which is comparable if not better than anywhere else in the region farmers should take advantage of this generous offer from government said dr masuka soya farmers are paid 171 495 a tonne and sunflower farmers 205 794 52 a tonne according to the gmb website and they will now be getting the extra us 90 a tonne if they deliver early fertiliser will now be sold in foreign currency in an open market since some components are imported but those accessing it using the government schemes the majority would pay in local currency reacting to the incentive one farmer organisations the zimbabwe women farmers trust has welcomed the incentive saying it will encourage them to deliver their crops early zimbabwe women farmers trust president mrs depinah nkomo told the herald last night that the incentive is welcome i think it is a good way of promoting the early delivery of maize to the gmb we commend the government for this but we recommend that this incentive should be offered every year from now so that farmers know that when they deliver their crops early they will get an incentive said mrs nkomo meanwhile commenting on why the government was not fully dollarising finance and economic development minister professor mthuli ncube said there were a number of challenges some very serious that would arise if this was done including the destruction of the banking sector and local industry will no longer be competitive and will be cut back sharply the last time zimbabwe went for dollarisation many factories closed or cut back on production and staff as imports took over this is what will happen on day one if you adopt the united states dollar as the only currency something nasty is going to happen four things as a minimum will happen you will wipe out the entire banking sector because you need to convert their zimbabwe dollar balances into us dollars banks will have negative balances you will have a crisis you will have no banking sector secondly very quickly you will have a cash crisis because you cannot print us dollars and there will be a divisibility problem the small denomination notes will be in short supply and you will start to have cash queues in the banking sector said prof ncube the advantage of having a domestic currency circulating with us dollar is we will have to manage the cash crisis we have been through this before if you remember we had to create something called the bond notes but that was before i arrived in order to deal with some of the cash crisis he said he said the economy particularly the manufacturing sector will lose its competitiveness if the domestic currency is done away with also you will do away with the monetary policy you need both fiscal and monetary policy or you will be walking with one leg so something nasty will happen if you just use the united states dollar said prof ncube on constant fuel price increases prof ncube said the situation would be worse if the country was not blending with ethanol
